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Abstract 
The src family kinases are key cellular regulators of acute neutrophilic 
inflammation. When uncontrolled, this causes numerous inflammatory 
disorders, including the acute respiratory distress syndrome (ARDS). This is 
associated with an unacceptably high 90-day mortality and prolonged hospital 
admissions. ARDS currently has no effective pharmacological treatment. 
The work contained in this thesis aimed to characterise the anti-inflammatory, 
pro-resolutionary effects of src kinase inhibition on various neutrophil functions, 
using novel in vitro and in vivo models of acute inflammation and resolution.  
Results show that the src kinase inhibitors, PP1 and dasatinib, attenuate in vitro 
neutrophil extracellular degranulation in response to stimulation with formylated 
peptide, lipopolysaccharide and live bacteria. They also exert additional effects 
on integrin-dependent neutrophil functions, but have no effect on neutrophil fate 
or bacterial killing efficiency.  
Src kinase inhibition of neutrophils also attenuates in vitro epithelial cell damage 
and promotes a pro-resolutionary environment, with improved macrophage 
efferocytosis of apoptotic neutrophils, by inhibiting the release of an unidentified 
soluble factor believed to be a product of neutrophil degranulation. 
Extending these findings to in vivo murine models of bacteria- and acid-induced 
experimental lung inflammation, dasatinib exerts an inhibitory effect on markers 
of neutrophil degranulation in each model, at doses of 1mg/kg and 5mg/kg, 
respectively. At 10mg/kg, a detrimental effect is observed, as evidenced by 
reduced bacterial clearance, increased alveolar leak and extrapulmonary 
toxicity in the infection model and increased neutrophil influx, degranulation and 
alveolar haemorrhage in the acid model.  
These findings highlight a possible therapeutic role of src kinase inhibition in 
inflammatory conditions driven by neutrophil influx and degranulation that is 
worthy of further study in other models of lung inflammation. Future work should 
focus on developing more specific inhibitors to offer selective control over 
neutrophil granule processing, and careful dosing to avoid undesired effects on 
bacterial killing mechanisms. 
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Chapter 1. Introduction 
 Chapter Overview 1.1
This thesis addresses the acute inflammatory responses that are believed to 
cause acute lung injury (ALI) and its important clinical sequelae, namely the 
acute respiratory distress syndrome (ARDS). It describes my studies 
investigating cellular mechanisms involved in the pathogenesis of ARDS, a 
better understanding of which may unlock new avenues of research for novel 
therapeutic approaches for this condition, which is associated with a high 
mortality and considerable healthcare resource usage. 
In this first chapter I shall summarise the current mechanistic and clinical 
understanding of ALI and ARDS, together with the hypotheses I set out to 
investigate. Subsequent chapters describe, detail and discuss the methods 
used and results obtained, followed by a general discussion. 
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 Acute Lung Injury and Acute Respiratory Distress Syndrome 1.2
1.2.1 Definitions 
The 1994 American-European Consensus Conference (AECC) defined ALI and 
ARDS as two distinct severe respiratory conditions differentiated by the severity 
of hypoxaemia, and requiring the following criteria to be met: 
• Acute and persistent onset 
• Bilateral pulmonary infiltrates on chest radiograph 
• Impaired oxygenation independent of positive end-expiratory pressure 
(PEEP) delivered: 
o PaO2:FiO2 ratio ≤ 300 mmHg (40 kPa) = ALI 
o PaO2:FiO2 ratio ≤ 200 mmHg (26.7 kPa) = ARDS 
• Exclusion of cardiogenic pulmonary oedema by clinical criteria 
(absence of left atrial hypertension) or by direct measurement of 
pulmonary capillary wedge pressure of < 18mmHg (2.4kPa) 
PaO2 = partial pressure of oxygen in arterial blood, FiO2 = fraction of inspired 
oxygen. Adapted from AECC 1994 definition (Bernard et al. 1994). 
 
Figure 1-1 Chest radiographs of a healthy adult and a patient with ARDS 
The chest radiograph of the patient with ARDS in B shows bilateral white (fluid-
filled) pulmonary infiltrates compared to the black (air-filled) lung fields of a 
healthy adult in A.  
A number of issues of reliability and validity with these definitions led a panel of 
international experts to meet in 2011 and revise the definition by consensus 
process. The “Berlin definition” removed the term “ALI” and incorporated it into 
three levels of ARDS severity graded by degree of hypoxaemia: 
A B 
   
  3 
• Impaired oxygenation (with a minimum PEEP of 5 cm H2O) with a 
reduced PaO2:FiO2 ratio 
o Mild ARDS: ratio is 201-300 mmHg  (26.6-29.9 kPa) 
o Moderate ARDS: ratio is 101-200 mmHg  (13.3-26.6 kPa) 
o Severe ARDS: ratio ≤ 100 mmHg  (≤13.3 kPa) 
with: 
• Acute onset lung injury (within 1 week of an apparent clinical insult with 
progressive respiratory symptoms) 
• Bilateral pulmonary infiltrates on chest radiograph not explained by 
another respiratory pathology (e.g. pleural effusion, pneumothorax or 
pulmonary nodules) 
• Exclusion of heart failure or volume overload as explanation of 
respiratory failure 
Adapted from 2012 Berlin ARDS definition (Ranieri et al. 2012). 
The term “Acute Lung Injury” or “ALI” is still nonetheless used clinically, but in 
the scientific literature it more commonly refers to experimentally induced lung 
injury in animal or human models. 
1.2.2 Epidemiology and mortality 
The largest prospective epidemiological study in 1999-2000 in the United States 
(US) estimated an age-adjusted incidence of 190,600 adult cases of ARDS in 
the US each year (Rubenfeld et al. 2005). There is some evidence to suggest 
the incidence has been decreasing over the last decade (Li et al. 2011). 
Inpatient mortality rates vary between 31 to 74% depending on the precise 
definition criteria used, with respiratory failure causing death in only 9 – 16% 
cases (Ware & Matthay 2000; Rubenfeld et al. 2005; Frutos-Vivar et al. 2004; 
Vincent et al. 2003). The Berlin definition was validated in 269 patients and 
predicts 90-day mortality according to the underlying severity: mild ARDS = 
20% (11-31 95% Confidence interval - CI), moderate ARDS = 41% (33-49%) 
and severe ARDS = 52% (36-68%), overall ARDS mortality = 36% (Ranieri et 
al. 2012).  
   
  4 
ARDS prolongs intensive care unit (ICU) admissions and leads to secondary 
hospital-acquired infections; per year in the US it was estimated to be 
associated with 3.6 million hospital days (Rubenfeld et al. 2005). 
1.2.3 Aetiology and risk factors 
The clinical conditions associated with the development of ARDS are divided 
into those originating within the lung itself (direct lung injury) and those distant 
from the lung (indirect lung injury), as shown in Table 1-1 below: 
Table 1-1 Clinical conditions associated with the development of ARDS 
Table adapted from Ware and Matthay, 2000 
In a series of 1113 patients, the commonest condition was severe sepsis (79% 
of all cases) from a suspected pulmonary (46%) or extrapulmonary source 
(33%). Less commonly associated was aspiration (11%), severe trauma (7%), 
blood transfusion (3%), drug overdose (3%) and acute pancreatitis (3%) 
(Rubenfeld et al. 2005). When 2 or more associated conditions are present, the 
risk of developing ARDS is significantly higher (Pepe et al. 1982). 
DIRECT LUNG INJURY INDIRECT LUNG INJURY 
 
Common causes 
• Pneumonia 
• Aspiration of gastric acid 
contents 
Less common causes 
• Inhalational injury 
• Pulmonary contusions 
• Fat emboli 
• Near drowning episode 
• Reperfusion injury following 
lung transplantation or 
pulmonary embolectomy 
 
 
 
Common causes 
• Severe sepsis 
• Severe trauma with shock  
                     
Less common causes 
• Cardiopulmonary bypass 
• Drug overdose 
• Acute pancreatitis 
• Transfusion-related acute lung 
injury (TRALI) 
• Disseminated intravascular 
coagulation 
• Head injury 
• Burns 
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The main independent risk factors for a poor outcome include disease severity 
as assessed by the Acute Physiology and Chronic Health Evaluation III 
(APACHE III) or the Simplified Acute Physiology II (SAP II) scores (Cooke et al. 
2008), age >60, minute ventilation >13.9L/min, respiratory rate > 21, renal 
failure, liver failure and shock (Brown et al. 2011). Additional environmental risk 
factors of particular research interest are chronic alcohol abuse (Moss et al. 
1996) and passive or active exposure to cigarette smoke, demonstrated in 
patients undergoing elective oesophagectomy (Tandon et al. 2001; Zingg et al. 
2011), or following blunt chest trauma (Calfee et al. 2011). The mechanisms of 
cigarette smoke are not fully understood but may include activation of type II 
alveolar epithelial cells with consequent neutrophil influx in response to 
mechanical ventilation (Hirsch et al. 2014). 
Research into genetic polymorphisms predisposing to the development of 
ARDS using genetic association studies has identified well over 20 candidate 
genes, whose functions in lung injury and repair give important clues about the 
pathogenesis of the condition (Gao & Barnes 2009). More recently, genome-
wide association studies have identified single nucleotide polymorphisms 
(SNPs) in the FARP2 gene (encoding a guanine nucleotide exchange factor 
that activates Rac-1, crucial in actin polymerisation, cell movement, adhesion 
and integrin signalling) and the PPFIA1 gene (encoding liprin α, also involved in 
cell adhesion, integrin function and cell-matrix interactions) as major risk 
variants for ARDS (Wurfel et al. 2014; Christie et al. 2012). 
1.2.4 Pathogenesis of ARDS 
The following processes are central to the pathophysiology of ARDS within the 
lung and occur simultaneously. Our understanding is largely inferred from 
pathohistological appearances at post mortem. 
1. Dysregulated lung inflammation with recruitment and influx of innate 
immune cells, particularly neutrophils, macrophages and dendritic cells. 
2. Exaggeration and perpetuation of the inflammatory response through 
excessive neutrophil degranulation and synthesis of inflammatory 
mediators, including proteases, reactive oxygen species and cytokines. 
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3. Damage to and death of endothelial and epithelial cells, leading to 
increased permeability and leakage of leukocytes, erythrocytes, platelets 
and protein-rich exudative fluid into the alveolar space, impaired 
synthesis and release of pulmonary surfactant with subsequent  
formation of hyaline membranes on the basement membrane, causing 
impaired gas exchange and hypoxaemia. 
4. Uncontrolled activation of the clotting cascade causing capillary 
microthromboses and impaired fibrinolysis within the alveoli. 
(Ware & Matthay 2000; Han & Mallampalli 2015) 
Ware and Matthay’s schematic diagram summarises these processes well (see 
Figure 1-2 below) 
 
Figure 1-2 Cellular processes within the alveolus during the acute phase 
of ARDS 
Image taken directly from Ware and Matthay, 2000 
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1.2.5 ARDS as a systemic disease 
Although most typically manifested in the lung, ARDS should be considered as 
a systemic inflammatory disease (Han & Mallampalli 2015). Both alveolar and 
serum levels of key pro-inflammatory cytokines such as Tumor necrosis factor α 
(TNFα), Interleukin-1β (IL-1β), IL-6 and IL-8 are raised and persist in 
unresolving cases of ARDS (Meduri et al. 2009). There is also evidence of 
systemic immunosuppression with C5a anaphylatoxin-mediated peripheral 
blood neutrophil dysfunction (Solomkin et al. 1981; Huber-Lang et al. 2002) and 
endotoxin tolerance in peripheral blood mononuclear cells (Buttenschoen et al. 
2008) that are likely to predispose ARDS patients to developing secondary 
hospital-acquired infections (HAIs). A breakdown in immune tolerance is also 
seen in over half of ARDS patients with rapid production of autoantibodies 
(Burbelo et al. 2010). 
1.2.6 Resolution of ARDS 
Effective resolution of ARDS requires re-establishment of intact epithelial and 
endothelial barrier function through proliferation and differentiation of resident 
type II alveolar epithelial cells (Adamson & Bowden 1974) or possibly from 
progenitor cells (McQualter et al. 2010), clearance of apoptotic neutrophils and 
cell debris by M2 (alternatively activated) alveolar macrophages in a process 
known as “efferocytosis” and reabsorption of alveolar fluid (Matthay et al. 2012). 
1.2.7 Animal and human models of ARDS 
Although rodent models have proven extremely useful in the study of certain 
mechanisms involved in ARDS, it should be stressed early on in this thesis that 
no single model has been able to replicate the three key features seen in ARDS 
patients: severe neutrophilic infiltration, hyaline membrane deposition and 
microthrombi formation. In essence these models allow scientists to test 
hypotheses in reproducible models of acute alveolar inflammation. Furthermore, 
myeloid cell development and distribution, pulmonary anatomy and physiology 
are markedly different between rodents and humans, meaning that translation 
of findings into human disease is challenging.  
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On the other hand, human models of ARDS such as one-lung ventilation, 
cardiopulmonary bypass, inhaled lipopolysaccharide (LPS) and ex vivo lung 
perfusion (EVLP) more closely replicate the biological mechanisms of ARDS, 
but are themselves limited by the low level of the inflammatory response as well 
as organ availability (Proudfoot et al. 2011). 
1.2.8 Existing treatments for ARDS 
The formation of the US ARDS Network (ARDSNet) by the National Heart, Lung 
and Blood Institute (NHLBI) and National Institute of Health (NIH) in 1994 has 
contributed significantly to a number of multicentre randomised clinical trials in 
ARDS. Clinical trials have tested a range of anti-inflammatory strategies with 
disappointingly little success.  
9 small randomised trials of methylprednisolone in ARDS were reviewed in a 
recent meta-analysis; although there was a trend towards a positive mortality 
benefit when administered after the onset of ARDS, no statistically significant 
effect was evident (Peter et al. 2008). Sivelestat is a potent neutrophil elastase 
inhibitor that is used widely in clinical practice in the treatment of ARDS in 
Japan. A meta-analysis of 8 clinical trials of sivelestat showed no 30-day 
mortality benefit or increase in ventilator-free days (Iwata et al. 2010), despite 
promising data from trials of experimental lung inflammation in rats (Wang et al. 
2014). Statins can influence inflammatory responses and are thought to have a 
role in predisposition to sepsis. A large ARDSNet trial of rosuvastatin in sepsis-
associated ARDS was stopped early due to futility (Truwit et al. 2014), and a 
further large multicentre double-blinded clinical trial of 540 ARDS patients given 
either 80 mg simvastatin or placebo daily showed no difference in terms of 
ventilator-free days, days free from non-pulmonary organ failure, or mortality at 
28 days (Boyle et al. 2015). 
Inhaled nitric oxide (NO) is a potent pulmonary vasodilator and inhibitor of 
neutrophil adhesion. Although a preliminary phase II trial in ARDS showed 
impressive physiological effects with improved mean PaO2 levels (Dellinger et 
al. 1998), these findings did not translate to any reversal of ARDS or mortality 
benefit (Lundin et al. 1999). 
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Exogenous surfactant therapy is of benefit in the respiratory distress syndrome 
in children, but showed no mortality benefit in a randomised, double-blind trial of 
448 adult patients with ARDS, when delivered intratracheally for 24 hours only. 
There was however a significant improvement in oxygenation compared to 
patients receiving standard therapy (Spragg et al. 2004). 
Other large randomised-controlled clinical studies showing no difference in 
mortality have tested liposomal prostaglandin E1 (Abraham et al. 1999), 
ketoconazole (ARDSNet 2000a), lisofylline (a synthetic anti-inflammatory 
molecule) (ARDSNet 2002), aerosolised β2 agonist (Matthay et al. 2011), 
intravenous β2 agonist (Gates et al. 2013) and Omega-3 fatty acid 
supplementation (Rice et al. 2011). 
The only randomised-controlled trial in ARDS to show unequivocal improved 
mortality was non-pharmacological, using “lung-protective ventilation” to limit 
ventilator-induced alveolar overdistension, or “volutrauma”. This trial compared 
the outcome of 861 ALI or ARDS patients randomised to ventilation with either a 
traditional tidal volume (VT) of 12 ml/kg of predicted body weight and higher 
airway pressures or a VT of 6 ml/kg and lower airway pressures (ARDSNet 
2000). The trial was prematurely stopped because the mortality was 
significantly lower in the 6 ml/kg group (31% vs 39.8%; p=0.007). The lower VT 
group spent significantly fewer days on a ventilator and suffered less 
extrapulmonary organ failure. Interestingly the 6 ml/kg group were numerically 
‘sicker’ despite the improved mortality, with lower PaO2, increased PaCO2 and 
lower pH values. This led to the term “permissive hypercapnia” being adopted in 
ARDS clinical management. 
A number of studies have tried to investigate the optimum level of PEEP to 
maximise oxygenation through alveolar recruitment and prevention of cycles of 
recruitment and derecruitment (“atelectrauma”), without causing circulatory 
depression and further lung injury from alveolar stretch. Another big ARDSNet 
trial in 2004 tested whether higher PEEP in ALI/ARDS patients (of less than 36 
hours) receiving mechanical ventilation with a VT of 6ml/kg improves clinical 
outcomes (Brower et al. 2004). The study was stopped early at the second 
interim analysis due to futility. Higher PEEP levels were actually associated with 
increased airway pressure, dead space and decreased venous return. A further 
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study in 2008 compared the “open-lung” strategy of a VT of 6 ml/kg, plateau 
airway pressures of ≤ 40cm H2O, recruitment manoeuvres and higher levels of 
PEEP with the control established strategy of a VT of 6 ml/kg, plateau airway 
pressures of ≤ 30cm H2O and lower levels of PEEP in 983 patients with ARDS 
(Meade et al. 2008). The open-lung strategy resulted in no difference in hospital 
mortality or barotrauma. A similar study tested whether increasing alveolar 
recruitment while limiting hyperinflation by setting a level of PEEP to achieve a 
plateau airway pressure of 28-30 cm H2O reduced mortality (Mercat et al. 
2008). Although there was no effect on mortality, the strategy improved lung 
function and decreased duration of mechanical ventilation and organ failure. 
Prone position ventilation is known to improve oxygenation in severe ARDS by 
a number of mechanisms. A recent non-blinded, randomised-controlled trial in 
severe ARDS compared early prone positioning for at least 16 consecutive 
hours per day with supine positioning and found a 50% relative reduction in 28-
day mortality in the prone group (16% prone vs 32.8% supine; p<0.001) and a 
significant reduction in unadjusted 90-day mortality (23.6% prone vs 41% 
supine; p<0.001) (Guérin et al. 2013). The control (supine) group were however 
more severely ill with higher Sequential Organ Failure Assessment (SOFA) 
scores and increased vasopressor requirements, whereas the prone group 
received more neuromuscular blockers, making the results more difficult to 
interpret.  
Early administration of short-term neuromuscular blockers in severe ARDS may 
be of benefit (Papazian et al. 2010). Although the authors report a significant 
adjusted in-hospital 90-day mortality benefit (31.6% vs 40.7%; p=0.08), the 
trial’s original primary outcome was crude 90-day mortality (i.e. mortality rate at 
90 days irrespective of location), affecting the validity of the results. The study 
needs to be repeated. 
Further key clinical studies in ARDS have aimed to assess whether patients 
should be managed with fluid restriction or diuresis. Theoretically this should 
reduce pulmonary microvascular pressure and resultant alveolar oedema, 
which contributes to the marked hypoxaemia in ARDS. In 1000 ALI/ARDS 
patients, haemodynamic management guided by pulmonary artery catheter 
insertion offered no improvement in survival or organ function over central 
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venous catheter insertion, and was actually associated with more complications 
(Wheeler et al. 2006). In the same patients, liberal fluid management was 
compared with conservative fluid management (using fluid restriction or 
diuresis) according to explicit protocols and although 60-day mortality was 
unchanged, lung function and duration on a ventilator or in intensive care were 
reduced in the conservative fluid group, with no increased need for 
cardiovascular or renal support (Wiedemann et al. 2006). 
There are no published guidelines in ARDS, but the current principles of best 
practice are summarised below: 
1. Treat underlying cause (e.g. antibiotics for pneumonia or sepsis) 
2. Protective lung ventilation with low tidal volumes and plateau-pressure 
limitation 
3. Titration of FiO2 and PEEP to achieve O2 saturations of > 88% 
4. Conservative fluid management once shock is treated 
5. Consider neuromuscular paralysis, prone positioning, extracorporeal 
membrane oxygenation (ECMO) or high frequency oscillatory ventilation 
(HFOV) in severe ARDS with refractory hypoxaemia 
6. Standard supportive care of critically ill patients with thromboprophylaxis 
to prevent deep vein thrombosis, optimum blood glucose control, 
prophylaxis against stress-induced gastrointestinal bleeding, 
haemodynamic support to maintain a mean arterial pressure >60mmHg, 
enteral nutrition and blood transfusions in patients with haemoglobin 
<7g/dL. 
Adapted from BMJ Best Practice Online (Ware 2014) 
1.2.9 Emerging treatments for ARDS 
A myriad of studies have tested treatment strategies for ALI and ARDS in a 
variety of in vitro, ex vivo and in vivo human and animal models. These have all 
furthered our understanding of the pathogenesis of the condition. I have 
focussed on a few potential therapeutic targets below: 
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1. Cellular therapy with allogeneic human mesenchymal stem cells 
Mesenchymal stem cells (MSCs) represent a promising new potential therapy in 
ARDS. They are simple to culture from adipose tissue or bone marrow and do 
not raise the same ethical issues as embryonic stem cells. The cells can 
differentiate into alveolar epithelial or pulmonary endothelial cells to repair 
cellular injury in ARDS. In mice subjected to intratracheal delivery of E. coli, 
intravenous murine non-autologous MSCs reduced markers of oxidative stress 
within bronchoalveolar fluid (BALF) but markers of bacterial survival and 
replication were not measured (Shalaby et al. 2014). These findings were 
recently replicated in a similar E. coli model in rats, in which MSC treatment 
actually enhanced antimicrobial activity in the lung through antimicrobial peptide 
(LL37) release.  The capacity of ex vivo peripheral blood monocytes to 
phagocytose live bacteria was also increased in mice receiving MSC treatment. 
MSCs also increased the in vitro phagocytic capacity of the murine macrophage 
U937 cell line (Devaney et al. 2015). The mechanism of action of MSCs is 
fascinating. Using vital imaging with confocal and 2-photon microscopy, Islam et 
al. convincingly showed that bone-marrow derived stromal cells delivered 
intranasally appear to transfer mitochondria to pulmonary alveolar epithelial 
cells through connexin 43-containing gap junctional channels to increase 
alveolar adenosine triphosphate (ATP) levels and attenuate LPS-induced 
murine lung inflammation (Islam et al. 2012). Intratracheal therapy is also 
effective in an ex vivo perfused human lung model of E. coli endotoxin-induced 
injury and the mechanism is mediated by secretion of keratinocyte growth factor 
(KGF) (Lee et al. 2009). This finding led to a study testing whether recombinant 
KGF (palifermin) reduces alveolar injury in a human model of ARDS, in which 
healthy volunteers inhale LPS. Intravenous KGF was safe and although it did 
not affect levels of alveolar neutrophil recruitment or protein leak, KGF 
promoted surfactant protein D release and induced a pro-resolutionary 
environment in the lung (Shyamsundar et al. 2014). A multicentre randomised 
placebo-controlled trial of KGF is now underway to test whether KGF itself can 
improve oxygenation in patients with ARDS (Cross et al. 2013). 
Furthermore, a Phase 1 study of intravenous adipose tissue-derived MSC 
therapy in 12 ARDS patients demonstrated safety (Zheng et al. 2014) and a 
further Phase 1/2 trial of intravenous bone-marrow derived MSCs in 69 
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moderate/severe ARDS patients in the US is currently recruiting (Liu et al. 
2014), with a United Kingdom (UK) study also in preparation.  
2. Aspirin 
Neutrophil-platelet interactions contribute to inflammation in ARDS (Bozza et al. 
2009). In a prospective study of 202 ARDS patients, aspirin therapy (either pre-
hospital, in intensive care, or both) was associated with reduced mortality after 
multivariate analysis (Boyle et al. 2015). Aspirin was effective in attenuating 
lung injury in transfusion-related and acid-induced murine lung inflammation 
(Looney et al. 2009) and a clinical trial to test whether aspirin therapy is 
preventative in patients at high risk of developing ALI is recruiting at present 
(Kor et al. 2012). 
3. Ubiquitin-proteasome system 
Ubiquitin is a small molecule widely expressed across most mammalian cells. It 
marks proteins for degradation in the proteasome in a process known as 
“ubiquitination”. The final step of this process involves the action of one of 
hundreds of different ubiquitin ligases (E3 ligases) and offers a mechanism for 
selective therapeutic intervention (Bonifacino & Weissman 1998; Han & 
Mallampalli 2015). In ARDS the ubiquitin-proteasome system is activated 
(Vadász et al. 2012). One example of its action is the regulation of the Na, K-
ATPase pump on alveolar epithelial cells that drives lung fluid clearance. In 
hypoxic conditions, the ion pump is degraded by ubiquitination, reducing 
alveolar fluid clearance (Dada et al. 2007). Proteasome inhibitors are in 
development as cancer therapies and evidence suggests that they may induce 
anti-inflammatory effects (Mallampalli et al. 2013). 
1.2.10 Neutrophils and ARDS 
Neutrophils are key cellular mediators involved in rapidly responding to and 
clearing bacterial and fungal infection. They are recruited early to the alveoli of 
patients with ARDS and their levels correlate with degree of hypoxia and protein 
leak and clinical outcome (Parsons et al. 1985; Weiland et al. 1986; Steinberg 
et al. 1994). When neutrophils are depleted in mice with cyclophosphamide or 
anti-neutrophil antibodies, LPS or haemorrhage-induced lung inflammation is 
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significantly reduced in mice, indicating a causative role (Abraham et al. 2000). 
Similarly, IL-8-mediated neutrophil recruitment is blocked when rabbits exposed 
to acid-induced lung inflammation are pre-treated with an anti-IL-8 monoclonal 
antibody (Folkesson et al. 1995). 
Acute alveolar inflammation induces release of inflammatory mediators from 
platelets (Bozza et al. 2009), alveolar macrophages and epithelial cells, 
including the cytokines IL-1, IL-6, IL-8 and TNFα (Donnelly et al. 1993; Pugin et 
al. 1996; Chollet-Martin et al. 1996). The lung is unique in that primed 
circulating neutrophils become trapped or ‘sequestered’ in both postcapillary 
venules of the systemic circulation and alveolar capillaries of the pulmonary 
circulation through selectin and integrin-dependent mechanisms of tethering, 
rolling, activation and adhesion (Zemans et al. 2009; Gane & Stockley 2012). 
The activated neutrophils can then migrate through the inflamed endothelium 
along chemotactic gradients into the lung alveoli or interstitium (Maniatis et al. 
2008). Interestingly, it has been put forward that the lung has the capability of 
regulating this process by ‘deactivating’ neutrophils, since only about 60% of 
peripheral blood neutrophils are activated in an acute inflammatory response, 
when 100% of the cardiac output passes through the lung vasculature 
(Summers et al. 2010).  
Appropriately activated neutrophils transmigrate the endothelium and release 
their granule contents extracellularly through a process known as degranulation. 
Neutrophil apoptosis is delayed by macrophages to maximise pathogen 
recognition, phagocytosis and killing (Chopra et al. 2009).  
Phagocytosis and killing of invading pathogenic microorganisms by neutrophils 
is a complex mechanism involving ingestion of opsonised organisms, fusion of 
the resulting phagosome with intracellular granules to form a phagolysosome 
and simultaneous assembly of the enzyme nicotinamide adenine dinucleotide 
phosphate (NADPH) oxidase to generate reactive oxygen and reactive nitrogen 
species. The microorganism is rapidly degraded by the combined action of 
proteases, reactive species and pH changes of the phagolysosomal 
environment just minutes after being phagocytosed (Segal 2005; Nauseef 
2007).  
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Predicting the precise fate of the neutrophil after phagocytosis and bacterial 
killing is not fully understood. We know that activated neutrophils can lyse, 
necrose, apoptose or undergo an alternative programmed cell death sometimes 
known as ‘NETosis’ involving neutrophil extracellular trap (NET) formation. 
NETs are composed of chromatin and selected granule and cytoplasmic 
proteins. They are potently microbicidal and are thought to contribute to further 
extracellular bacterial killing in vivo (Brinkmann et al. 2004). 
Overexuberant neutrophil activation causes direct and indirect tissue injury by 
release of proteases, cytokines and reactive oxygen species (ROS) (Grommes 
& Soehnlein 2011). Extracellular release of granule products is potently anti-
microbial, pro-inflammatory and can therefore be considered as a physiological 
response when regulated, but dependent on the size of the inflammatory 
stimulus and the intensity of the neutrophil response, excessive neutrophil 
granule release may become pathological by causing damage to the alveolar 
epithelium, increased permeability and protein-rich fluid leak into the alveolar 
space (Hogg 1994). Human neutrophil elastase (HNE) degrades pulmonary 
surfactant, further contributing to alveolar collapse and injury (Liau et al. 1996). 
Neutrophil-dependent processes have therefore been the therapeutic targets of 
numerous previous animal models of acute lung inflammation. More than 50 
inhibition or knockout studies have targeted cytokines (TNFα, IL-1β), 
chemokines (IL-8 and its neutrophil receptor CXCR2), cell adhesion molecules 
(selectins and β2 integrins), granule proteins (HNE, matrix metalloproteinases = 
MMP-8 and 9, cathepsin-G) or free radical release (through inhibition or gene 
deletion of NADPH oxidase and nitric oxide synthase) (Grommes & Soehnlein 
2011). The majority of these studies demonstrated a protective effect, but it is 
important to consider publication bias in favour of positive studies. Translation 
of neutrophil therapies into clinical trials has proven difficult due to the 
heterogeneous nature of ARDS patients and redundancy of the molecules 
involved. 
This thesis sought to tackle the challenge of inhibiting the mechanisms of 
degranulation in neutrophils, while maintaining sufficient neutrophil recruitment 
and function to achieve effective bacterial phagocytosis and killing.  
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 Regulation of Degranulation in Neutrophils 1.3
1.3.1 Granule sorting 
Neutrophils comprise 60-70% of circulating white blood cells in humans, but 
only 10-20% in mice (Doeing et al. 2003). They possess a short lifespan but 
their numbers in peripheral blood can increase several-fold when mobilised 
from bone marrow in response to infection. When fully mature, they have limited 
ability to synthesise proteins de novo, but their cytoplasm is packed with pre-
formed granules capable of being released in large quantities into phagosomes 
or extracellularly by degranulation.  
In the literature, the term ‘degranulation’ is commonly confused with the term 
‘exocytosis’. For clarification, ‘exocytosis’ refers to the energy-dependent fusion 
of an intracellular vesicle with the plasma membrane, whereas ‘degranulation’ 
refers to the process by which granules containing anti-microbial cytotoxic 
molecules are released extracellularly from the plasma membrane or into 
intracellular membrane-bound phagosomes (or both).  
During the stages of neutrophil differentiation, groups of granule proteins are 
sequentially generated and packaged into specific granule subsets: first 
primary, or “azurophilic” granules, containing potent enzymes such as 
myeloperoxidase (MPO), proteinase-3, cathepsins, defensins and HNE; then 
secondary or “specific” granules, predominantly containing the antimicrobial 
protein lactoferrin (LTF), lysozyme and alkaline phosphatase and then finally 
the tertiary granules, containing mainly MMP-8 and MMP-9 (Gullberg et al. 
1997). A separate, fourth granule containing L-ficolin-1, an opsonin capable of 
activating the lectin complement pathway, has also been identified (Rorvig et al. 
2009). “Secretory vesicles” are also present and contain albumin and de novo 
synthesised cytokines. The precise mechanisms of granule sorting are not fully 
understood. Most granule enzymes are synthesised in an inactive form and 
require conversion into their active form through proteolytic cleavage, a process 
dependent on the charged acidic environment generated within lysosomes 
(Sheshachalam et al. 2014). 
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1.3.2 Granule release 
Upon stimulation, granule subsets have variable propensities for release by 
degranulation.  Granules formed later in neutrophil differentiation are released 
more readily. When stimulated with N-Formylmethionyl-leucyl-phenylalanine 
(fMLP), human neutrophils release 100% secretory vesicles, 38% tertiary 
granules, 22% of secondary granules and 7% of primary granules; their release 
appears dependent on relative sensitivity to increasing intracellular Ca2+ 
concentrations (Sengeløv et al. 1993; Sengeløv et al. 1995). 
 
Figure 1-3 Schematic diagram of the main neutrophil signalling pathways 
regulating degranulation 
GPCR=G-protein coupled receptor, Src=src kinase, Syk=syk kinase, 
PI3K=phosphoinosotide 3-kinase, PLC=phospholipase C, PKC=protein kinase 
C, Pyk2=proline rich kinase 2. Adapted from Sheshachalam et al, 2014 
The mechanisms that regulate granule mobilisation and degranulation are 
highly complex and of central importance to this thesis. Figure 1-3 summarises 
the main identified pathways. Granules are mobilised by translocation along 
actin and tubulin networks, a process regulated by Rab, a small GTPase in the 
Ras superfamily. Membrane fusion is mediated by the formation of Soluble N-
ethylmaleimide-sensitive factor Attachment Protein Receptor (SNARE) 
complexes between vesicle SNARE proteins (v-SNAREs) and target SNARE 
proteins (t-SNAREs) (Toonen & Verhage 2003; Lacy & Eitzen 2008). 
granule(
granule(
granule(
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1.3.3 Granule mobilisation is controlled by src kinases 
Upstream of the fusion machinery, it is believed that degranulation is controlled 
by two binary signals, both of which signal via the src family of non-receptor 
tyrosine kinases (Sheshachalam et al. 2014). Tyrosine kinases are 
phosphorylated by receptor stimulation and are differentiated by their 
association to either the intracellular component of receptors (receptor tyrosine 
kinases) or cytoplasmic enzymes (non-receptor tyrosine kinases).  
The first of these two binary signals is adhesion-dependent, involving β2 
integrins (Sengeløv et al. 1995) in vivo or by contact with biological surfaces in 
vitro (Nathan 1987). Complement receptor 3 (CR3)-mediated phagocytosis is 
itself mediated through β2 integrin, inducing conformational changes through 
Rho G-protein activation (Caron & Hall 1998). Mocsai et al. identified a central 
role of the src family kinases Hck and Fgr in adhesion-dependent degranulation 
(Mócsai et al. 1999). Neutrophils adherent to fibrinogen or tissue culture plastic 
exhibit impaired degranulation when treated with the pan-src kinase inhibitor 
PP1. Similarly, neutrophils from Hck-/- Fgr-/- double knock-out mice adhere 
normally but cannot degranulate. This observation was not replicated in single 
knock-out Hck-/- or Fgr-/- mice. 
A role for the highly expressed cytosolic non-receptor tyrosine kinase, proline-
rich kinase 2 (pyk2), in transducing integrin-dependent signals to granule 
mobilisation has been discovered in pyk2-/- deficient mice (Kamen et al. 2011). 
The mechanism was shown to be dependent on phosphorylation of Vav (a Rac 
activator) and paxillin (microtubule assembly). 
The second binary signal is dependent on receptor-mediated activation, leading 
to phosphorylation of src kinases and initiation of a kinase cascade. For 
example, the formylated peptide receptor 1 (FPR1) is a G-protein coupled 
receptor (GPCR) activated by formylated peptides formed by bacteria 
degradation and tissue injury. Neutrophils from Hck-/- Fgr-/- and Hck-/- Fgr-/- Lyn-/- 
knock-out mice do not degranulate or release extracellular superoxide in 
response to fMLP, but can increase Ca2+ influx (Fumagalli et al. 2007). The 
precise mechanisms linking GPCR activation with src kinase phosphorylation 
are not fully understood, but they are likely to occur in parallel to GPCR 
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activation of the phosphoinosotide 3-kinase γ (PI3Kγ) and phospholipase Cβ 
(PLCβ) pathways (Futosi et al. 2013).  
Fcγ receptors on neutrophils, particularly FcγR1 (CD64), recognise 
immunoglobulin (Ig)G-opsonised microbes and initiate phagocytosis via Cdc42 
and Rac (Caron & Hall 1998). The mechanism of degranulation was previously 
thought to be independent of src kinases, through activation of another 
important non-receptor tyrosine kinase Syk kinase, also downstream of src 
kinases in the kinase cascade (Kiefer et al. 1998; Mócsai et al. 2002). However, 
recently published data by Mocsai’s group showed that Hck-/- Fgr-/- Lyn-/- triple 
knock-out mice were unable to generate an in vivo pro-inflammatory 
environment in a model of autoantibody (FcR)-mediated skin inflammation, 
suggesting that src kinases are also integral to FcR-mediated degranulation 
(Kovács et al. 2014). Although no myeloid cells accumulated at the site of 
inflammation (resembling the phenotype of β2 integrin deficient mice), there was 
not a true impairment in migration, confirmed when they produced chimeras 
with ½ wild-type myeloid cells and ½ Hck-/- Fgr-/- Lyn-/- deficient cells. 
Although both the binary signals described above are mediated through src 
kinase phosphorylation, each signal requires an activation threshold to initiate 
degranulation, preventing the adverse effects of degranulation with lesser 
stimuli (Sheshachalam et al. 2014). However, this tight regulation is lost in a 
number of inflammatory conditions, including ARDS, severe asthma, 
rheumatoid arthritis, septic shock and ischaemia/reperfusion injury. Further 
understanding the mechanisms of degranulation, particularly those regulating 
individual granule subset translocation and fusion with specific membranes,  
may offer a number of exciting new therapeutic targets in these conditions. 
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 Src Kinases 1.4
1.4.1 Biology of src kinases 
 
Figure 1-4 Regulation of src kinase activation 
SH3 = Src Homology 3 Domain, SH2 = Src Homology 2 Domain. Adapted from 
Frame 2002 
The Src family of tyrosine kinases includes 8 identified members in human cells: 
c-src, Fyn and Yes are ubiquitously expressed in all cell types; Fgr, Hck and 
Lyn are predominantly expressed in granulocytes, monocytes and 
macrophages; whereas Blk and Lck are also found in lymphocytes (Thomas & 
Brugge 1997). All src kinases share a common regulatory mechanism, shown in 
Figure 1-4 above. Activity is regulated at two sites: phosphorylation of Tyr416 in 
the catalytic domain switches on enzyme activity, while phosphorylation of 
Tyr527 in the carboxy-terminal tail switches off enzyme activity (Hunter 1987). 
Src kinases are activated by interaction with a variety of cell-surface receptors 
and they can activate enzymes at the plasma membrane, the actin cytoskeleton 
and at cell-cell adhesions. As a result, they have a pivotal role in regulating 
numerous key cellular functions, including proliferation, differentiation, survival, 
motility and acute inflammatory responses (Okutani et al. 2006). Indeed c-src 
(short for sarcoma) was the first discovered oncogene and led to a Nobel Prize 
for its discovery (Oppermann et al. 1979). C-src overexpression is observed in 
about 50% of colon, liver, lung, breast and pancreas tumours (Dehm & Bonham 
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2004). Most of the research into src kinases over the last 35 years has therefore 
been in the field of oncology, but many researchers have also studied their role 
in immune cell signalling. 
1.4.2 Src kinases and ARDS 
Much of our current understanding has come from in vivo studies of LPS-
induced lung inflammation in animals, using either pharmacological inhibition of 
src kinases or knock-out models. A number of small chemical src kinase 
inhibitors have been developed for cancer treatment, including the 
pyrrolopyrimidines PP1 and PP2. As discussed in section 1.2.7 above, when 
interpreting data from rodent models, a note of caution should be observed 
before applying it to ARDS in humans.  
A handful of key studies have implicated src kinase activation in the 
pathogenesis of ARDS. In rats subjected to oxidant stress induced by 
haemorrhagic shock/resuscitation followed by intratracheal LPS, alveolar 
macrophages showed increased Hck activation by Western blotting compared 
to sham animals treated with LPS. Pre-treatment with PP2 reduced this 
augmented effect in vivo (Khadaroo et al. 2004). Severgnini et al. demonstrated 
that both intraperitoneal and intranasal LPS exposure in mice induces signal 
transducers and activators of transcription (STAT) transcription factors in whole 
lung samples, peaking at 1 h (all lung cells) and 6 h (neutrophils and 
monocytes). Both Janus kinase (JAK) and src kinases are known to activate 
STAT3. Western blot analysis showed activation of JAK and src kinases at 30 
min with a peak at 2 h, correlating with the peak in STAT3. The same 
observation was seen in acid-induced lung inflammation (Severgnini et al. 
2004). The authors went on to test PP2 and another selective src kinase 
inhibitor, SU-6656, in the same model. Both inhibitors attenuated lung 
inflammation, capillary permeability and LPS-induced cytokines levels, even 
when given up to 6 h after LPS. Both STAT3 phosphorylation and JAK 
activation were reduced, suggesting that JAK/STAT are downstream of src 
kinases, as PP2 does not inhibit JAK. PP2 also reduced mortality when mice 
were given a lethal dose of LPS (Severgnini et al. 2005). Lee et al. then 
demonstrated that PP1 pre-treatment of mice undergoing LPS challenge 
blocked nuclear factor κB (NF-κB) activation, with an associated reduction in 
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integrin signalling. Pre-treated mice had less lung inflammation, as measured 
by alveolar protein leak, neutrophil recruitment and alveolar TNFα and MMP-9 
levels (Lee et al. 2007). 
As discussed earlier, mechanical ventilation may contribute to the pathogenesis 
of ARDS. Mechanical strain induces c-src activation in fetal rat lung cells and 
the injury is accentuated by phosphotyrosine phosphatases (which prevent 
deactivation of tyrosine kinases) and attenuated by tyrosine kinase inhibition 
(Liu et al. 1996; Parker et al. 1998). A more recent study investigated the anti-
inflammatory properties of the anaesthetic ropivacaine on a ‘double-hit’ murine 
model of ARDS, involving LPS exposure and volutrauma from high tidal volume 
ventilation (Piegeler et al. 2014). Ropivacaine reduced excess lung water 
parameters and MPO activity, and the effect appeared to be through inhibition 
of src activation and phosphorylation of intercellular adhesion molecule-1 
(ICAM-1) and caveolin-1, which maintain pulmonary endothelial barrier function. 
A major challenge to dissecting out the roles of individual src kinases is the lack 
of specificity of the available inhibitors. Specificity of expression in certain cell 
types and transgenic models give further clues about their individual roles, but 
like all tyrosine kinases they are likely to exhibit considerable redundancy in 
function. In an endotoxic shock model involving intraperitoneal injection of LPS, 
Hck-/- Fgr-/- double knock-out mice showed only 20% mortality at high dose LPS 
(30 mg/kg) and 0% mortality at lower doses (≤ 20 mg/kg), compared to wild type 
mice that showed 50% mortality at low dose LPS (5 mg/kg) and 100% mortality 
at doses ≥ 10 mg/kg (Lowell & Berton 1998). This effect was not observed in 
single knock-out mice. The double knock-out mice displayed clinical signs of 
endotoxaemia and had equally high levels of inflammatory cytokines. Unlike 
wild type mice, that became neutropenic in peripheral blood due to 
sequestration in the tissues with accompanying exponential end-organ injury 
until 48 h, Hck-/- Fgr-/- mice showed a dramatic rise in peripheral blood 
neutrophils after an initial 2-4 h dip, with markers of end-organ injury peaking at 
6 h and remaining stable until 48 h. It therefore seems that Hck and Fgr, in 
combination, are responsible for amplifying and perpetuating the inflammation 
induced by LPS. However, when Hck alone was rendered constitutively active 
in HckF/F “knock-in” mice, spontaneous lung inflammation occurs with extensive 
eosinophilic and mononuclear cell infiltration into the alveoli and lung 
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interstitium. Unsurprisingly these mice are exquisitely sensitive to LPS (Ernst et 
al. 2002). 
A role in mediating lung inflammation in ARDS has been attributed to other src 
kinases also expressed in non-myeloid cells, such as endothelial cells. In 
bovine pulmonary endothelial cells exposed to both LPS and TNFα, PP1 and 
PP2 inhibited inducible nitric oxide synthase (iNOS) expression and NO 
production (Chang et al. 2008). NO overproduction has been implicated in the 
pathogenesis of ARDS. The authors then used short interfering ribonucleic acid 
(siRNA) techniques on cultured human pulmonary microvascular endothelial 
cells to identify the specific src kinases involved. Fyn, Yes, c-src, Lyn, but not 
Blk, could all be inhibited by siRNA, but only Fyn inhibition prevented NO 
production in this model. Interestingly, Lyn has recently been shown to have an 
opposing role, compared to other endothelial src kinases, Yes and c-src (Han et 
al. 2013). Lyn-/- single knock-out mice showed increased mortality and vascular 
permeability in response to LPS or vascular endothelial growth factor (VEGF) 
challenge compared to wild type. The effect is mediated via focal adhesion 
kinase (FAK) co-localisation and phosphorylation by Lyn, leading to stabilisation 
of endothelial adherens junctions. 
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 Summary  1.5
Putting these findings together, the published literature suggest that src kinases 
have a central role in the acute inflammatory responses implicated in the 
pathogenesis of ARDS, through recruitment, activation and degranulation of 
leukocytes and dysregulation of vascular permeability. Src inhibition therefore 
holds great promise as a therapeutic strategy in ARDS, as well as other 
conditions characterised by an acute inflammatory response. Some of the side 
effects of long-term treatment with src kinase inhibitors are likely to be avoided 
with short-term use, but dosing and timing in relation to the inflammatory 
response remain a significant challenge. 
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 Unanswered Questions  1.6
Until now, in vivo studies have mainly been carried out using LPS to induce lung 
inflammation. Although this model utilises a reliable stimulus and permits 
identification of some underlying mechanisms, it is extremely difficult to draw 
direct parallels with the wide clinical spectrum of ARDS. More clinically relevant 
in vivo animal models should therefore test pathogen-induced lung 
inflammation. Until now these models have not been used to test src kinase 
inhibition. There is an obvious concern that, in the presence of infection, 
inhibition of acute inflammation may lead to detrimental effects by impairment of 
phagocytosis and bacterial killing by neutrophils and macrophages. For 
example, in mice exposed to intratracheal Pseudomonas aeruginosa, 
neutralising antibodies to CXCR2 (IL-8β receptor) markedly attenuated 
neutrophil recruitment, bacterial clearance and increased mortality (Tsai et al. 
2000). Conversely, when the anti-inflammatory cytokine IL-10 is neutralised in 
mice exposed to intratracheal Klebsiella pneumoniae, pre-treated mice had 
significantly less bacteria in lung homogenates with improved survival, 
suggesting that adequate clearance of bacteria requires a rapid and vigorous 
innate immune response (Greenberger et al. 1995). 
How src kinases control other key functions of neutrophils, such as CR3-
mediated and FcR-mediated phagocytosis, intracellular bacterial killing, 
apoptosis and oxidative burst, has not been fully characterised. While carrying 
out my in vitro studies described in Chapter 3, Mocsai’s group published an 
investigation into the effects of a clinically licensed oral src/Abl kinase inhibitor, 
dasatinib, on pro-inflammatory functions of human neutrophils (Futosi et al. 
2012). Interestingly there was little effect on phagocytosis and bacterial killing, 
raising further hope for a safe therapeutic role of src kinase inhibition in ARDS.  
When infection is not the initial trigger mechanism, such as in acid-induced lung 
inflammation, src kinase inhibition may prove effective in blocking excessive 
neutrophil degranulation. Although the mechanisms of lung inflammation differ 
from those already studied in LPS-induced injury, neutrophils remain key 
cellular mediators of injury. Acid aspiration is the third commonest cause of 
ARDS, accounting for 1 out of every 10 cases and therefore represents a valid 
and novel model in which to study src kinase inhibition. 
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The resolution phase of ARDS is equally as important as the initiation phase, 
though it is often overlooked in clinical research, where the focus is 
understandably on improving short-term mortality. It is also very challenging to 
research at an in vitro level, where the complex interplay of pro- and anti-
inflammatory signals are impossible to recreate. However, the secondary 
effects of inhibiting src kinases in neutrophils on subsequent apoptotic cell 
clearance has not been studied and would be of great interest. An anti-
inflammatory strategy such as this may actually promote effective resolution. 
Having identified these important areas of study, I will now present my thesis 
aims and hypotheses, based on my analysis of the published clinical and 
scientific literature to date. 
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 Aims and Hypotheses 1.7
In this thesis I will address 3 main bodies of work to test my 3 main hypotheses. 
They will comprise the three results chapters 3, 4 and 5. 
1.7.1 An investigation into the effects of src kinase inhibitors on 
neutrophil function in vitro 
In Chapter 3, I will test my first hypothesis: 
1. “In vitro src kinase inhibition in human neutrophils reduces extracellular 
degranulation in response to both chemical and live bacterial stimuli, without 
impairing efficient neutrophil phagocytosis and intracellular killing of 
bacteria” 
As part of this work, I will also aim to design and optimise assays for use in 
future in vivo and in vitro experiments. I will further describe the effect of src 
kinase inhibition on other key neutrophil functions, determine optimum 
concentrations of inhibitors for use in future experiments and select an inhibitor 
for use in in vivo models of bacteria and acid-induced lung inflammation. 
1.7.2 An investigation into the effect of src kinase inhibition on in vivo 
models of bacteria and acid-induced acute lung inflammation 
In Chapter 4, I will test my second hypothesis: 
2. “Inhibition of the src kinase pathway attenuates neutrophil recruitment to the 
alveolar and interstitial spaces, neutrophil degranulation and endothelial cell 
injury and leak in in vivo models of bacteria and acid-induced acute lung 
inflammation” 
This novel in vivo work will also test whether src kinase inhibitors, when 
administered systemically, may induce a detrimental outcome by inhibiting 
innate immune cell clearance of bacteria. 
1.7.3 An investigation into the effect of src kinase inhibitors on the 
processes of neutrophil-mediated epithelial cell damage and 
macrophage efferocytosis of apoptotic cells 
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The in vitro work in Chapter 5 is novel, but based on my interpretation of 
previously published data, I would hypothesise that: 
3. “In vitro src kinase inhibition of human neutrophils attenuates neutrophil-
mediated epithelial cell damage whilst promoting a pro-resolutionary 
environment, allowing efficient apoptotic cell clearance” 
I will also design in vitro and ex vivo models, with the common stimulus of live 
bacteria, to test my hypothesis and investigate underlying mechanisms. 
  
   
  29 
  
   
  30 
  
   
  31 
Chapter 2. Materials and Methods 
 Chapter Overview 2.1
This chapter details the experimental techniques I used to test my hypotheses. 
Materials, reagents and their suppliers are listed, followed by a detailed 
explanation of the methods, referencing the subsequent results chapter(s) in 
which each individual method is utilised. The precise experimental protocols for 
Chapter 5 are more complicated and I have therefore included these together 
with the results in Chapter 5 itself, to aid the reader in interpreting the data.  
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 Materials, Reagents, Animals, Bacteria and Cell Lines 2.2
This section details all the materials, reagents, animals, bacterial strains and 
cell lines used in the experiments, together with their suppliers. The details of 
individual laboratory machine equipment is included within the methods section. 
2.2.1 Materials 
Scientific Laboratory Supplies Ltd. (Nottingham, UK) 
• 40 µm cell strainer 
• Corning 75 cm2 tissue culture flasks 
• Corning tissue culture-treated 24-well sterile plates 
• NUNC Maxisorp flat bottom 96 well enzyme linked immunoabsorbent 
assay (ELISA) microplates 
Greiner Bio-One Ltd (Stonehouse, UK)  
• 15 ml and 50 ml Falcon tubes 
• 30 ml universal containers 
• 7 ml Bijou tubes 
• Polystyrene (96 well) flat bottom microplates 
Life Technologies (Paisley, UK) 
• 0.5, 1.5 and 2 ml eppendorf tubes 
• 0.2 um syringe filters 
Becton Dickinson (BD) Biosciences (Oxford, UK) 
• Fluorescence-activated cell sorting (FACS) tubes 
• Vacutainer® heparin tubes  
Appleton Woods Ltd. (Birmingham, UK) 
• Corning 24 well Transwell filters, clear polyester membrane, 6.5 mm, 3.0 
um pore size 
• Corning 24 well Transwell filters, clear polyester membrane, 6.5 mm, 0.4 
um pore size 
Merck Millipore (UK) Ltd. (Feltham, UK) 
• Millicell Hanging Cell Culture Insert, polyethylene terephthalate, 1.0 µm 
pore size 
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VWR International Ltd. (Leicester, UK) 
• 13 mm cover slips 
Miltenyi Biotec Ltd. (Surrey, UK) 
• CD14 microbeads 
• Human MACS Magnetic separation (MS) columns 
Bertin Technologies (France) 
• 2 ml homogeniser tubes (Precellys Ceramic Kit 1.4 mm) 
Sigma Aldrich Ltd. (Gillingham, UK) 
• 3MM Whatman blotting paper (10 cm x 100 m) 
• Corning microscope slides, frosted one end, one side 
GE Healthcare Life Science (Little Chalfont, UK) 
• Amersham Hyperfilm (18 x 24 cm) 
Beckman Coulter (UK) Ltd. (High Wycombe, UK) 
• Flow-Check Fluorospheres 
2.2.2 Reagents 
Sigma Aldrich Ltd. (Gillingham, UK) 
• 2% Gelatin solution 
• 4-(2-Aminoethyl) sulfonyl fluoride hydrochloride (AEBSF) 
• 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES)  
• 4′,6-diamidino-2-phenylindole dihydrochloride (DAPI) 
• Acetone 
• Bovine serum albumin (BSA) 
• Antipain 
• Aprotinin 
• Avertin 
• Benzamidine 
• Beta-mercaptoethanol 
• Calcium chloride 
• Chymostatin 
• Cytochalasin B 
• Cytochalasin D 
• Cytochrome c 
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• Dimethoxybenzidine (DMB) 
• Dimethyl sulfoxide (DMSO) 
• DPX 
• Dulbecco's phosphate buffered saline (PBS) 10X (no Ca2+, no Mg2+) and 
Dulbecco's PBS 1X (no Ca2+, no Mg2+) 
• Ethylenediaminetetraacetic acid (EDTA) 
• Foetal calf serum (FCS) 
• Giemsa stain 
• Glycerine 
• Glycine 
• Hanks' balanced salt solution (HBSS) with and without Ca2+ and Mg2+ 
• High resolution agarose 
• Hydrochloric acid (HCl) 
• IgG1 isotype control from murine myeloma 
• Leupeptin 
• Lipopolysaccharide (LPS) from E. Coli 026:B6 
• Luria Bertani (LB) broth and agar  
• Methanol 
• N-Acetyl-L-cysteine 
• N-formyl methinyl leucyl phenylalanine (fMLP) 
• Nonidet P-40 
• O-Dianisidine dihydrochloride 
• Platelet activating factor (PAF) 
• Paraformaldehyde 
• Pepstatin A 
• Phenylmethanesulfonyl fluoride (PMSF) 
• Phorbol myristate acetate (PMA) 
• Potassium Chloride  
• Potassium Phosphate monobasic  
• PP1 
• Sivelestat sodium salt hydrate 
• Sodium bicarbonate 
• Sodium carbonate  
• Sodium chloride 
• Sodium citrate 3.8% solution 
• Sodium Dodecyl Sulfate (SDS) 
• Sodium fluoride 
• Sodium orthovanadate 
• Sodium Phosphate dibasic 
• Streptavidin Peroxidase from S. avidnii 
• Sulphuric acid (H2SO4) 
• Superoxide dismutase (SOD)  
• Tetramethylethylenediamine (TEMED) 
• Triton X-100 solution 
• Trizma base 
• Trypan blue 
• Trypsin 
• Tween 20 
• Zymosan A from Saccharomyces cerevisiae 
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Life Technologies (Paisley, UK) 
• Ammonium-Chloride-Potassium (ACK) lysis buffer 
• Anti-human IL-1β, IL-6, IL-8, IL-1RA, IL-10, TNFα, Monocyte chemotactic 
protein (MCP)-1 antibody pairs for ELISA 
• Dihydrorhodamine 123 (DHR) 
• Fetal Bovine Serum 
• Iscove’s modified Dulbecco’s medium (IMDM) with and without phenol red 
• Molecular Probes CountBright™ Absolute Counting Beads 
• Penicillin/Streptomycin 100X solution 
• pHrodo red E. coli and green S. aureus bioparticles 
• Pierce bicinchoninic acid (BCA) Protein Assay kit 
• Pierce HALT protease & phosphatase inhibitor cocktail (100X) 
• Roswell Park Memorial Institute (RPMI)-1640 
Biolegend UK Ltd. (London, UK) 
• Allophycocyanin (APC)-conjugated mouse anti-human CD62L 
monoclonal antibody (IgG, κ) 
• APC-conjugated mouse anti-human CD63 monoclonal antibody (IgG1, κ) 
• Fluorescein isothiocyanate (FITC)-conjugated rat anti-mouse CD11b 
monoclonal antibody (IgG2b, κ) 
• Pacific Blue- conjugated rat anti-mouse Ly6G monoclonal antibody 
(IgG2a, κ) 
• Phycoerythrin (PE)-conjugated mouse anti-human CD66b monoclonal 
antibody (IgM, κ) 
• PE-conjugated rat anti-mouse CD63 monoclonal antibody (IgG2a, κ) 
• PE/Cy7-conjugated mouse anti-human CD16 monoclonal antibody (IgG1, 
κ)  
• PerCP/Cy5.5-conjugated mouse anti-human CD11b monoclonal antibody 
(IgG1, κ) 
• Rat anti-mouse CD16/32 Fc blocking monoclonal antibody (IgG2a, λ) 
Cell Signalling Technology (Danvers, MA, US) 
• Mouse anti-human total src IgG1 antibody 
• Rabbit anti-human phospho-p38 Mitogen-activated protein kinase (MAPK) 
antibody 
• Rabbit anti-human phospho-src Tyr416 antibody 
• Rabbit anti-human total p38 MAPK antibody 
Abcam (Cambridge, UK) 
• Biotin-conjugated rabbit anti-human LTF polyclonal antibody (IgG) 
• Human LTF protein 
• Mouse anti-human LTF monoclonal antibody (IgG1, κ)  
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Stratech Scientific Ltd. (Suffolk, UK) 
• Horseradish peroxidase (HRP)-conjugated goat anti-rabbit IgG secondary 
antibody 
• HRP-conjugated goat anti-mouse IgG secondary antibody 
R&D Systems Inc. (Abingdon, UK) 
• Anti-mouse keratinocyte chemoattractant (KC), IL-6, IL-10, TNFα, MPO, 
Chemokine ligand-2 (CCL-2) antibody pairs for ELISA 
eBioscience Ltd. (Hatfield, UK) 
• Mouse soluble IgM ELISA kit 
Novatein Biosciences (Woburn, MA, US) 
• Mouse LTF ELISA kit 
BD Biosciences (Oxford, UK) 
• FACS Lysing Solution 
• OptEIA 3,3’,5,5’-Tetramethylbenzidine (TMB)/Hydrogen peroxide (H2O2) 
Substrate reagent set 
• Pharmlyse Lysing buffer (10X concentrate) 
Pharmacosmos (Holbaek, Denmark) 
• Dextran T500  
GE Healthcare Life Science (Little Chalfont, UK) 
• Amersham Hybond enhanced chemiluminescent (ECL) 
• Percoll Plus 
Cambridge Bioscience Ltd. (Cambridge, UK) 
• 10x Annexin binding buffer 
• Annexin V APC 
• Bosutinib 
• Dasatinib 
• Propidium iodide solution 
Bio-Rad Laboratories Ltd. (Hemel Hempstead, UK) 
• 30% Acrylamide/Bis Solution (37.5:1)  
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• Precision Plus Protein Western C Standards 
IBG Immunor Ltd. (Shoreham-by-Sea, UK) 
• Reastain Diff-Quik stain 
Roche Diagnostics Ltd. (W Sussex, UK) 
• Collagenase D 
• Cytotoxicity lactate dehydrogenase (LDH) detection kit  
ChemoMetec A/S (Allerod, Denmark) 
• ChemoMetec reagent A-100 and reagent B 
Elanco Animal Health (Basingstoke, UK)  
• Atipamezole (Antisedan) 
• Medetomidine 
Pfizer UK Ltd. (Walton Oaks, UK) 
• Ketamine 
Tesco PLC (Cheshunt, UK) 
• Marvel original dried skimmed milk powder 
All chemicals were reconstituted upon arrival from suppliers in the appropriate 
solvents, aliquoted and stored at the suggested temperature according to the 
product datasheets. All reagents prepared in DMSO were aliquoted at an 
appropriate molar concentration to ensure that the final DMSO concentration in 
all assays did not exceed 0.02%. 
2.2.3 Animals 
8-10 week old female C57/BL6 mice were purchased from Harlan UK Ltd.  
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2.2.4 Bacteria 
Pseudomonas aeruginosa strain PA01 was a kind donation from Professor 
Kenn Geddes’ group, Institute for Cell and Molecular Biosciences, Newcastle 
University, UK. 
Staphylococcus aureus (SA) strain National Collection of Type Cultures (NCTC) 
8325 was a kind donation from Dr Elizabeth Veal’s group, Institute for Cell and 
Molecular Biosciences, Newcastle University, UK. 
Escherichia coli strain K-12 was a kind donation from Dr Anjam Khan’s group, 
Institute for Cell and Molecular Biosciences, Newcastle University, UK. 
Escherichia coli strain American Type Culture Collection (ATCC) 25922 was 
kindly provided by Professor Adriano Rossi’s group, Centre for Inflammation 
Research, University of Edinburgh, UK.  
2.2.5 Cell lines 
The A549 cell line (Chapter 5), or ‘adenocarcinomic human alveolar basal 
epithelial cell line’ was a kind donation from Professor John Kirby’s group, 
Institute of Cellular Medicine, Newcastle University, UK. The A549 cell line was 
originally derived from culturing explanted lung cancer tissue (Giard et al. 1973).  
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 Recruitment of Volunteers and Patients 2.3
2.3.1 Healthy volunteers  
(chapters 3 and 5) 
Staff and students from Newcastle University were recruited into the study 
named “Role of Inflammation in Human Immunity” (Research Ethics 
Committee number 12/NE/0121) and gave informed, written consent to donate 
blood. Up to 160 ml of fresh blood was taken from each volunteer via a 21 
gauge hypodermic needle or a 21 gauge butterfly infusion set and decanted 
immediately into 15 ml or 50 ml Falcon tubes containing sodium citrate at a final 
concentration of 0.38%. Blood was stored at room temperature and subsequent 
isolation of blood cell components was commenced within 30 min. For whole 
blood flow cytometry experiments, blood was collected into BD Vacutainer® 
heparin tubes and stored at room temperature. 
2.3.2 Patients  
(chapter 5) 
By December 2013, members of our research group began recruiting patients 
to a Medical Research Council (MRC) – Developmental Clinical Studies (DCS)- 
funded randomised trial “Does Granulocyte Macrophage Colony Stimulating 
Factor (GM-CSF) restore effective neutrophil function in critically ill 
patients?” (Research Ethics Committee number 12/YH/0083, EudraCT number 
2011-005815-10). 
Critically ill patients, defined as those admitted to ICU within the previous 48 h 
and meeting the criteria for the Systemic Inflammatory Response Syndrome 
(SIRS); namely at least two of: temperature of < 36oC or > 38oC; pulse > 90 
beats per minute; respiratory rate > 20 breaths per minute or a partial pressure 
of CO2 < 4.3 kPa; and a white cell count (WCC) < 4 x 109/L or > 12 x 109/L 
(American College of Chest Physicians - ACCP/Society of Critical Care 
Medicine - SCCM Consensus 1992). In addition all patients required support of 
at least one organ system (eg inotropic/vasopressor support, invasive 
ventilation or renal replacement therapy) and were expected to survive beyond 
48 h. Patients were recruited from four general ICUs situated in two teaching 
   
  40 
hospitals in Newcastle upon Tyne (Freeman Hospital and Royal Victoria 
Infirmary), a district general hospital in Gateshead (Queen Elizabeth Hospital) 
and a teaching hospital in Sunderland (Sunderland Royal Hospital). Exclusion 
criteria are listed in Table 2-1 below. 
Table 2-1: Exclusion criteria used for recruitment of critically ill patients 
 
In eligible patients with capacity, informed consent was taken. In patients 
without capacity, consent was taken from a personal legal representative (e.g. 
next of kin) or if no family member was present or available, it was provided by 
a professional legal representative (i.e. an independent ICU consultant 
physician not directly responsible for the patient’s care). A 15 ml blood sample 
was taken into sodium citrate (end concentration 0.38%) on day 0 prior to 
1) Absence/refusal of informed 
consent 
 
2) Current prescription of a colony 
stimulating factor 
 
3) Any history of allergy/adverse 
reaction to GM-CSF 
 
4) Total white cell count > 30 x 109/L 
at the time of screening 
 
5) Haemoglobin < 7.5 g/dL at the time 
of screening 
 
6) Age < 18 years 
 
7) Pregnancy or lactation 
 
8) Known in-born errors of neutrophil 
metabolism 
 
9) Known haematological malignancy 
and/or known to have >10% 
peripheral blood cell blasts 
 
10) Known aplastic anaemia or 
pancytopaenia 
 
11) Platelet count < 50 x 109/L 
 
12) Chemotherapy or radiotherapy 
within the last 24 h 
13) Solid organ or bone marrow 
transplantation 
 
14) Use of maintenance 
immunosuppressive drugs other 
than maintenance corticosteroids 
(allowed up to 10 mg 
prednisolone/day or equivalent) 
 
15) Known human immunodeficiency 
virus (HIV) infection 
 
16) Active connective tissue disease 
(eg. rheumatoid disease, systemic 
lupus erythematosus requiring 
active pharmacological treatment) 
 
17) ST segment elevation myocardial 
infarction, acute pericarditis (by 
electrocardiogram - ECG criteria) 
or pulmonary embolism 
(radiographically confirmed) in 
previous week 
 
18) Involvement in any study involving 
an investigational medicinal 
product in the previous 30 days 
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randomisation and an array of study-specific immunological assays were 
carried out by the study team. Isolated neutrophils surplus to the number 
required to complete the study were used in the A549 epithelial cell damage 
model, as outlined in the study protocol and approved by the Research Ethics 
Committee (REC) (see Chapter 5). 
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 Isolation of Neutrophils 2.4
(Chapters 3 and 5) 
Neutrophils were isolated from citrated whole blood by dextran sedimentation 
and fractionation through isotonic discontinuous Percoll gradients (Haslett et al. 
1985). Briefly, citrated blood was centrifuged for 20 min at 300g. The upper 
layer of platelet rich plasma was removed (Figure 2-1A), placed in a glass 
serum tube and 1M CaCl2 solution was added (110 µl per 5 ml) before 
incubating at 37oC to induce platelet aggregation (Figure 2-1E) and form 
autologous serum, used in subsequent experiments. Meanwhile 2.5 ml of 
warmed filter-sterilised 6% dextran solution was added per 10 ml of cell pellet, 
the volume made up to 50 ml with warmed 0.9% normal saline and allowed to 
sediment for 30 min (Figure 2-1B). The upper leucocyte layer was then 
transferred to a fresh 50 ml Falcon tube, additional saline added and 
centrifuged for 5 min at 200g. 2.5 ml of Percoll Plus in phosphate buffered 
saline without Ca2+ or Mg2+ ions (PBS-) was added to the cell pellet and layered 
onto 2.5 ml of 77% Percoll, layered above 2.5 ml of 81% Percoll in a 15 ml 
Falcon tube (Figure 2-1C), then centrifuged for 20 min at 700g. The upper 
peripheral blood mononuclear cell (PBMC) layer and lower granulocyte layers 
(Figure 2-1D) were harvested separately and transferred to fresh tubes before 
washing once in HBSS without Ca2+ or Mg2+ ions (HBSS-). A cell count was 
then performed using a haemacytometer before a second wash with HBSS-. At 
this point, cells were resuspended at assay-dependent concentrations in 
warmed Iscove's modified Dulbecco's medium (IMDM) with phenol red, IMDM 
(phenol red-free) or HBSS with Ca2+ and Mg2+ ions (HBSS+), depending on the 
specific assay.  
Cell viability of each preparation was assessed using trypan blue exclusion and 
cell purity by morphology on cytocentrifuge preparations (cytospins). Cytospins 
were prepared throughout using a ThermoScientific Shandon Cytospin 3 
centrifuge (Fisher Scientific UK Ltd., Paisley, UK); 12g for 3 min. Slides were 
air-dried, fixed in acetone for 10 min and stained in Giemsa for 10 min. Only 
preparations containing >95% neutrophil purity and with >95% viability were 
used in experiments (Figure 2-1F). 
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Figure 2-1 Isolation of neutrophils from human blood (Percoll method) 
Centrifugation of citrated whole blood to form a platelet rich plasma (A), dextran 
sedimentation to form a leucocyte rich layer (B), fractionation through isotonic 
discontinuous Percoll gradients to form PBMC and granulocytes layers (C and 
D), generation of autologous platelet-free serum (E) and appearance of 
Giemsa-stained, purified neutrophils on cytocentrifuge preparation (F). 
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 Isolation of Monocytes 2.5
(Chapter 5) 
PBMCs were isolated from citrated whole blood by density gradient separation 
using Ficoll-Paque™ (density = 1.077g/ml) according to the manufacturer’s 
instructions, with slight modifications. Briefly, 20 ml of citrated blood was diluted 
1:2 with warmed PBS- and layered upon 10 ml of Ficoll solution in a 50 ml 
Falcon tube (Figure 2-2A) and centrifuged at 700g for 15 min. The PBMC layer 
was harvested and transferred to a fresh 50 ml tube (Figure 2-2B), washed 
twice in 50 ml of warmed PBS- for 10 min at 300g before performing a cell 
count with assessment of cell viability and purity as described in methods 
section 1.1 (Figure 2-2D). A typical yield was 2 x 107 PBMCs from 20 ml of 
blood. After a further wash the cell pellet was resuspended in 80 µl of ice-cold 
wash buffer (composed of PBS-, pH 7.2, 0.5% BSA and 2 mM EDTA) and 20 µl 
CD14 MACS microbeads per 107 total cells and incubated at 4oC for 15 min. 
The cells were washed by adding 2 ml of ice-cold buffer per 107 cells, the pellet 
resuspended in 500 µl buffer and added to a pre-moistened MACS MS column 
fixed to a MACS column magnet (Figure 2-2C). The column was washed 
through three times with 500 µl wash buffer to remove CD14 negative cells. The 
column was then removed from the magnet and the CD14 positive cells were 
flushed into a fresh 50 ml tube using 1 ml of wash buffer. A further cell count 
with assessment of purity and viability was carried out (Figure 2-2E), before 
resuspending in pre-warmed assay medium at the desired cell concentration 
and plating onto 24-well tissue culture plates.  
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Figure 2-2 Isolation of CD14 positive monocytes from human blood 
Centrifugation of diluted citrated blood over Ficoll solution (A) to form platelet 
rich plasma and a layer of PBMCs (B). CD14 MACS microbeads are incubated 
with PBMCs and passed through a MACS MS column surrounded by a MACS 
column magnet (C). Representative cytospin preparations of PBMCs before 
CD14 selection (D) and monocytes after CD14 selection (E) 
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 Chemical Pre-treatment of Isolated Neutrophils and Blood 2.6
(Chapters 3 and 5) 
Unless otherwise indicated, chemical pre-treatment of neutrophils was carried 
out in the final assay medium supplemented with 1% autologous serum in 2 ml 
round-bottomed eppendorf tubes, 15 or 50 ml Falcon tubes for 30 min at 37oC 
in a shaking water bath. In experiments involving adherent neutrophils, 
chemicals were added for 30 min after a 30 min adherence step. In whole blood 
flow cytometry experiments, heparinised blood was pre-treated in 2 ml round-
bottomed eppendorfs for 30 min in a 37oC incubator. 
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 Culture of Monocyte-derived Macrophages (MDMs) from Monocytes 2.7
(Chapter 5) 
CD14 positive monocytes isolated from whole blood (see section 1.1) were 
resuspended at 2.5 x 105/ml in warmed IMDM (containing phenol red) and 
added to 24-well tissue culture plates at 2.5 x 105 per well. After 60 min 
incubation at 37oC and 5% CO2, the culture medium was supplemented with 
10% autologous serum with penicillin and streptomycin (final concentrations 
100 units/ml and 100 µg/ml respectively). The medium was then changed at 
days 3 and 5 and matured MDMs were used in experiments at day 7 or 8. Purity 
of MDMs was assessed by cell morphology on cytospin staining of detached 
cells and direct staining of well bottoms, as well as by CD11b/CD14 staining on 
flow cytometry. 
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 Culture of A549 Cells 2.8
(Chapter 5) 
A549 cells were grown to 90% confluence in RPMI-1640 medium supplemented 
with 10% heat-inactivated foetal calf serum (FCS) and penicillin/streptomycin in 
7.5 cm2 tissue culture flasks at 37oC with 5% CO2. To use or split cells, the 
flasks were rinsed once in PBS- to remove serum before adding 5 ml of 
Trypsin/EDTA solution and incubating at 37oC for 5 to 10 min. Before use, cells 
were counted and washed twice in phenol red-free IMDM. 
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 Western Blotting 2.9
(Chapter 3) 
2.9.1 Sample preparation 
5 x 106 healthy neutrophils in 1 ml IMDM/1% serum were used per condition. 
Cells were pre-treated with various concentrations of inhibitors/vehicle control 
for 30 min in round-bottomed eppendorf tubes in a shaking waterbath at 37oC. 
Stimulation was initiated with 100 ng/ml LPS (pre-incubated for 60 min in 
serum) or control for 15 min at 37oC. Tubes were placed on ice, washed twice 
in ice-cold PBS- containing 1 mM sodium orthovanadate and 1 mM 
phenylmethanesulfonylfluoride (PMSF). 100 µl of lysis buffer containing 
protease and phosphatase inhibitors (composed of 100 nM Tris-Hydrochloric 
acid - HCl pH 8.0, 100 mM Sodium Chloride - NaCl, 2 mM EDTA, 1% Nonidet-
P40, 5 mM sodium orthovanadate, 50 mM sodium fluoride, 0.3 U/ml aprotinin, 2 
mM PMSF, 50 µg/ml benzamidine and 5 µg/ml of antipain, leupeptin, 
chymostatin and pepstatin A) was added to each cell pellet and incubated on 
ice for 20 min with vigorous aspiration up and down through a P200 pipette tip 
to aid lysis. After 5 min of centrifugation at 12,000 g/4oC, supernatants were 
transferred to fresh tubes and frozen immediately at -80oC, after removing 20 µl 
for measurement of total protein using the BCA protein assay. Using this 
method of sample preparation, approximately 100 µg protein was retrieved per 
5 x 106 neutrophils. 
2.9.2  Polyacrylamide gel electrophoresis and transfer to nitrocellulose 
membrane 
Samples were thawed and denatured by adding 5X reducing sample buffer 
(10% sodium dodecyl sulphate, 25% 2-mercaptoethanol, 50% glycerol, 0.001% 
bromophenol blue and 0.32 M Tris HCl) and the mixture boiled at 95oC for 5 
min. Each tube was vortexed briefly before centrifuging for 5 min at 12,000 g. 
40 µg of each supernatant (appropriate volumes calculated using the BCA 
assay total protein measurements) was loaded onto a 10% polyacrylamide gel 
with a separate lane for molecular weight markers. The gel was submerged in 
running buffer (25 mM Tris base, 190 mM glycine, 0.1% SDS; pH 8.3) and run 
at 70 mA until the migration front reached the bottom of the gel. Proteins were 
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transferred onto a nitrocellulose membrane in transfer buffer (25 mM Tris base, 
190 mM glycine, 0.1% SDS, 20% methanol; pH 8.3) at 100 V for 1 h. 
2.9.3 Incubation with primary and secondary antibodies 
Membranes were washed in Tris-buffered saline Tween (TBS-T; made by 
adding 0.1% Tween 20 to a 1:10 dilution of 10X TBS in ultrapure water (10X 
TBS = 24.23g Trizma HCl, 80.06g NaCl mixed in 1000 ml total volume ultrapure 
water; pH 7.6) and blocked in either 5% Marvel milk powder in TBS-T or 5% 
BSA in TBS-T (depending on the individual antibody) for 1 h under agitation. 
Primary antibodies were diluted in 5% BSA/TBS-T or 5% milk/TBS-T at the 
manufacturer’s suggested dilution and incubated at 4oC overnight. 
The following morning, the membrane was washed three times for 10 min in 
TBS-T before adding either HRP-conjugated goat anti-rabbit IgG or HRP-
conjugated goat anti-mouse IgG secondary antibodies, diluted 1:2000 in TBS-T 
and incubated under agitation for 2 h. The membranes were washed a final 3 
times in TBS-T, before adding enhanced chemiluminescent (ECL) for 60 s, 
removing the excess and developing on X-ray film in a dark room. 
The antibodies listed in table 2.2 opposite were used to test phosphorylation of 
src kinases and p38 MAPK by neutrophils in response to LPS.
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Table 2-2 List of primary and secondary antibodies used in Western 
blotting 
Primary 
antibody 
Dilution Blocking 
buffer 
Secondary 
antibody 
Dilution 
Mouse anti-
human total 
src IgG1 
1:1000 5% milk in 
TBS-T 
HRP-conjugated 
goat anti-mouse 
IgG 
1:2000 
Rabbit anti-
human 
phospho-src 
Tyr416  
1:1000 5% BSA in 
TBS-T 
HRP-conjugated 
goat anti-rabbit 
IgG 
1:2000 
Rabbit anti-
human total 
p38 MAPK 
1:1000 5% milk in 
TBS-T 
HRP-conjugated 
goat anti-rabbit 
IgG 
1:2000 
Rabbit anti-
human 
phospho-p38 
MAPK 
1:2000 5% milk in 
TBS-T 
HRP-conjugated 
goat anti-rabbit 
IgG 
1:2000 
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 Enzyme-linked Immunoabsorbent Assay (ELISA) 2.10
(Chapter 3, 4 and 5) 
Sandwich ELISA using paired antibodies was an experimental technique used 
throughout the project to measure the concentration of a variety of pro- and 
anti-inflammatory cytokines in cell supernatant or murine BALF. ELISA kits were 
purchased and the assay carried out according to the manufacturer’s 
instructions, with some slight modifications. Briefly, 96-well NUNC Maxisorp 
plates were coated overnight at 4oC with 50 µl of coating antibody dissolved in 
0.1 M bicarbonate buffer; pH 9.4 (made by dissolving 4.3 g sodium bicarbonate, 
5.3 g sodium carbonate in 1000 ml distilled water). The next day, plates were 
washed twice with 200 µl of PBS-/0.5% Tween before blocking for 1 h at room 
temperature with 200 µl assay buffer (0.5% BSA and 0.1% Tween 20 dissolved 
in PBS-). 
Meanwhile, 7 standards (including assay buffer alone) were prepared by 1:2 
serial dilutions in assay buffer on ice and samples were thawed and diluted in 
assay buffer if necessary, as directed by previous titration experiments. 50 µl of 
standards and samples (in duplicate) were pipetted into designated wells. 50 µl 
of detection antibody diluted in assay buffer were added to each well and the 
plate incubated for 2 h at room temperature with continual shaking (450 rpm). 
The plate was then washed 5 times with 200 µl of PBS Tween and 100 µl 
streptavidin-HRP solution diluted in assay buffer added to each well and 
incubated for 30 min at room temperature with continual shaking (450 rpm). The 
plate was washed a final 5 times with PBS Tween before adding 100 µl of a 
freshly prepared 1:1 mixture of 3,3’,5,5’-Tetramethylbenzidine (TMB) solution 
and hydrogen peroxide (H2O2) solution. The plate was then incubated for 30 
min at room temperature with continual shaking before stopping the reaction 
with the addition of 100 µl of 2N sulphuric acid. The absorbance of each well 
was measured at 450 nm within 30 min of adding the stop solution on a 
FLUOstar Omega spectrophotometer (BMG Labtech, Ortenberg, Germany). 
Results were calculated using a 4-parameter fit standard curve. Standard curve 
r2 values were routinely above 0.95. Values falling outside of the standard curve 
values were excluded. In initial titration experiments, sample dilutions that 
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yielded optical density (OD)450 values falling within the exponential part of the 
standard curve were used for all subsequent experiments.  
The following ELISA antibody pair kits were used: human IL-6, IL-8, IL-1RA, IL-
10, TNFα, MCP-1 (Fisher Scientific UK Ltd., Paisley, UK); mouse KC, IL-6, IL-
10, TNFα, MPO, CCL-2 (R&D Systems Inc., Abingdon, UK), mouse soluble IgM 
(eBioscience Ltd., Hatfield, UK). A pre-coated ELISA kit was purchased to 
measure mouse LTF concentrations (Novatein Biosciences, Woburn, US). 
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 Efferocytosis by Monocyte-derived Macrophages (MDMs) 2.11
(Chapter 5) 
These assays were adapted and optimised for use from previously published 
protocols from Edinburgh (Hart et al. 2008; Dorward et al. 2014) 
2.11.1 Preparation of apoptotic neutrophils 
Freshly isolated neutrophils were incubated in suspension at 4 x 106/ml in 
IMDM (containing phenol red) supplemented with 0.5% BSA and 
penicillin/streptomycin for 24 h at 37oC. Apoptosis rates were checked using 
cytospin staining and cell morphology and flow cytometric analysis with Annexin 
V APC/Propidium iodide (PI) staining (see section 0). Apoptotic neutrophils 
were recounted and washed three times with warm IMDM prior to use in MDM 
efferocytosis assays. 
2.11.2 Phagocytosis of apoptotic neutrophils by MDMs 
Mature MDMs (day 7 or 8) cultured at 2.5 x 105 per well in 24-well plates were 
rinsed with warm IMDM before adding 1 ml fresh IMDM containing 1 x 106 non-
autologous apoptotic neutrophils (ratio ~ 1 MDM : 4 apoptotic neutrophils), 10% 
autologous serum and penicllin/streptomycin. They were incubated for 18 h at 
37oC/5% CO2 to allow phagocytosis of the apoptotic neutrophils by the MDMs 
and adequate production of pro- and anti-inflammatory cytokines. At this point, 
supernatants were removed, aliquoted and stored at -80oC prior to cytokine 
analysis. Remaining adherent cells were washed at least three times with PBS- 
to remove excess non-internalised apoptotic neutrophils, air dried, fixed in 4% 
paraformaldehyde for 15 min and stained for MPO with PBS- containing 0.03% 
(v/v) hydrogen peroxide and 0.1 mg/ml dimethoxybenzidine (DMB) for 30 min at 
37oC. Development of a brown colour indicated the presence of a neutrophil, 
which stain intensely for MPO. Cells were examined through a Nikon TMS 
Inverted microscope (Nikon UK Ltd., Kingston upon Thames, UK). The 
percentage of MDMs containing at least one MPO+ apoptotic neutrophil was 
determined by counting four randomly selected fields containing at least 100 
MDMs. 
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2.11.3 Cytokine measurement in MDM supernatant 
Aliquoted supernatants were thawed at room temperature and analysed by 
ELISA (see ELISA method 1.1) for the presence of pro-inflammatory cytokines 
(IL-6, IL-8, TNFα, MCP-1, IL-1β) and anti-inflammatory cytokines (IL-1RA, IL-
10). IL-1β, IL-6, IL-10 and TNFα were analysed on neat samples; IL-1RA and 
MCP-1 on 1:2 diluted samples and IL-8 on 1:50 diluted samples. 
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 Phagocytosis Assays 2.12
(Chapters 3 and 4) 
2.12.1 Opsonised zymosan 
This in vitro phagocytosis assay has been validated in the literature (Morris et 
al. 2011; Conway Morris et al. 2009). Briefly, 5 x 105 freshly isolated neutrophils 
were left to adhere to tissue culture plastic in IMDM (containing phenol red) 
supplemented with 1% autologous serum for 30 min at 37oC/5% CO2. Cells 
were then incubated for 30 min with 0.02 mg autologous serum-opsonised 
zymosan (50% autologous serum for 60 min at 37oC). Neutrophils were then 
washed 3 times with PBS-, air dried, fixed with methanol and stained with 
Giemsa. Using a Nikon TMS Inverted microscope (Nikon UK Ltd., Kingston 
upon Thames, UK), the percentage of neutrophils ingesting two or more 
zymosan particles was quantified by counting a minimum of 100 cells in four 
randomly selected fields (see Figure 2-3 below). 
 
 
Figure 2-3 Phagocytosis of serum-opsonised zymosan particles 
Representative x400 magnification images of healthy control neutrophils 
ingesting zymosan particles (A) compared with dysfunctional neutrophils from 
critically ill patients (B). Images from 4 experiments using samples from 4 
independent volunteers. 
2.12.2 pHrodo™ Bioparticles 
These killed fluorescent Staphylococcus aureus (pHrodo SA) and Escherichia 
coli (pHrodo EC) bioparticles are conjugated to pH-sensitive phrodo Green and 
Red dyes, respectively. They are non-fluorescent outside a cell at a neutral pH, 
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but will fluoresce brightly at an acidic pH, such as in a neutrophil 
phagolysosome. This removes the need for wash or quenching steps. SA and 
EC were chosen as common, representative Gram positive and negative 
species, respectively.  
In whole blood phagocytosis assays, the bioparticles were reconstituted in 
IMDM (no phenol red) at 2 mg/ml, vortexed for 30 s and placed in a sonicating 
waterbath for 30 s to achieve a monocellular suspension. To 100 µl of 
heparinised blood pre-treated with control or src kinase inhibitors in 2 ml round-
bottomed eppendorf tubes, 20 µl of bioparticle suspension was added and 
incubated for 30 min in a shaking water bath at 37oC. The presence of serum in 
blood removed the need for a separate opsonisation step. Tubes were placed 
on ice for 5 min to prevent further phagocytosis before adding 1.8 ml of 
Pharmlyse solution at room temperature for 15 min. Cells were washed using 2 
cycles on a BD FACS Lyse Wash Assistant machine (BD Biosciences, Oxford, 
UK) and stored at 4oC in the dark before analysis. Flow cytometric analysis 
(FACSCanto II, BD Biosciences, Oxford, UK) involved gating on neutrophils by 
forward/side scatter properties and measuring their median fluorescence 
intensity (MFI) at the appropriate laser wavelengths (Figure 2-4). Phrodo green 
SA particles have 509nm/533nm excitation/emission properties and were 
therefore analysed using a 488 530/30 laser. Phrodo red EC particles have 
560nm/585nm excitation/emission properties and were analysed using a 488 
585/42 laser.  
To measure phagocytosis by adherent neutrophils, freshly isolated neutrophils 
were resuspended at 2 x 106/ml in IMDM (no phenol red) with 1% autologous 
serum and 100 µl (2 x 105 cells) was added to triplicate wells of a flat-bottomed 
96-well tissue culture plate. Titration experiments demonstrated this to be the 
optimal cell density to achieve maximum phagocytosis (as estimated by mean 
fluorescence). After 30 min adherence at 37oC/5% CO2, neutrophils were pre-
treated with appropriate chemicals/control medium for 30 min before adding 100 
µl of a 1:15 dilution of a 1 mg/ml stock suspension of autologous-serum-
opsonised phrodo SA or EC bioparticles, prepared as detailed above. This 
dilution factor was chosen in order to achieve a multiplicity of infection (MOI) of 
10 bioparticles : 1 neutrophil, after estimating bioparticle concentrations using a 
haemacytometer and light microscope with a x100 oil immersion objective. 
   
  58 
Plates were centrifuged for 5 min at 200g to bring the bioparticles in contact 
with the adherent neutrophils, before incubating for a further 30 min and then 
placing on ice. Plates were read immediately using a TECAN Infinite® 200 Pro 
spectrophotometer (Tecan UK Ltd., Reading, UK). The median fluorescence of 
triplicate wells (16 flashes per well) was corrected for IMDM/1% autologous 
serum values. Phrodo SA was excited at 500 nm (+/- 9 nm) and its emission 
recorded at 520 nm (+/-20 nm); phrodo EC was excited at 550 nm (+/-9 nm) 
and its emission recorded at 585 nm (+/-20 nm). 
 
Figure 2-4 Gating strategy for analysis of phagocytosis of phrodo SA by 
neutrophils in whole blood 
Neutrophils are identified and gated by their forward and side scatter properties 
and the 530nm fluorescence distribution of the gated population plotted (top left 
plot). Neutrophils alone have minimal autofluorescence (top right). The control 
condition at 4oC inhibits neutrophil phagocytosis (bottom right) but at 37oC the 
neutrophils phagocytose phrodo SA (bottom left). Representative plots from 3 
control experiments. 
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phrodo%SA%at%
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 Live Bacterial Killing Assay 2.13
(Chapters 3 and 5) 
The ability of neutrophils to kill Pseudomonas aeruginosa, S. aureus and E. coli 
was tested in vitro by adapting previously described methods (Hampton et al. 
1994; Hampton & Winterbourn 1999; Conway Morris et al. 2009). Briefly, P. 
aeruginosa strain PA01, S. aureus strain NCTC 8325 and E. coli strain K-12 
W3110 were grown for 12 h in LB broth at 37oC in a shaking incubator, before 
being sub-cultured into 20 ml of fresh LB Broth at 1:200 dilution in a 50 ml 
Falcon tube and grown for a further 150 min to enter early/mid logarithmic 
phase. Aliquots of this early log culture were taken and diluted to an optical 
density of 0.2 at 595 nm in IMDM.  
 
Figure 2-5 Cytospin preparations demonstrating healthy neutrophils 
ingesting P.aeruginosa and S. aureus 
x1000 photographs of Giemsa-stained cytospin preparations of healthy 
neutrophils (A), and neutrophils ingesting live PA01 (B), live S. aureus (C) and 
both live PA01 and SA (D). Giemsa stains both Gram +ve and Gram –ve cocci 
and bacilli purple. Representative images from 3 control experiments. 
A" B"
D"C" 20µm 
20µm 
20µm 
20µm 
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Based on previously calculated growth curves for all 3 strains, the resulting 
suspensions were diluted 1:2 (SA), 1:6 (PA01) and 1:4 (EC) to achieve a 
bacterial concentration of 2 x 107 colony forming units (cfu)/ml. 50% autologous 
serum was added to promote opsonisation for 30 min at 37oC, then washed 
twice with IMDM and resuspended at the original concentration. 500 µl of the 
bacterial suspension was added to 1 x 106 neutrophils suspended in 500 µL 
IMDM or control medium alone (corresponding to a live bacteria: neutrophil ratio 
of approximately 10:1) and the mixture incubated at 370C in a tube rotator 
(Bibby Scientific Ltd., Stone, UK), to keep the neutrophils in suspension (Figure 
2-5). Duplicate samples were taken at 0 min (control only) and 30 min (control 
and neutrophil samples), treated with 0.1% Triton to lyse cells and release 
intracellular bacteria for 5 min at room temperature before diluting by a factor of 
1:10,000 by serial dilution in PBS-. 100 µl of the resulting bacterial suspensions 
was plated out onto duplicate plates containing LB agar and incubated 
overnight at 37oC to determine colony counts.  
Neutrophils were exposed to an MOI of 10:1 for 30 min because initial 
experiments showed that at this ratio, healthy neutrophils were at least 
‘bacteriostatic’ and often ‘bactericidal’ and their function could be significantly 
manipulated by inhibitors. Also neutrophil viability diminishes rapidly after 30 
min exposure, particularly in response to P. aeruginosa but also S. aureus (data 
not shown). Efficiency of killing was expressed as the fold change in bacterial 
concentration of the final bacterial suspension compared to the original 
concentration: 
𝑩𝒂𝒄𝒕𝒆𝒓𝒊𝒂𝒍  𝒌𝒊𝒍𝒍𝒊𝒏𝒈  𝒆𝒇𝒇𝒊𝒄𝒊𝒆𝒏𝒄𝒚   =    cfu/ml  at  t = 30  mincfu/ml  at  t = 0  min  
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 Under-agarose Chemotaxis Assay 2.14
(Chapter 3) 
This assay was based on the original protocol described by Nelson et al. 
(Nelson et al. 1975). Two clean glass slides per condition were dipped in 0.5% 
gelatin solution and allowed to dry. Meanwhile agarose medium was prepared 
with IMDM (with phenol red) containing 1% BSA, 1% melted agarose and 
0.25% gelatin and 5 ml poured onto each slide and allowed to set at 4oC. Using 
a template and 3 mm diameter hollow cutting needle attached to a vacuum 
pump, two sets of 3 wells were prepared in each slide immediately before use 
(see Figure 2-6 opposite). 
Freshly isolated neutrophils were resuspended at 2.5 x 107/ml in IMDM 
containing 1% autologous serum and 10 µl (250,000 cells) placed in each 
central well. 10 µl chemoattractant (fMLP in PBS-, final concentration 100 nM) 
was placed in one well and 10 µl control PBS- in the other well. The slides were 
then incubated at 37oC/5% CO2 for 2 h before fixation in 2.5% 
paraformaldehyde for at least 30 min. The slides were then rinsed, dried and 
stained with Giemsa solution. 
Neutrophil migration patterns were photographed through a x4 objective using a 
Nikon Eclipse light microscope and camera (Nikon UK Ltd., Kingston upon 
Thames, UK). Results were expressed as a ‘relative chemotactic index’ in 
arbitrary units, defined as: 
𝑹𝒆𝒍𝒂𝒕𝒊𝒗𝒆  𝒄𝒉𝒆𝒎𝒐𝒕𝒂𝒄𝒕𝒊𝒄  𝒊𝒏𝒅𝒆𝒙= 1000  ×    𝐷𝑖𝑠𝑡𝑎𝑛𝑐𝑒  𝑚𝑖𝑔𝑟𝑎𝑡𝑒𝑑  𝑡𝑜  𝑓𝑀𝐿𝑃 𝐷𝑖𝑠𝑡𝑎𝑛𝑐𝑒  𝑚𝑖𝑔𝑟𝑎𝑡𝑒𝑑  𝑡𝑜  𝑐𝑜𝑛𝑡𝑟𝑜𝑙𝐷𝑖𝑠𝑡𝑎𝑛𝑐𝑒  𝑚𝑖𝑔𝑟𝑎𝑡𝑒𝑑  𝑡𝑜  𝑐𝑜𝑛𝑡𝑟𝑜𝑙  
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Figure 2-6 Under-agarose chemotaxis assay method 
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 Adhesion Assay 2.15
(Chapter 3) 
This flow cytometric assay of neutrophil adhesion to plastic was adapted from 
that described by Clark et al. (Clark et al. 1997). Briefly, fresh neutrophils were 
resuspended at 1 x 106/ml in IMDM (with phenol red) with 1% autologous serum 
and 500 µl cell suspension added to wells of a 24 well plate as well as a round-
bottomed eppendorf tube to use for the total cell count. Chemicals and inhibitors 
were added in addition to fMLP (50 nM final concentration) to promote 
adhesion. After 60 min incubation at 37oC/5% CO2, the wells were washed 
twice with PBS- to remove non-adherent cells. 250 µl of IMDM and 250 µl of 
Trypsin/EDTA were added per well and aspirated up and down to detach all 
cells into suspension. 400 µl of each suspension (and the ‘total cell count’ tube) 
were transferred to FACS tubes and 20 µl of well-vortexed CountBright™ 
Absolute Counting Beads added (exact concentration of beads is lot-specific but 
approximately 20,000 in 20 µl) prior to analysing using flow cytometry. The 
number of neutrophils analysed per 2000 beads was counted and the results 
expressed as % adherence (see Figure 2-7 opposite). 
%  𝑨𝒅𝒉𝒆𝒓𝒆𝒏𝒄𝒆   = 100%  ×   𝑁𝑢𝑚𝑏𝑒𝑟  𝑜𝑓  𝑎𝑑ℎ𝑒𝑟𝑒𝑛𝑡  𝑛𝑒𝑢𝑡𝑟𝑜𝑝ℎ𝑖𝑙𝑠𝐼𝑛𝑖𝑡𝑖𝑎𝑙  𝑡𝑜𝑡𝑎𝑙  𝑐𝑒𝑙𝑙  𝑐𝑜𝑢𝑛𝑡  
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Figure 2-7 Measurement of neutrophil adhesion using CountBright 
Absolute counting beads 
Representative control flow cytometry plots with % adherence calculations 
showing that only 22.4% of unstimulated neutrophils become firmly adherent to 
tissue culture plastic (left-hand plot) compared to 74.1% of neutrophils 
stimulated by 100 nM fMLP (middle plot). Plots from 4 experiments using 
samples from 4 independent volunteers.  
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 Measurement of Neutrophil Apoptosis 2.16
(Chapter 3) 
Isolated neutrophils were resuspended at 1 x 106/ml in IMDM with 1% 
autologous serum, treated with chemicals and inhibitors and incubated at 
37oC/5% CO2. At 30 min, 6 h and 24 h, aliquots were removed and analysed for 
rates of apoptosis by performing a cytospin, counting the percentage of 
apoptotic cells (by morphological criteria at light microscopy) and also by 
staining with Annexin V APC and PI. Briefly, 500 µl cell suspension was washed 
twice with cold PBS- and resuspended in 1 x Annexin V Binding buffer at 1 x 
106/ml. 100 µl of the suspension was transferred to a FACS tube and 5 µl 
Annexin V APC and 1 µl of 1 mg/ml PI added, mixed and the tube incubated in 
the dark at room temperature for 15 min. 400 µl of 1x binding buffer was added 
and the sample analysed by flow cytometry, gating on neutrophils and recording 
at least 5000 events. No compensation was required for APC and PI 
fluorescence. The gating strategy is shown opposite in Figure 2-8. 
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Figure 2-8 Gating strategy used to measure neutrophil apoptosis by 
Annexin V/PI binding 
Neutrophils are distinguished from debris by their forward/side scatter 
properties and their relative binding to Annexin V APC and PI expressed 
(bottom right plot). Annexin V-PI- cells are alive, Annexin V+PI- cells are in the 
early stages of apoptosis whereas Annexin V+or– PI+ cells are either necrotic or 
undergoing late apoptosis. Plots from 3 control experiments. 
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 Assessment of Cytotoxicity by LDH Release 2.17
(Chapter 3) 
Direct cytotoxicity induced by pre-treating healthy neutrophils with different 
chemicals was tested using a Roche lactate dehydrogenase (LDH) cytotoxicity 
kit according to the manufacturer’s instructions. Briefly, 5 x 104 neutrophils in 
100 µl of IMDM (no phenol red) were added to triplicate wells of a 96-well plate 
and chemicals to be tested were added in a further 100 µl of IMDM. In control 
samples, Triton X-100 (final concentration 1%, as positive control) or IMDM 
alone (as negative control) were added. The plate was incubated for 60 min at 
37oC/5% CO2 before being placed on ice and centrifuged for 5 min at 200g. 100 
µl of each supernatant was transferred to a fresh plate and 100 µl of freshly 
prepared LDH reaction mixture added, before incubating for 30 min at room 
temperature in the dark. IMDM-corrected absorbance values at 490 nm were 
measured using a TECAN Infinite® 200 Pro spectrophotometer.  Results were 
expressed as % LDH release, where: 
%  𝑳𝑫𝑯  𝒓𝒆𝒍𝒆𝒂𝒔𝒆 =   𝑂𝐷  𝑣𝑎𝑙𝑢𝑒  𝑜𝑓  𝑝𝑟𝑒𝑡𝑟𝑒𝑎𝑡𝑒𝑑  5  ×  10!  𝑐𝑒𝑙𝑙𝑠𝑂𝐷  𝑣𝑎𝑙𝑢𝑒  𝑜𝑓  𝑇𝑟𝑖𝑡𝑜𝑛𝑖𝑠𝑒𝑑  5  ×  10!  𝑐𝑒𝑙𝑙𝑠  
Initial titration experiments established that the optimum cell density to avoid 
over-crowding of cells (by direct microscopic visualisation) and a sufficient OD 
difference between an equivalent number of untreated and fully lysed cells was 
5 x 104 per well (Figure 2-9 opposite). 
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Figure 2-9 Titration experiments for LDH cytotoxicity assay 
OD490 values for a range of cell densities per individual well of a 96-well plate 
were compared with OD values from the same concentration of fully lysed cells 
to determine the optimum cell density of 5 x 104 per well. Data are expressed as 
the mean of 2 experiments using neutrophils derived from 2 independent 
volunteers. 
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 Degranulation Assays 2.18
(Chapter 3) 
2.18.1 Induction of degranulation 
Samples (whole blood or isolated human neutrophils) were stimulated in four 
separate ways to induce degranulation: 
• 100 nM PMA for 20 min 
• 10 µM cytochalasin B for 5 min followed by 1 µM fMLP for 10 min 
• 100 ng/ml LPS for 30 min (LPS pre-incubated with human serum to 
provide LPS-binding protein (LBP) for Toll-like receptor 4 (TLR4) ligation) 
• Autologous serum-opsonised live PA01 or SA for 30 min 
All experiments were carried out in 2 ml round-bottomed eppendorf tubes and 
incubated at 37oC with continual mixing. 
2.18.2 CD63, CD66b and CD11b expression on human neutrophils in whole 
blood 
CD63 is an integral membrane protein expressed on the membrane of azurophil 
(primary) granules in human neutrophils. It is also expressed in neutrophil 
lysosomes (Cham et al. 1994). CD66b is a member of the carcinoembryonic 
antigen family expressed only on the surface membrane of specific (secondary) 
granules and CD11b/CD18 (Mac-1) is a β2 integrin expressed across specific, 
gelatinase (tertiary) and secretory vesicles (Faurschou & Borregaard 2003). All 
3 proteins are expressed extracellularly when these granules fuse with the 
extracellular membrane and can be measured alone or in combination as 
surrogate markers of degranulation in whole blood flow cytometry assays 
(Hashiguchi et al. 2005). 
A flow cytometry panel of the following antibodies and dyes was set up. 
Fluorescence compensation values were calculated in separate experiments 
using single and multi-stained samples. 
• PE/Cy7-conjugated mouse anti-human CD16 monoclonal antibody 
(IgG1, κ) to identify neutrophil population 
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• DAPI stain to exclude dead cells 
• APC-conjugated mouse anti-human CD63 monoclonal antibody (IgG1, κ) 
• PE-conjugated mouse anti-human CD66b monoclonal antibody (IgM, κ) 
• PerCP/Cy5.5-conjugated mouse anti-human CD11b monoclonal 
antibody (IgG1, κ) 
Briefly, 100 µl of heparinised blood was pre-treated with potential inhibitors or 
control for 30 min before adding the antibodies listed above at the 
manufacturer’s suggested concentration. Samples were stimulated as 
described in method 2.18.1 to induce degranulation. The assay was then 
stopped on ice for 5 min and 1.8 ml of Pharmlyse was added for 15 min at room 
temperature, before washing twice. 50 µl DAPI was added to each sample 5 
min before analysing them on a BD FACSCanto II machine, according to the 
gating strategy shown in Figure 2-10 below.  
 
Figure 2-10 Gating strategy used in whole blood assay to measure 
markers of degranulation in human neutrophils 
Live neutrophils are identified by their forward/side scatter properties as well as 
CD16 positivity and negative DAPI staining, before measuring the relative 
fluorescence of fluorophore-conjugated antibodies binding live neutrophil CD63 
(primary granules), CD66b (secondary granules) and CD11b (secondary, 
tertiary and secretory granules). Plots from 3 control experiments. 
A slight modification in the bacterial preparation method was required when 
carrying out whole blood assays. In assays involving isolated neutrophils, 
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healthy blood volunteers were consented and venesected between 08:30 and 
09:00 most mornings, giving sufficient time to prepare a subculture of bacteria 
to early/mid log growth phase and carry out a neutrophil preparation 
simultaneously. Depending on their growth phase, bacteria can behave very 
differently in terms of virulence towards immune cells and subsequent viability. 
To avoid this effect and prepare early/mid log phase bacteria for use with 
heparinised whole blood by 09:00, bacteria were prepared as shown in Figure 
2-11 below. 
 
Figure 2-11 Preparation of early/mid log phase bacteria for use in whole 
blood flow cytometry assays 
A 1:200 dilution of an overnight culture was prepared in a weighted 50 ml 
Falcon tube fitted with a polystyrene ring and suspended in packed ice inside a 
large plastic bottle (e.g. 5 kg sucrose bottle) in a 37oC incubator at 9pm. A 
digital timer was set for 05:30, at which point the incubator was turned on, the 
ice melted and bacterial growth began. At 09:00 the subculture was in early/mid 
log phase with very similar OD measurements compared to the routine method 
(see section 2.13)  
2.18.3 MPO release assay 
To complement the results of measurements of neutrophil degranulation in 
whole blood, granule components released extracellularly into the supernatant 
from isolated neutrophils were also measured. MPO is the defining protein of 
azurophil granules (Bainton & Farquhar 1966) and its presence in cell 
supernatant can be measured by ELISA, or more simply its enzymatic activity 
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can be quantified by using an adaptation of the TMB/H2O2 colorimetric assay 
(Palić et al. 2005).  
1 x 106 neutrophils in IMDM (no phenol red) with 1% autologous serum were 
stimulated as described in section 2.18.1 in a total assay volume of 1 ml. This 
allowed simultaneous measurement of live bacterial killing if required. At the 
end of stimulation, tubes were placed on ice and centrifuged for 5 min at 300g 
(if neutrophils alone present) or 1 min at 10,000g (if bacteria also present). Cell-
free supernatants were transferred to fresh tubes for immediate storage at -
80oC for later analysis. 200 µl was used immediately for the MPO release 
assay. 100 µl of each supernatant was placed in duplicate wells of a 96-well 
plate and 100 µl of a freshly prepared 1:1 mixture of TMB and H2O2 solutions 
was added to each well and the plates incubated in the dark for 20 min. A 
separate control sample of 1 x 106 neutrophils lysed with 0.1% Triton was used 
to represent ‘100% MPO release’. 50 µl of 2N sulphuric acid was added to each 
well to stop the reaction and the absorbance read at 450 nm using a FLUOstar 
Omega spectrophotometer, correcting for medium alone.  
Results were expressed as % MPO release, defined by: 
%  𝑴𝑷𝑶  𝒓𝒆𝒍𝒆𝒂𝒔𝒆 =   100%  ×    𝑂𝐷  𝑣𝑎𝑙𝑢𝑒  𝑜𝑓  𝑠𝑎𝑚𝑝𝑙𝑒𝑂𝐷  𝑣𝑎𝑙𝑢𝑒  𝑜𝑓  𝑇𝑟𝑖𝑡𝑜𝑛𝑖𝑠𝑒𝑑  𝑐𝑒𝑙𝑙𝑠 
2.18.4 Lactoferrin ELISA 
Lactoferrin is constitutively stored in the specific granules of neutrophils and is 
released readily in high concentrations upon degranulation. A sandwich ELISA 
was designed and optimised to measure LTF concentrations in the 
supernatants generated in experiments above. A mouse anti-human LTF 
monoclonal antibody (IgG1, κ) at 1 µg/ml was paired with a biotin-conjugated 
rabbit anti-human LTF polyclonal antibody (IgG) at 0.5 µg/ml, using streptavidin-
HRP at 0.5 µg/ml. All the coating and colorimetric steps were as in section 1.1. 
Lactoferrin standards were prepared with serial 1:2 dilutions of human LTF 
protein from 320 ng/ml to 10 ng/ml.  
Initial titration experiments revealed that both a 1:10 and a 1:20 dilution of 
thawed supernatants in ELISA assay buffer were required to obtain all sample 
OD values within the exponential part of the standard curve, depending on the 
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potency of the stimulant. Results were expressed as ng/ml LTF released per 1 x 
106 neutrophils. 
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 L-selectin Shedding 2.19
L-selectin (also known as CD62L) is an adhesion molecule expressed on 
leukocytes with a crucial role in neutrophil recruitment to sites of inflammation. It 
binds to ligands expressed on vascular endothelium to promote adhesion. 
When neutrophils are activated by chemokines or by contact with an activated 
endothelium, or indeed upon initiation of apoptosis, L-selectin is cleaved from 
neutrophils by the metalloprotease ADAM-17, while expression of the integrin 
Mac-1 (CD11b/CD18) is increased to promote transmigration through the 
endothelial cell layer (Li et al. 2006). The degree of L-selectin shedding by 
neutrophils in response to activation can be measured using a whole blood flow 
cytometry assay. Briefly, samples of 100 µl of heparinised blood were pre-
treated with inhibitors/vehicle control for 30 min at 37oC before staining with 
APC-conjugated mouse anti-human CD62L monoclonal antibody (IgG, κ) at the 
manufacturer’s suggested concentration for 15 min in the dark at room 
temperature. Samples were then stimulated with vehicle control or 10 nM fMLP 
for 15 min at 37oC before placing on ice and adding 2 ml of 1X Pharmlyse to 
each sample for 15 min at room temperature. The samples were transferred to 
FACS tubes and washed twice before analysing on a BD FACSCanto II 
machine. Although CD62L staining in quiescent, unstimulated neutrophils was 
weak (see Chapter 3 results), there was a sufficient difference between the 
median fluorescence intensities of stimulated and unstimulated neutrophils to 
assess an effect of inhibitors on the mechanism. 
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 Extracellular Superoxide Release (Cytochrome C reduction assay) 2.20
The extracellular release of superoxide anions by freshly isolated neutrophils in 
response to priming by platelet-activating factor (PAF) and activation by fMLP 
was determined using a cytochrome C reduction assay (Kitchen et al. 1996). 
Briefly, 50 µl of neutrophils at 1 x 107/ml in HBSS+ were placed in 2 ml round-
bottomed eppendorf tubes. Potential inhibitors/control and the priming agent 
PAF (final concentration 100 nM) were placed on the underside of the tube lids 
before inverting the tubes simultaneously to commence the reaction. Tubes 
were incubated in a shaking water bath at 37oC for 10 min, before adding fMLP 
at 100 nM and cytochrome C at 1 mg/ml (end volume 500 µl) and reincubating 
for a further 15 min. For each sample, a control with 200 U/ml superoxide 
dismutase (SOD) was included to verify the specificity of cytochrome C 
reduction by superoxide anions. The reaction was terminated on ice for 5 min 
and tubes centrifuged at 10,000g for 3 min at 4oC. Triplicate 100 µl samples of 
supernatant were transferred to a 96-well plate to measure the absorbance at 
550 nm in a FLUOstar Omega spectrophotometer. The superoxide dismutase-
inhibitable reduction of cytochrome C was determined for each sample using 
the following equation: 𝑆𝑢𝑝𝑒𝑟𝑜𝑥𝑖𝑑𝑒  𝑟𝑒𝑙𝑒𝑎𝑠𝑒   𝑛𝑎𝑛𝑜𝑚𝑜𝑙𝑒𝑠  𝑜𝑓  𝑂!!  𝑝𝑒𝑟  10!  𝑐𝑒𝑙𝑙𝑠=   159  ×   𝑂𝐷!!"  𝑤𝑖𝑡ℎ𝑜𝑢𝑡  𝑠𝑢𝑝𝑒𝑟𝑜𝑥𝑖𝑑𝑒  𝑑𝑖𝑠𝑚𝑢𝑡𝑎𝑠𝑒𝑂𝐷!!"  𝑤𝑖𝑡ℎ  𝑠𝑢𝑝𝑒𝑟𝑜𝑥𝑖𝑑𝑒  𝑑𝑖𝑠𝑚𝑢𝑡𝑎𝑠𝑒  
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 Intracellular Oxidative Burst (dihydrorhodamine 123 assay) 2.21
The dihydrorhodamine 123 (DHR) assay measures ROS production. Cells 
readily take up the non-fluorescent compound DHR 123 intracellularly, which is 
oxidised to the highly fluorescent compound rhodamine 123 by the ROS 
produced during activation of the oxidative burst (van Pelt et al. 1996). Briefly, 
500 µl of freshly isolated healthy neutrophils at 1 x 106/ml in HBSS+/1% 
autologous serum in 2 ml round-bottomed eppendorf tubes were pre-treated 
with vehicle control or potential inhibitors for 30 min at 37oC before loading with 
DHR at a final concentration of 1 µM for 15 min in the dark at 37oC. PMA (final 
concentration 50 nM) or vehicle control were then added and incubated for 15 
min at 37oC before transferring the samples to FACS tubes and analysing them 
on a BD FACSCanto II machine. Data were expressed as the median 
fluorescence intensity of the neutrophil population at 530 +/- 30 nm, excited by 
a 488 nm laser.  
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 In Vivo Murine Experiments 2.22
(Chapter 4) 
In the absence of an animal project licence within our own research group to 
test our hypotheses in vivo, we sought collaboration with Dr D Dorward, Clinical 
Research Fellow in Professor Adriano Rossi’s Lung Inflammation research 
group, Centre for Inflammation Research, Edinburgh University. With another 
Clinical Research Fellow (Dr C Lucas), Dr Dorward had previously optimised 
the in vivo murine models of sterile and non-sterile acute lung inflammation 
described here. The wide range of assays used to measure neutrophil 
activation, influx and epithelial leak in response to the noxious stimuli were 
adapted for the purposes of my experiments.  
For the E. coli experiments using 1 mg/kg and 10 mg/kg dasatinib, and for the 
acid injury experiment using 5 mg/kg dasatinib, I was present for the duration of 
the experiments during 3 separate 3-4 day trips to Edinburgh. Dr Dorward 
performed all work involving direct contact with mice and I assisted him. After 
culling of mice and harvesting of samples, I worked with Dr Dorward to process 
the samples immediately. All ELISAs, cytospin counts, slide photography, data 
preparation and analysis were carried out by myself. 
To complete our data set and firmly test our initial hypotheses, Dr Dorward and 
Dr Lucas kindly carried out the final acid injury experiment at a dose of 10 
mg/kg dasatinib, as I was not able to attend on this occasion. For these 
experiments I analysed all the data. 
2.22.1 E. coli model of acute lung inflammation 
8-10 week old female C57/BL6 mice were purchased from Harlan UK and were 
used in all in vivo model experiments, under project licence number PPL 60-
4531 and personal licence number PIL 60/12746 (Dr Dorward), according to the 
Animals (Scientific Procedures) Act 1986. 
E. coli (ATCC 25922 strain) was grown in overnight culture by inoculating 10 ml 
of LB broth with a single colony from a fresh agar plate and placing in a shaking 
incubator at 37oC. A further 2 hour incubation of a 1:20 sub-dilution in 10 ml of 
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LB broth was carried out the following morning to reach early log growth phase. 
The suspension was centrifuged at 4000g for 5 min and the pellet resuspended 
in 1 ml sterile PBS- in a 1.5 ml eppendorf tube, before washing 3 times in PBS- 
at 4000g for 1 min. The OD600 of the suspension was measured and diluted to a 
value of exactly 1.0, approximating to an E. coli concentration of 2 x 108 cfu/ml, 
as estimated by previously calculated growth curves. From previous 
experiments carried out by Dr Dorward and Dr Lucas, an intratracheal 
instillation of 5 µl of an OD600=1.0 suspension per mouse, resuspended in a 
total volume of 50 µl sterile PBS- (equating to approximately 1 x 106 cfu E. coli 
per mouse), was a sufficiently robust stimulus to induce a moderate 
inflammatory response in the lungs without significant organ dysfunction or 
systemic sepsis. In each experiment, the actual bacterial concentration of the 
inoculum was retrospectively calculated by serially diluting it by factors of 10 
and pipetting 3 x 10 µl drops of each dilution onto an LB agar plate and 
incubating overnight at 37oC. An average colony count was taken from a 
‘countable’ dilution and the original inoculum size derived from this value by 
multiplying by a factor of 50,000 (see Figure 2-12 overleaf). In 2 separate 
experiments, estimated inoculum total values of 1.3 x 106 and 1.5 x 106 
cfu/mouse were achieved. 
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Figure 2-12 Colony counting method for retrospective calculation of total 
number of viable bacteria inoculated per mouse 
In this example, the 1:104 dilution of the original bacterial suspension 
highlighted by the red oval is countable.  An average of 3 colony group numbers 
in 10 µl is calculated (30 colonies) and used to derive the figure of 1.5 x 106 cfu 
of E. coli per mouse. 
As soon as the E. coli suspension was prepared, mice (8-10 per 
control/treatment group) were pre-treated i.p. with either 20 µl control DMSO or 
20 µl dasatinib (at the desired concentration assuming an average weight of 20 
g per mouse) dissolved in DMSO. After 30 min, the mice were anaesthetised 
with i.p. 665 µg ketamine and 8.75 µg medetomidine made up to a final volume 
of 100 µl with sterile H2O, then 50 µl of prepared E. coli suspension was 
administered directly to the lungs via the trachea of all mice via a catheter, 
followed by 2 flushes with 200 µl air (see Figure 2-13 opposite). Anaesthetic 
was reversed with 200 µl s.c. Antisedan (Atipamezole, 20 µg in 200 µl H2O) 
after approximately 20 min, before mice were transferred to individually 
ventilated cages at 28oC, given fresh food and sterile water and observed 
closely. 
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Figure 2-13 Method of intratracheal administration of acid or bacteria in 
mice 
Image reproduced by kind permission of Dr D Dorward. 
Dasatinib or control DMSO were readministered i.p. at 12 h. This double 
treatment regime was based on previous experimental time course data 
showing that the peak neutrophil influx into the lung interstitium occurs at 12 h 
compared to 24 h into the BALF (see Figure 2-14 below). 
 
Figure 2-14 Time course experiments showing neutrophil influx into lung 
interstitium and BALF following i.t. E. coli 
Data kindly provided by Dr D. Dorward 
At 24 h mice were culled with terminal anaesthesia using Avertin with 
exsanguination. Blood sampling occurred prior to death with BAL and collection 
of tissues following death of the animal. 
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Following anaesthesia, the chest wall of the animal was opened by a midline 
abdominal incision and blood sampled by direct cardiac puncture through the 
diaphragm into a pre-citrated syringe. 40 µl blood was diluted 1:2 and mixed 
well with 3.8% sodium citrate solution in a 500 µl eppendorf tube and the 
remainder used to fill a Microvette CB 300 LH (lithium heparin) serum tube. 
Next, a tracheostomy was performed and a plastic-coated 25 gauge needle 
inserted into the trachea as far as the carina and tied securely in place. 3 x 
sequential 800 µl sterile PBS- lavages were performed, the 1st (cellular) return 
being placed in a 1.5 ml eppendorf (Tube 1) and the 2nd and 3rd combined into a 
2 ml eppendorf tube (Tube 2). The spleen and right lobe of liver were then 
dissected out and placed in separate 2 ml homogeniser tubes pre-filled with 1 
ml sterile PBS- (Precellys Ceramic Kit 1.4mm) before the lung vasculature was 
flushed anterogradely with 10 ml of sterile, through cannulation of the right 
ventricle. Once the lungs blanched, the right lung was removed and placed in a 
2 ml eppendorf pre-filled with 1 ml sterile PBS- All samples were placed on ice 
immediately. 
2.22.2 Acid model of acute lung inflammation 
The experimental plan was very similar to that used in the E. coli model (section 
2.22.1), with some subtle changes as follows: The acid stimulus used per 
mouse was 50 µl of pH 2.0 HCl, prepared by diluting a stock solution of pH 1.0 
HCl 1:10 in 0.9% NaCl solution. As pH 2.0 acid is a potent pulmonary stimulus, 
less anaesthetic was used. The resulting acidaemia also affects binding of 
anaesthetic drugs with serum proteins, prolonging their duration of action and 
increasing the animal’s recovery time. A 200 µl bolus of 0.9% NaCl was 
administered i.p. as fluid resuscitation, to counteract the immediate effects of 
fluid shift into the lung parenchyma. Mice were then placed in a humidified 
chamber supplemented with 2 l/min O2 at 28oC for 30 min before the 
anaesthesia was reversed with s.c. Antisedan.  
At retrieval, the liver and spleen were not taken, as no bacterial work was 
required in this model. The left lung was taken in addition to the right lung and 
placed into a pre-filled homogeniser tube, for cytokine analysis. 
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2.22.3 Processing of individual samples in preparation for subsequent 
assays 
 Blood – Serum tubes were centrifuged at room temperature for 5 min at 
850g to make serum, which was aliquoted and stored at -80oC for later 
analysis. 20 µl citrated blood was transferred to individual FACS tubes and 
stored at 4oC prior to staining. 
 BALF – The exact volume of BALF returned was measured using scales 
zeroed to empty 1.5 ml and 2 ml eppendorf tubes, then both tubes were 
centrifuged at 850g for 5 min at room temperature. Supernatants from the 
1.5 ml (Tube 1) and 2 ml (Tube 2) eppendorfs were aliquoted and stored 
separately at -80oC, with some fresh supernatant taken for immediate use. 
The remaining cell pellets from tubes 1 and 2 were combined and 
resuspended in 500 µl PBS- for use in subsequent assays. 
 Liver and spleen – In the E. coli model, these samples were homogenised 
by placing the tubes in a Precellys homogeniser (Bertin Technologies, 
France) and disaggregated with three cycles of 6800 rpm for 30 s. 
 Right lung – Lung samples were cut into smaller pieces and incubated in 
500 µl of 5 mg/ml collagenase D for 1 h at 37°C in a shaking heat block at 
400 rpm. After disaggregation through a 19 gauge needle, samples were 
centrifuged at 300g for 5 min, resuspended in 500 µl ACK lysis buffer and 
incubated for 5 min on ice, before washing in 500 µl PBS- at 300g for 5 min.  
Cells were then resuspended in 1 ml of PBS- and passed through a 40 µm 
cell sieve. The cells were resuspended in 250 µl PBS- and incubated for 10 
min with 2.5 µl rat anti-mouse CD16/32 Fc blocking monoclonal antibody 
(IgG2a, λ) prior to antibody staining. 
 Left lung – In the acid model experiment using 5 mg/kg dasatinib, the left 
lung was also taken and homogenised as described above, spun at 850g for 
5 min and the supernatant aliquoted and stored at -80oC for subsequent 
cytokine analysis. 
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2.22.4 Measurement of neutrophil/cellular influx into alveolar space 
50 µl of the resuspended cellular pellet from BALF Tube 1 was placed in a 
round-bottomed 96 well plate and 50 µl of both ChemoMetec reagent A-100 
and reagent B added. The sample was loaded onto a Nucleocassette and cell 
concentration measured using a NucleoCounter© NC-100™ machine 
(ChemoMetec A/S, Allerod, Denmark). Using the previously measured total 
BALF volume, a cellular concentration expressed in cells/µl BALF could be 
calculated. To determine cell purity, cytocentrifuge preparations of 7.5 x 105 
cells were fixed with methanol, stained with Reastain Diff-Quik for 1 min in each 
solution, mounted with DPX and viewed at x1000 using a conventional 
benchtop light microscope, counting the % neutrophils in 3 randomly selected 
fields of at least 100 cells. 
2.22.5 Measurement of neutrophil activation and recruitment by flow 
cytometry 
Citrated blood (20 µl), BALF cell suspension (20 µl) and digested lung 
parenchymal cells (20 µl) in individual FACS tubes were stained with FITC-
conjugated rat anti-mouse CD11b monoclonal antibody (IgG2b, κ), PE-
conjugated rat anti-mouse CD63 monoclonal antibody (IgG2a, κ), Pacific Blue- 
conjugated rat anti-mouse Ly6G monoclonal antibody (IgG2a, κ) for 30 min at 
4oC in the dark, before adding 2 ml of 1X FACSLyse solution and storing at 4oC 
in the dark overnight for analysis the following day. Immediately before analysis, 
the samples were centrifuged at 300g for 5 min and the cells resuspended in 
200 µl PBS-. 50 µl of Beckman Coulter flow check beads were added to each 
sample, mixed well and analysed on a BD FACSAria II machine, capturing a 
total 5000 beads with all associated events. The gating strategy is shown in 
Figure 2-15 opposite. 
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Figure 2-15 Gating strategy used to analyse total neutrophil number, % of 
total cells and activation markers within 3 compartments: peripheral 
blood, BALF and lung parenchyma 
Single neutrophils are gated by their forward/side scatter properties, from which 
CD11b+ Ly6G+ cells are selected and analysed for CD63 and CD66b staining. 
Representative plot from 4 experiments. 
2.22.6 Measurement of epithelial damage/leak 
Duplicate 10 µl samples of BALF from tube 1 were used to measure total 
protein content with a Pierce BCA Protein Assay Kit against a set of standard 
concentrations (31.25-2000 µg/ml), according to the manufacturer’s instructions. 
BALF stored at -80oC was analysed 48 h later using a soluble IgM ELISA kit, 
according to the manufacturer’s instructions. Multiple dilutions of single samples 
were tested to obtain accurate results within the ELISA standard curve. 
2.22.7 Measurement of bacterial survival 
3 x 10 µl drops of citrated blood were placed on a LB agar plate and incubated 
overnight to look for evidence of bacteraemia. BALF, homogenised liver, lung 
and spleen samples were all serially diluted 1:10 in LB Broth and 3 x 10 µl 
drops of each were incubated on LB agar to assess for local and distant 
bacterial spread. As described in section 2.22.1, colony counts were used to 
calculate bacterial concentrations. 
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2.22.8 Measurement of systemic toxicity 
As surrogate measures of systemic sepsis and drug toxicity, prepared plasma 
samples were tested for levels of lactate in mmol/l and alanine transaminase 
(ALT) in u/l. Briefly, samples of citrated blood were centrifuged at 850g for 3 
min. Plasma was aliquoted and stored at -80oC for later analysis by Dr Forbes 
Howie, Edinburgh University. ALT and lactate were quantified by using 
commercial kits (from Alpha Laboratories Ltd, Eastleigh, UK and Randox 
Laboratories Ltd, Crumlin, UK respectively) adapted for use on a Cobas Fara 
centrifugal analyser (Roche Diagnostics Ltd, Burgess Hill, UK).  
2.22.9 Measurement of inflammatory cytokines in BALF and homogenised 
lung 
The MPO content of the BALF was measured in two ways. 50 µl of fresh BALF 
from Tube 1 was placed in a 96-well plate and 100 µl of a premixed 1:1 
TMB/H2O2 solution was added and incubated in the dark at room temperature 
for 20 min or until no further blue colour developed. The reaction was stopped 
with 50 µl of 2N sulphuric acid and the absorbance measured at 450nm. Frozen 
BALF and homogenised lung (in the acid model only) samples were thawed and 
analysed for the presence of MPO using a MPO ELISA kit, in addition to LTF, 
IL-6, KC, CCL-2, IL-10 and TNFα with their respective ELISA kits. As before, 
multiple dilutions of single samples were tested to obtain appropriate OD 
values. 
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 Statistical Analysis and Graphical Presentation of Data 2.23
Flow cytometry data were analysed using Flojo version 10.0.7 (Ashland, OR, 
US). Statistical analysis and graphical presentation were carried out using 
Prism version 5.0f (Graphpad Software, La Jolla, CA, US). 
Parametric data were analysed with the student’s T-test when comparing two 
conditions and with a repeated measures Analysis of Variance (ANOVA) for 
greater than two conditions, using Dunn’s post-hoc analysis test to compare 
individual conditions with the control condition. 2-way ANOVA analysis was 
used when two simultaneous variables were tested.  
Non-parametric data were analysed with the Mann Whitney test for two 
conditions and with either the Kruskal-Wallis test or Friedman test for greater 
than two conditions, also using Dunn’s post-hoc analysis test to compare 
individual conditions with the control condition. A significance level of less than 
5% was used in all statistical tests.  
Data are presented in tabular or graphical form as medians with range or 
interquartile range (IQR) if taken from non-parametrically distributed 
populations, or means with standard deviations (SD)/standard errors (SE) if 
taken from parametrically distributed populations. The graphical results of 
optimisation or control experiments are generally displayed in black and white, 
whereas the results of experiments used to test hypotheses are displayed in 
colour, in which the control conditions are displayed in red. 
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Chapter 3. An Investigation into the Effects of Src Kinase 
Inhibitors on Neutrophil Function In Vitro 
 Chapter Overview  3.1
This chapter details the work I carried out to investigate the effects of src kinase 
inhibition on in vitro neutrophil function in acute inflammation and infection. The 
following hypothesis was tested: 
“In vitro src kinase inhibition of human neutrophils reduces extracellular 
degranulation in response to both chemical and live bacterial stimuli, 
without impairing efficient neutrophil phagocytosis and intracellular 
killing of bacteria” 
The experiments initially focus on the key process of neutrophil degranulation, 
establishing an optimum concentration of PP1 required to attenuate 
extracellular degranulation from healthy volunteer neutrophils in response to a 
number of ‘physiological’ chemical and bacterial stimuli.  
The key experiments are then repeated to establish an optimum concentration 
of a clinically licensed src kinase inhibitor to use subsequently in further in vitro 
functional assays.  
Throughout the results chapters, I have endeavoured to keep a standardised 
structure to aid the reader in interpreting the results. Within each subsection, 
where possible, I generally detail the experiment rationale, design and the 
results in the text opposite each figure and legend, together with comments 
analysing the results and explaining how they led onto the next experiment. 
Details of experimental methods have not been repeated, and can be referred 
to in Chapter 2 on page 31. 
The results are discussed in relation to published data throughout each chapter, 
before concluding with a summary of the key findings. 
3.1.1 Parametric and non-parametric data 
When examining the in vitro data in Chapters 3 and 5, it is important for the 
reader to consider that each experiment was typically repeated a maximum of 3 
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- 6 times due to a limited supply of blood donors and the logistics of performing 
several different assays within the limited lifespan of neutrophils. With such 
small experimental numbers, it is impossible to carry out any meaningful test of 
normality, so if values were reproducible between individual healthy volunteers, 
I chose to make the assumption that the sample was taken from a normally 
distributed population and have therefore displayed the data as mean +/- 
SD/SE and analysed them with t-tests and ANOVAs. Conversely, in some 
assays such as apoptosis by cell morphology (Section 3.5.2) and superoxide 
release (Section 3.5.8), there was little reproducibility of values between 
individual volunteers and the data are presented as median +/- IQR and 
analysed with Mann Whitney tests or Friedman/Kruskal-Wallis tests.  
As expected, values from ex vivo experiments involving neutrophils from 
critically ill patients (Section 5.3) showed marked variability and as such were 
displayed and analysed as non-parametric data. 
In vivo murine experiments (Chapter 4) were carried out using 8 – 10 animals 
per group. Given the larger sample numbers and reliability of the assays, these 
data have been displayed and analysed as parametric in distribution for all 
except the bacterial survival assays. 
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 Experimental Techniques to Stimulate Human Neutrophil 3.2
Degranulation with Sterile and Non-sterile Stimuli 
There are numerous effective techniques of experimentally inducing human 
neutrophil degranulation via different intracellular pathways, using chemical 
stimuli in vitro, some of which are more physiologically relevant. I chose to use 
the following stimulants: 
3.2.1 Cytochalasin B/fMLP 
In Ca2+-replete neutrophils pre-treated with cytochalasin B, the bacterial protein-
derived chemoattractant, fMLP, ligates its G protein-coupled receptor FPR1, 
inducing both phospholipase C (PLC) and phospholipase D (PLD) activation in 
a PI3K-dependent manner. The resulting secondary messengers inositol-1,4,5-
triphosphate (IP3) and 1,2-diradyl-sn-glycerol (DG) activate protein kinase C 
(PKC) and mobilise intracellular Ca2+ stores to initiate degranulation (Mullmann 
et al. 1993; Mansfield et al. 2002; Lacy 2006). 
3.2.2 Phorbol myristate acetate 
Phorbol myristate acetate (PMA) is a potent PKC agonist that can be used to 
study the mechanisms controlling NADPH oxidase assembly and degranulation 
in both the plasma membrane and the granule membrane. The traditional 
theory is that PMA acts independently of PI3K, however there is some evidence 
to show that PMA-induced superoxide production is PI3K-dependent in the 
granule membrane and PI3K-independent at the plasma membrane (Karlsson 
et al. 2000). The same observation has yet to be demonstrated in the 
mechanisms controlling neutrophil degranulation, which is usually measured by 
extracellular release. 
3.2.3 Lipopolysaccharide 
In the presence of LPS-binding protein, LPS released from the outer membrane 
of Gram negative organisms ligates CD14 on macrophages, neutrophils and 
monocytes, which, via its co-receptor TLR4, initiates intracellular signalling 
resulting in activation of NF-κB (Kitchens 2000; Lu et al. 2008). Although 
lipopolysaccharides from different Gram negative bacteria differ in their 
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molecular weight depending on their carbohydrate content, LPS from E. coli is 
capable of inducing neutrophil extracellular degranulation at a concentration of 
100 ng/ml (Hayashi et al. 2003; Sabroe et al. 2005). LPS has also long been 
studied in in vivo models of sepsis and acute lung inflammation. 
3.2.4 Live bacteria 
Live bacteria represent the most physiologically relevant stimuli of neutrophil 
degranulation. They are less studied in the literature due to a number of factors 
including: variation in individual pathogen, strain virulence strategies and host-
pathogen interactions, the challenge of obtaining reproducible results due to the 
sensitivity of bacteria to their immediate environment and the interference of 
bacterial presence (and ongoing multiplication) on assay performance. I chose 
to use PA and SA as they represent Gram negative and Gram positive 
organisms commonly isolated from the lungs of critically ill patients. They 
comprised the two most common organisms isolated in 1689 cases of 
ventilator-associated pneumonia (VAP) in a series of 24 studies with an 
isolation frequency of 24.4% and 20.4% respectively (Chastre & Fagon 2002). I 
used serum-opsonised live bacteria and was therefore predominantly studying 
complement receptor (CR3)-mediated phagocytosis and degranulation (Caron 
& Hall 1998). 
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 Src Kinase Inhibition of Neutrophil Degranulation with PP1 3.3
Initial experiments sought to replicate previously published data showing that 
the specific src tyrosine kinase inhibitor, PP1, can inhibit adhesion-dependent 
degranulation (Mócsai et al. 1999) and fMLP-induced degranulation (Mócsai et 
al. 2000) and establish an optimum concentration of PP1 for use in subsequent 
experiments. 
3.3.1 PP1 inhibits c-src Tyr416 phosphorylation in stimulated neutrophils 
without affecting p38 MAPK phosphorylation 
When c-src is activated, Tyr527 is dephosphorylated, allowing destabilisation of 
its regulatory SH2 and SH3 domains, revealing the kinase required for the 
autophosphorylation of Tyr416 (Cooper et al. 1986).  
Results: Figure 3-1 opposite suggests that at concentrations of 10 µM and 
above, PP1 inhibits autophosphorylation of c-src Tyr416 in purified neutrophils 
both unstimulated or stimulated by 100 ng/ml LPS, with no effect on activation 
of the control p38 MAPK pathway.  
Comments: It is interesting to observe that in these experiments, the control 
neutrophils without PP1 pre-treatment demonstrate a relatively high degree of 
baseline c-src Tyr416 phosphorylation, irrespective of LPS stimulation and 
despite the addition of phosphatase inhibitors to the lysis buffer. This may be 
caused by unavoidable activation during the Percoll method of neutrophil 
purification. 
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Figure 3-1 PP1 inhibits src kinase activity in human neutrophils stimulated 
with LPS 
Western blot of lysates from 5 x 106 neutrophils (from healthy volunteers) pre-
treated with control, 10 µM PP1 or 30 µM PP1 and stimulated for 15 min with 
100 ng/ml LPS or control. Lysates were probed with antibodies directed towards 
phospho-src Tyr416, total src kinase, phospho-p38 MAPK and total p38 MAPK. 
Representative image from one of three separate experiments using neutrophils 
from independent volunteers. 
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3.3.2 PP1 inhibits neutrophil degranulation of primary granules in 
response to fMLP in a dose dependent fashion 
I used MPO as a surrogate marker of primary granule degranulation as its 
relative activity in extracellular fluid can be measured simply by exploiting its 
ability to reduce H2O2 in the colorimetric TMB/H2O2 assay. Using this method 
makes the assumptions that the MPO activity is directly proportional to the 
amount of actual enzyme present and that the MPO released by neutrophil 
degranulation in response to the various stimulants is all functional. In the 
murine experiments in chapter 5 I therefore modified my methods to measure 
both MPO antigen presence using ELISA and activity using the TMB/H2O2 
assay.  
Results: Figure 3-2 opposite shows that neutrophils adherent to tissue culture 
plastic (B) and in free suspension (C) release significantly less MPO in 
response to fMLP when pre-treated with at least 10 µM (C) and 30 µM (B) of 
PP1.  
Comments: The control experiment in A demonstrates that this effect cannot 
be explained by an inhibitory effect of high concentrations of PP1 itself on the 
enzymatic activity of MPO in the TMB/H2O2 assay.  
Control adherent neutrophils appear to release less than half the amount of 
functional MPO released by neutrophils in suspension. The mechanism of 
adhesion via integrin activation and ligation represents an important stimulator 
of degranulation. I used 1 x 106 neutrophils in both adherent and suspension 
conditions: 1 x 106 neutrophils adherent to the base of a single well of a 24-well 
plate represents a very crowded fit. It is therefore conceivable that any MPO 
released is either taken up by adjacent neutrophils or remains within the 
neutrophil monolayer rather than being circulated into suspension in the media. 
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Figure 3-2 PP1 inhibits primary granule release of MPO from neutrophils 
in response to cytochalasin B/fMLP 
Control experiment to demonstrate no effect of the presence of 30 µM PP1 on 
the reduction of H2O2 by MPO in the TMB/H2O2 assay (A). Data show mean + 
SD of OD values of the neutrophil lysates from 3 independent healthy 
volunteers. Dose response of PP1 pre-treatment on MPO release from 106 
neutrophils (from healthy volunteers) stimulated with 10 µM cytochalasin B for 5 
min followed by 1 µM fMLP for 10 min, adherent to tissue culture plastic (B) and 
in suspension (C). All conditions except the left-hand column were stimulated 
with cytochalasin B+fMLP. Data show mean and SD values of samples from 5 
experiments using neutrophils from 5 independent volunteers. p<0.0001 by 
repeated measures ANOVA ***p<0.001 by Dunn’s post-hoc test comparing with 
‘no pre-treatment’ control. 
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3.3.3 PP1 inhibits neutrophil degranulation of secondary granules in 
response to fMLP 
Lactoferrin was chosen as a surrogate marker for secondary granule release. 
Although secondary granules are released ahead of primary granules both 
temporally and in magnitude, both granules are released within the 
experimental endpoint of 30 min (Lacy & Eitzen 2008).  
Results: Figure 3-3 below shows very similar inhibitory thresholds of PP1 as for 
MPO release. Again, considerably less LTF is detected in the supernatant from 
adherent neutrophils than from suspension neutrophils. 
 
Figure 3-3 PP1 inhibits secondary granule release of LTF from neutrophils 
in response to cytochalasin B/fMLP  
Dose response of PP1 pre-treatment on LTF release from 106 neutrophils (from 
healthy volunteers) stimulated with 10 µM cytochalasin B for 5 min followed by 1 
µM fMLP for 10 min in adherent (A) and suspension (B) conditions. All 
conditions except the left-hand column were stimulated with cyto B+fMLP. Data 
show mean and SD values from 5 experiments using neutrophils from 5 
independent volunteers. p<0.0001 by repeated measures ANOVA; *p<0.05, 
***p<0.001 by Dunn’s post-hoc test comparing with ‘no pre-treatment’ control. 
3.3.4 PP1 inhibits neutrophil degranulation in whole blood in response to 
fMLP 
To reproduce these observations using a second experimental method, the 
relative expression of CD63 (primary granules), CD66b (secondary granules) 
and CD11b (a commonly studied marker of neutrophil activation expressed on 
secondary, tertiary and secretory vesicles) on the extracellular membranes of 
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be noted that I used one timepoint of 30 min stimulation. In reality there is 
continual cycling of membrane proteins from intracellular vesicles to the plasma 
membrane with subsequent degradation by ubiquitination (Bonifacino & 
Weissman 1998) but this ‘snapshot’ measurement gives an estimation of the 
degree of granule translocation and fusion with the plasma membrane in 
response to stimuli. 
Results: Although the effect of PP1 in whole blood appears less marked than in 
purified neutrophils, there is significant reduction of all three markers when pre-
treated with at least 30 µM PP1, as shown in Figure 3-4 below.  
 
Figure 3-4 PP1 inhibits primary and secondary granule extracellular fusion 
in response to cytochalasin B/fMLP 
Dose response of PP1 pre-treatment on extracellular expression of the primary 
granule marker CD63 (A), the secondary granule marker CD66b (B) and the 
secondary/tertiary granule/secretory vesicle marker CD11b (C) by neutrophils in 
whole blood (from healthy volunteers), in response to cytochalasin B/fMLP 
stimulation. All conditions except the left-hand column were stimulated with cyto 
B+fMLP. Data show mean and SE MFI values from 4 experiments using 
samples from 4 independent volunteers. p<0.0001 by repeated measures 
ANOVA; *p<0.05, ***p<0.001 by Dunn’s post-hoc test comparing with ‘no pre-
treatment’ control. 
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3.3.5 PP1 inhibits neutrophil degranulation of primary and secondary 
granules in response to LPS in a dose dependent fashion 
I chose to perform subsequent degranulation experiments on neutrophils in 
suspension and in whole blood only because the relative release of primary and 
secondary granules was significantly blunted in adherent conditions.  
Results: Pre-treatment with at least 10 µM PP1 is capable of significantly 
reducing both MPO and LTF release from purified neutrophils in response to 
100 ng/ml LPS, but a higher concentration of 30 µM is required to significantly 
reduce CD63, CD66b and CD11b expression (Figure 3-5 below and Figure 3-6 
opposite).  
Comments: LPS induces similar levels of CD66b and CD11b expression to 
stimulation with cytochalasin B/fMLP, but markedly less CD63 expression. This 
observation is also, to a lesser extent, seen in the MPO/LTF values and is likely 
to be explained by differences in the relative timing and speed of granule 
release with and without the addition of the co-stimulant cytochalasin B, as 
shown in the original granule kinetic studies (Bentwood & Henson 1980). 
 
Figure 3-5 PP1 inhibits primary granule MPO release and secondary 
granule LTF release in response to LPS 
Dose response of PP1 pre-treatment on MPO (A) and LTF (B) release from 106 
neutrophils (from healthy volunteers) in suspension stimulated with 100 ng/ml 
LPS for 30 min. All conditions except the left-hand column were stimulated with 
LPS. Data show mean and SD values from 5 experiments using samples from 5 
independent volunteers. p<0.0001 by repeated measures ANOVA; *p<0.05, 
***p<0.001 by Dunn’s post-hoc test comparing with ‘no pre-treatment’ control. 
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Figure 3-6 PP1 inhibits primary and secondary granule extracellular fusion 
in response to LPS 
Dose response of PP1 pre-treatment on extracellular expression of CD63 (A), 
CD66b (B) and CD11b (C) by neutrophils in whole blood (from healthy 
volunteers), in response to 100 ng/ml LPS stimulation. All conditions except the 
left-hand column were stimulated with LPS. Data show mean and SE MFI 
values from 4 experiments using samples from 4 independent volunteers. 
p<0.0001 by repeated measures ANOVA; **p<0.01, ***p<0.001 by Dunn’s post-
hoc test comparing with ‘no pre-treatment’ control. 
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3.3.6 PP1 does not inhibit PMA-induced neutrophil degranulation 
Results: As expected, PP1 pre-treatment only reduces neutrophil degranulation 
(MPO and LTF release; CD63 and CD11b expression) in response to PMA at 
an exceptionally high concentration of 100 µM (see Figure 3-7 below and Figure 
3-8 opposite).  
Comments: PMA is a potent PKC agonist and stimulates neutrophil 
degranulation independent of src kinases. This important experimental control 
shows that src kinase inhibition with PP1 does not globally inhibit neutrophil 
inflammatory pathways and functions.  
 
Figure 3-7 PP1 only inhibits primary granule MPO release and secondary 
granule LTF release in response to PMA at high concentrations 
Dose response of PP1 pre-treatment on MPO (A) and LTF (B) release from 106 
neutrophils (from healthy volunteers) in suspension stimulated with 100 nM 
PMA for 30 min. All conditions except the left-hand column were stimulated with 
PMA. Data show mean and SD values from 5 experiments using samples from 
5 independent volunteers. p=0.007 (A) and p=0.0017 (B) by repeated measures 
ANOVA, *p<0.05 by Dunn’s post-hoc test comparing with ‘no pre-treatment’ 
control. 
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Figure 3-8 PP1 only inhibits primary and secondary granule extracellular 
fusion in response to PMA at high concentrations 
Dose response of PP1 pre-treatment on extracellular expression of CD63 (A), 
CD66b (B) and CD11b (C) by neutrophils in whole blood (from healthy 
volunteers), in response to 100 nM PMA stimulation. All conditions except the 
left-hand column were stimulated with PMA. Data show mean and SE MFI 
values from 4 experiments using samples from 4 independent volunteers. 
p=0.0024 (A), p=0.0063 (B) and p=0.015 (C) by repeated measures ANOVA; 
*p<0.05, **p<0.01 by Dunn’s post-hoc test comparing with ‘no pre-treatment’ 
control. 
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3.3.7 PP1 inhibits neutrophil degranulation in response to live bacteria 
Novel data came from challenging degranulation experiments involving live 
bacteria. I chose to use the P. aeruginosa strain PA01 rather than clinically 
isolated strains as it is a relatively predictable non-virulent laboratory strain 
commonly used in scientific research. However in whole blood flow cytometry 
experiments, direct inoculation of blood with live PA01 resulted in rapid 
neutrophil death, as evidenced by high % DAPI staining (data not shown). For 
whole blood experiments I therefore used the S. aureus strain SA NCTC 8325 
that did not induce significant cell death in this assay.  
An MOI of approximately 10 bacteria per neutrophil was used because 
preliminary data showed that at this ratio, significant neutrophil degranulation 
occurred with net bacterial killing. At lower MOIs, the bacteria were all killed too 
rapidly and did not offer a robust stimulus whereas at higher MOIs the bacteria 
multiplied too quickly during the assay and overwhelmed the neutrophils (data 
not shown), consistent with earlier published observations (Li et al. 2002; Li et 
al. 2004). As such, results from experiments in which the retrospectively 
estimated MOI was markedly different from 10:1 were excluded for analysis. I 
found that after careful practice and strict timings, this potential variable was 
minimised. 
As shown in Figure 3-9 opposite, I carried out degranulation experiments on 
purified neutrophils both in free suspension on a tube rotator (B+D) and 
adherent to plastic (A+C). Whole blood measurements of CD63/66b/11b 
expression were in suspension. Serum-opsonised bacteria initiate phagocytosis 
and neutrophil degranulation upon ligation of the opsonin C3bi with its receptor 
CR3 on neutrophils. In this very simple in vitro model of alveolar infection and 
inflammation, purified neutrophils maintained in free suspension or in whole 
blood were chosen to represent neutrophils within extracellular or alveolar fluid, 
whilst adherent neutrophils represented activated neutrophils adherent to 
capillary endothelial cells or alveolar epithelial cells via integrin expression and 
ligation. 
Results: In both experimental conditions, at least 10 µM PP1 is required to 
significantly inhibit both primary and secondary granule release in response to 
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live PA01. A similar effect is observed when studying CD63, CD66b and CD11b 
expression on neutrophils in suspension in whole blood (Figure 3-10 overleaf).  
Comments: These observations will be discussed together with the 
phagocytosis and killing data presented in sections 3.5.7 to 3.5.9 below. 
 
Figure 3-9 PP1 inhibits primary granule MPO release and secondary 
granule LTF release in response to live serum-opsonised bacteria 
Dose response of PP1 pre-treatment on MPO (A+B) and LTF (C+D) release 
from 106 neutrophils (from healthy volunteers) adherent to tissue culture plastic 
(A+C) or in suspension (B+D), stimulated with serum-opsonised P. aeruginosa 
(MOI~10 PA01: 1 polymorphonuclear leukocyte - PMN) for 30 min. All 
conditions except the left-hand column were stimulated with PA01. Data show 
mean and SD values from 5 experiments using samples from 5 independent 
volunteers. p<0.0001 by repeated measures ANOVA; ***p<0.001 by Dunn’s 
post-hoc test comparing with ‘no pre-treatment’ control. 
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Figure 3-10 PP1 inhibits primary and secondary granule extracellular 
fusion in response to live serum-opsonised bacteria 
Dose response of PP1 pre-treatment on extracellular expression of CD63 (A), 
CD66b (B) and CD11b (C) by neutrophils in whole blood (from healthy 
volunteers), in response to stimulation by live S. aureus. All conditions except 
the left-hand column were stimulated with S. aureus. Data show mean and SE 
MFI values from 4 experiments using samples from 4 independent volunteers. 
p<0.0001 by repeated measures ANOVA; *p<0.05, ***p<0.001 by Dunn’s post-
hoc test comparing with ‘no pre-treatment’ control. 
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 Src Kinase Inhibition of Neutrophil Degranulation with Clinically 3.4
Licensed Src Kinase Inhibitors 
The next set of experiments aimed to test whether the observations made using 
PP1 were replicated using other src kinase inhibitors. I specifically chose two 
safe, clinically licensed src kinase inhibitors: dasatinib and bosutinib. The 
experiments were designed to identify a drug to take forward into in vivo murine 
models of acute lung inflammation (Chapter 4) as well as an optimum in vitro 
concentration for use in further in vitro experiments (Chapter 5). Although 
dasatinib inhibits the non-receptor tyrosine kinases Abl, c-src and c-kit with an 
IC50 of 0.6 nM, 0.8 nM and 79 nM respectively, these concentrations were 
established using in vitro kinase autophosphorylation assays on glutathionine-
sepharose beads (O’Hare 2005; Shah et al. 2006) and higher concentrations 
are required in cellular assays to act intracellularly. Indeed, at least 10 nM was 
required to observe an effect in functional assays on human neutrophils (Futosi 
et al. 2012). 
Bosutinib is considered a potent dual inhibitor of c-src and Abl with comparable 
IC50 values to dasatinib in kinase assays: 1.2 nM and 1.0 nM respectively 
(Boschelli et al. 2001; Golas et al. 2003). It has also been shown to inhibit other 
members of the src family kinases such as Hck, Fgr, Lyn that are found only on 
haematopoietic cells (Remsing Rix et al. 2009). 
An initial concentration range of 10 nM to 1 µM of both dasatinib and bosutinib 
was therefore used for the majority of the initial experiments that follow. 
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3.4.1 The src/Abl kinase inhibitors dasatinib and bosutinib inhibit c-src 
Tyr416 phosphorylation in stimulated neutrophils 
Results: The Western blots reproduced opposite in Figure 3-11 show a marked 
attenuation in c-src Tyr416 autophosphorylation when human neutrophils are 
pre-treated with 100 nM dasatinib and a complete absence of c-src kinase 
activity using a concentration of 1  µM.  
With bosutinib there appears to be a biphasic response with increased c-src 
kinase activation at lower concentrations (100 nM) but a significant reduction at 
1 µM. The experiments below were carried out at the same time and the 
observations reproduced using neutrophils from 3 different healthy volunteers 
on 3 separate days.  
Comments: The results of the bosutinib Western blot will be interpreted in light 
of functional assay data shown below in section 3.4.2. 
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Figure 3-11 Dasatinib and bosutinib inhibit src kinase activity in human 
neutrophils stimulated with LPS 
Western blot of lysates from 5 x 106 neutrophils (from healthy volunteers) pre-
treated with control, 100 nM or 1 µM dasatinib, 100 nM or 1 µM bosutinib and 
stimulated for 15 min with 100 ng/ml LPS or control. Lysates were probed with 
antibodies directed towards phospho-src Tyr416, total src kinase, phospho-p38 
MAPK and total p38 MAPK. Representative image from one of three separate 
experiments using neutrophils from independent volunteers. 
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3.4.2 Effect of dasatinib and bosutinib on lactoferrin release from 
stimulated neutrophils 
I decided to measure only LTF as a surrogate marker of degranulation because 
it was released more readily and reliably than MPO in response to all stimuli 
tested in the PP1 experiments above. It is a stable molecule resistant to protein 
degradation (Brock et al. 1976) and can be measured accurately by ELISA.  
Results: In dose response experiments shown opposite (Figure 3-12), pre-
treatment with at least 100 nM dasatinib is required to inhibit LTF release from 
neutrophils stimulated by cytochalasin B/fMLP, LPS or live S. aureus, with a 
trend towards an effect at 10 nM. Little effect is seen with bosutinib except at a 
concentration of 1 µM. 
Comments: My observations build on those made by Futosi et al. by the 
addition of live bacteria as a stimulus (Futosi et al. 2012). Similar to PP1, no 
effect is seen with PMA stimulation, demonstrating specificity in dasatinib’s 
action. The equivalent results for bosutinib are consistent with the Western blot 
shown in Figure 3-11 and suggest that concentrations of at least 1 µM of 
bosutinib are required to observe an inhibitory effect in functional assays. 
 
 
 
 
 
Figure 3-12 Dasatinib and bosutinib (at very high concentrations) inhibit 
LTF release from neutrophils in response to both sterile and non-sterile 
stimuli 
Dose response of dasatinib (A,C,E,G) and bosutinib (B,D,F,H) pre-treatment on 
LTF release from 106 neutrophils (from healthy volunteers) in suspension, 
stimulated by cytochalasin B 10 µM/fMLP 1 µM (A+B), LPS 100 ng/ml (C+D), 
PMA 100 nM (E+F) and serum-opsonised live S. aureus (MOI~10 SA: 1 PMN) 
(G+H). All conditions except the left-hand column were stimulated. Data show 
mean and SD values from 4 experiments using samples from 4 independent 
volunteers. p<0.001 by repeated measures ANOVA; **p<0.01, ***p<0.001 by 
Dunn’s post-hoc test comparing with ‘no pre-treatment’ control. 
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3.4.3 Effect of dasatinib on CD63/CD66b/CD11b expression on stimulated 
neutrophils 
Based on the results in sections 3.4.1 and 3.4.2 above, dasatinib was a better 
option than bosutinib to take forward into further in vitro and in vivo 
experiments.  
Results: In whole blood degranulation assays (Figure 3-13 opposite), dasatinib 
reliably exerts an inhibitory effect on CD63 and CD66b expression at 
concentrations of 100 nM and above, in response to stimulation with 
cytochalasin B/fMLP, LPS and live S. aureus, with no effect on PMA stimulation. 
CD11b expression is only affected by dasatinib in response to live S. aureus. 
Comments: These results complement the lactoferrin release data shown 
above in Figure 3-12. They show that both primary (CD63) and secondary 
(CD66b) granule exocytosis is inhibited by dasatinib. Dissimilar to the PP1 data, 
dasatinib only inhibits CD11b expression in response to CR3 (integrin-
mediated) serum-opsonised S. aureus stimulation, with no effect on fMLP (G-
protein coupled receptor-mediated) activation or LPS-mediated activation. 
Reassuringly, Futosi et al. showed similar findings, using different assays 
involving isolated adherent neutrophils (Futosi et al. 2012)  
As briefly discussed previously, the validity of these in vitro observations 
depends entirely on demonstrating that the drugs themselves are not directly 
cytotoxic to neutrophils at the equivalent concentrations shown to inhibit 
degranulation. At a final PP1 concentration of 100 µM in IMDM, I often observed 
that the drug precipitated when diluted 1:100 from its stock concentrate (10 mM 
in DMSO). A 1 in 100 dilution of DMSO is usually sufficient to avoid the 
inhibitory effects of the diluent itself on neutrophil function. 
Figure 3-13 Dasatinib inhibits primary and secondary granule extracellular 
fusion in response to sterile and non-sterile stimuli 
Dose response of Dasatinib pre-treatment on extracellular expression of CD63 
(A-D), CD66b (E-H) and CD11b (I-L) by neutrophils in whole blood (from 
healthy volunteers), in response to stimulation by cytochalasin B 10 µM/fMLP 1 
µM (A,E,I), LPS 100 ng/ml (B,F,J), PMA 100 nM (C,G,K) and serum-opsonised 
live S. aureus (MOI~10 SA: 1 PMN) (D,H,L). Data show mean and SE MFI 
values from 4 experiments using samples from 4 independent volunteers. 
p<0.001 by repeated measures ANOVA; *p<0.05, **p<0.01 and ***p<0.001 by 
Dunn’s post-hoc test comparing with ‘no pre-treatment’ control. 
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 Effect of Src Kinase Inhibition on Cell Viability 3.5
The total duration of exposure to PP1 or dasatinib in the functional assays was 
typically 60 min (30 min pre-treatment followed by 30 min assay), so I chose to 
assess direct drug-induced cytotoxicity by LDH release after 60 min exposure. I 
also assessed neutrophil apoptosis at 30 min, as well as the traditional 
timepoints of 6 h and 24 h using both Annexin V/PI staining and cell 
morphology. 
3.5.1 Direct drug-induced cytotoxicity 
Results: As shown in Figure 3-14 opposite, dasatinib is not directly cytotoxic to 
neutrophils at all concentrations tested. However PP1 exposure induces a small 
but nevertheless significant rise in LDH release at 10 µM, but over double the 
control level (~10% to 20%) at concentrations of 30 µM and above, in excess of 
the positive control using 100 nM PMA.  
Comments: How a doubling of the relatively low background rate of cell lysis 
(as measured by LDH release) would affect the functional release of granule 
products is hard to predict, but it seems more likely to reduce neutrophil 
function, and may partly explain the inhibitory effect of PP1 seen at 30 µM. One 
can therefore conclude that the optimum effective in vitro concentration of PP1 
in these assays must lie somewhere in a tight ‘therapeutic window’ between 10 
µM and 30 µM.  
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Figure 3-14 PP1, but not dasatinib, induces direct neutrophil cytotoxicity 
at high concentrations 
Dose response of PP1 (A) and dasatinib (B) pre-treatment on extracellular 
release of LDH from 5 x 104 neutrophils (from healthy volunteers), expressed as 
a percentage of the total LDH released from the same number of cells lysed 
with 1% Triton X-100. Data show mean and SE values from 3 experiments 
using triplicate samples from 3 independent volunteers. p<0.001 by repeated 
measures ANOVA; *p<0.05, **p<0.01 by Dunn’s post-hoc test comparing with 
‘No pre-treatment control’ 
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3.5.2 Neutrophil apoptosis 
Results: Figure 3-15 opposite shows the relative proportion of neutrophils that 
are alive (Ann V-/PI-), early apoptotic (Ann V+/PI-) or late apoptotic/dead (Ann V 
+/-/PI+) after 30 min, 6 h and 24 h exposure to 10 µM PP1 or 100 nM dasatinib at 
37oC. Even at 30 min, PMA induces the production of cell debris, explaining 
why the bars do not approximate to 100%.  
Comments: In these experiments, 30 min and 6 h are too early for apoptosis to 
occur, and only by 24 h are there significant levels of neutrophil apoptosis. The 
death rates do not correlate directly with the LDH release data shown above; 
however the two assays measure cytotoxicity in different ways. Lactate 
dehydrogenase is a stable cytoplasmic enzyme released extracellularly only 
when plasma membrane damage occurs. PI binds exposed deoxyribonucleic 
acid (DNA) in damaged and dead cells to become fluorescent and therefore 
potentially offers a more accurate count of dead cells in a population. 
 
 
 
 
 
 
 
 
Figure 3-15 PP1 and dasatinib treatment does not affect neutrophil 
apoptosis, as assessed by Annexin V/PI staining 
Neutrophils (from healthy volunteers), at 106/ml, were treated with control, 100 
nM PMA, 10 µM PP1 or 100 nM dasatinib and aliquots removed at 30 min (A), 6 
h (B) and 24 h (C) before staining with Annexin V APC and PI and assessed 
using a BD FACSCanto II machine. Data show mean and SD values for % 
alive, early apoptotic and late apoptotic/dead neutrophils from 5 experiments 
using samples from 5 independent volunteers. p=1.00 (A+B), p=0.373 (C) by 2-
way ANOVA, using treatment and viability as variables. 
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Results: Figure 3-16 opposite and Figure 3-17 overleaf support the flow 
cytometry data using a different experimental technique. After 30 min and 6 h 
exposure, there are minimal levels of apoptosis as assessed by cell morphology 
on cytospin staining. 24 h exposure to PP1 or dasatinib does not increase or 
decrease levels of apoptosis from control levels.  
Comments: Taken together, the cytotoxicity and apoptosis data are crucial as 
they show that at therapeutic concentrations of 10 µM PP1 and 100 nM 
dasatinib, there is no significant change in background apoptosis or necrosis 
rates in unstimulated healthy human neutrophils, suggesting that any inhibitory 
effect on degranulation or other functional responses is a true effect. At higher 
concentrations of PP1 (over 30 µM) the drug exerts a direct cytotoxicity effect. 
This finding may explain some of the inhibitory effects observed previously at 
such concentrations of PP1. 
In the context of ARDS, this is important as it means that src kinase inhibition 
with either drug should not induce excessive neutrophil death at the site of lung 
inflammation, nor should it result in an imbalance in the resolution phase of 
acute lung inflammation. 
 
 
 
 
 
 
Figure 3-16 PP1 and dasatinib treatment does not affect neutrophil 
apoptosis, as assessed by cell morphology 
Neutrophils (from healthy volunteers) at 106/ml, were treated with control, 100 
nM PMA, 10 µM PP1 or 100 nM dasatinib and aliquots removed at 30 min (A), 6 
h (B) and 24 h (C) for cytocentrifuge preparation and counting of % apoptotic 
neutrophils by morphology under light microscopy. Data show median and IQR 
values from 4 experiments using samples from 4 independent volunteers. 
p=0.0329 (A), p=0.0046 (B) and p=0.0417 (C) by Friedman test, excluding PMA 
positive control values.  
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Figure 3-17 PP1 and dasatinib treatment has no effect on neutrophil 
apoptosis 
X400 images of cytocentrifuge preparations of neutrophils exposed to control, 
10 µM PP1 or 100 nM dasatinib for 30 min, 6 h and 24 h. Representative 
images from one of three separate experiments using neutrophils from 
independent volunteers. 
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3.5.3 Effect of Src Kinase Inhibition on Key Neutrophil Functions 
Having established reliable inhibitory concentrations of both PP1 and dasatinib 
in degranulation assays, I proceeded to test the effect of src kinase inhibition on 
a number of pro-inflammatory functions of neutrophils. 
Neutrophils are recruited to the inflamed lung through interaction with the 
inflamed endothelium, using first selectin and then integrin activation. The src 
family kinases and downstream Syk kinases are integral to the intracellular 
signalling pathways that induce adhesion, spreading, chemotaxis, and 
superoxide production through oxidative burst (Zarbock & Ley 2008). It would 
therefore follow that src kinase inhibition results in reduced neutrophil 
recruitment to site of lung inflammation. In ARDS, where excessive neutrophil 
recruitment and degranulation is a major factor in the pathogenesis of the 
condition, this effect may prove beneficial. 
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3.5.4 Cell adhesion 
Results: Using a simple assay to test adhesion of neutrophils to tissue culture 
plastic in response to 50 nM fMLP in the presence of 1% autologous serum 
(Figure 3-18 opposite), the results show that src kinase inhibition with at least 
30 µM PP1 or 100 nM dasatinib results in significantly reduced levels of 
adhesion. 
Comments: Adhesion is inhibited to near the level of the negative control with 
cytochalasin D. Cytochalasin D is a potent inhibitor of actin polymerisation and 
prevents any degree of neutrophil shape change required for effective adhesion 
(Casella et al. 1981). Seen through inverted microscopy, the effect is marked, 
with the majority of treated neutrophils remaining spherical in free suspension or 
loosely adherent, rather than firmly adherent and spread over the plastic 
surface. 
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Figure 3-18 PP1 and dasatinib inhibit neutrophil adhesion to tissue culture 
plastic at higher concentrations 
Dose response of PP1 (A) and dasatinib (B) treatment on the ability of 
neutrophils (from healthy volunteers) in suspension to become adherent to 
tissue culture plastic when stimulated for 60 min with 50 nM fMLP in the 
presence of 1% autologous serum. Data show mean and SE values from 3 
experiments using samples from 3 independent volunteers. p<0.001 by 
repeated measures ANOVA; ***p<0.001 by Dunn’s post-hoc test comparing 
with ‘Control + fMLP’. 
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3.5.5 L-selectin shedding 
L-selectin (CD62L) is constitutively expressed at high levels on neutrophil 
plasma membranes and is one of the first adhesion molecules to interact with 
inducible ligands on the inflamed endothelium. Once neutrophils become firmly 
adherent, they become activated to allow transmigration and L-selectin is ‘shed’ 
by enzymatic cleavage with a subsequent increase in β2 integrin expression 
(Allport et al. 1997).  
Downregulation of surface CD62L expression in response to fMLP can be 
measured simply by flow cytometry.  
Results: Figure 3-19 opposite demonstrates that neutrophil stimulation with just 
10 nM fMLP reduces CD62L fluorescence to near the level of the isotype 
control antibody.  
Comments: In these experiments the maximum fluorescence in unstimulated 
neutrophils is surprisingly low (~400 arbitrary units) which may indicate weak 
binding or brightness of the CD62L APC antibody. Despite this, there is a 
sufficiently wide fluorescence intensity range to observe an inhibition of L-
selectin shedding at 30 µM PP1 but no effect at 10 µM PP1 or 100 nM 
dasatinib.  
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Figure 3-19 PP1, but not dasatinib, inhibits L-selectin shedding from 
neutrophils in response to fMLP at high concentrations 
Heparinised blood samples (from healthy volunteers) were pre-treated with 
control, 10 µM or 30 µM PP1, or 100 nM dasatinib before staining with anti-
human CD62L APC (L-selectin) and stimulating with 10 nM fMLP or control. 
Data show mean and SD MFI values from 4 experiments using samples from 4 
independent volunteers (A) and a representative image showing gating strategy 
and a fluorescence overlay plot (B). p<0.0001 by repeated measures ANOVA; 
***p<0.001 by Dunn’s post-hoc test comparing with ‘Stimulated CD62L APC’ 
condition. 
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3.5.6 Chemotaxis 
The next logical investigatory step was to investigate neutrophil transmigration 
through Transwell pore membranes or through monolayers of endothelial or 
epithelial cells. I was unable to optimise the experimental technique involving 
Transwell membranes. However Futosi et al. were able to show that dasatinib 
does not affect migration through membranes and only chemotaxis and 
adhesion are inhibited, suggesting that there is redundancy in the role of src 
kinases and that several other (unidentified) protein tyrosine kinases regulate 
the complex mechanisms of transmigration (Futosi et al. 2012; Zarbock 2012). 
Instead I measured chemotaxis across a glass slide toward the chemoattractant 
fMLP using the under-agarose technique. 
Results: As expected, and consistent with previously published data, src kinase 
inhibition with both PP1 and dasatinib significantly reduces neutrophil 
chemotaxis across glass towards the chemoattractant fMLP (Figure 3-20 
below). 
 
Figure 3-20 Both PP1 and dasatinib inhibit neutrophil chemotaxis towards 
the chemoattractant fMLP 
Neutrophils (from healthy volunteers) were treated with control, 10 µM PP1 or 
100 nM dasatinib and their chemotaxis measured along a chemotactic gradient 
towards a peak concentration of 100 nM fMLP. Data shown are mean and SD 
values from 3 experiments using duplicate samples from 3 independent 
volunteers. p=0.0293 by repeated measured ANOVA; *p<0.05 by Dunn’s post-
hoc test comparing with ‘no pre-treatment’ control. 
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3.5.7 Phagocytosis 
I examined the effect of PP1 and dasatinib on neutrophil phagocytosis of 
fluorescent killed pHrodo S. aureus and E. coli particles in adherent conditions 
(Figure 3-21 overleaf) and in heparinised blood (Figure 3-22 overleaf). These 
killed bacteria offer physiologically relevant Gram +ve and Gram –ve phagocytic 
stimuli and allow a controllable stimulus size. The bacteria are bound to a 
pHrodo ‘pH-sensitive’ fluorogenic dye that only becomes fluorescent upon 
acidification within a phagolysosome, so it is possible to discriminate 
phagocytosed from adherent or extracellular particles. Other methods I tried 
involved quenching extracellular fluorescence from alternative fluorescent 
particles with trypan blue or crystal violet, but the methodology was less 
reproducible. The pHrodo phagocytosis experiment also depends on a 
functioning NADPH oxidase system, so it can indirectly give some insight into 
NADPH oxidase function. 
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Results: In adherent neutrophils there is a significant effect of PP1 on 
phagocytosis of both SA and EC particles at all concentrations tested, to the 
level of the negative control (cytochalasin D) at higher concentrations. Dasatinib 
concentrations of 100 nM and above also reduce phagocytosis to both stimuli. 
In heparinised whole blood, modest concentrations of PP1 (10 µM) and 
dasatinib (100 nM) have absolutely no effect on phagocytosis.  
Comments: From earlier degranulation experiments it has already been shown 
that both drugs are exerting an effect on neutrophils in whole blood at such 
concentrations. Futosi et al. also found no effect of using up to 1 µM dasatinib 
on phagocytosis of live green fluorescent protein (GFP)-expressing S. aureus 
by purified neutrophils in suspension but did not assess adherent neutrophils 
(Futosi et al. 2012). 
 
Figure 3-21 PP1 and dasatinib inhibit phagocytosis of pHrodo S. aureus 
and E. coli particles by adherent neutrophils 
Effect of PP1 (A+C) and dasatinib (B+D) treatment on adherent neutrophils 
(from healthy volunteers) exposed to pHrodo S. aureus (A+B) and E. coli (C+D) 
particles. Data shown are mean and SE MFI values from 4 experiments using 
triplicate samples from 4 independent volunteers. p<0.0001 by repeated 
measures ANOVA; **p<0.01, ***p<0.001 by Dunns post-hoc test comparing 
with ‘Control PMNs + EC/SA’ and excluding cyto D control values. 
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Figure 3-22 PP1 and dasatinib do not affect phagocytosis of pHrodo S. 
aureus and E. coli particles by neutrophils in suspension in heparinised 
blood 
Heparinised blood samples (from healthy volunteers) pre-treated with 10 µM 
PP1 or 100 nM dasatinib were exposed to pHrodo S. aureus (A) and E. coli (B) 
particles. Data shown are mean and SE MFI values from 4 experiments using 
samples from 4 independent volunteers. p=0.0919 (A) and p=0.288 (B) by 
repeated measures ANOVA comparing with ‘Control PMNs + EC/SA’ and 
excluding 4oC and cytochalasin D control values. 
  
M
ed
ia
n 
flu
or
es
ce
nc
e 
in
te
ns
ity
 (a
rb
itr
ar
y 
un
its
)
Co
ntr
ol 
PM
Ns
 + 
SA
Co
ntr
ol 
PM
Ns
 4
o C 
+ S
A
Cy
toc
ha
las
in 
D 
+ S
A
10
µM
 P
P1
 + 
SA
10
0n
M 
Da
sa
tin
ib 
+ S
A
0
10000
20000
30000
40000
50000
ns
M
ed
ia
n 
flu
or
es
ce
nc
e 
in
te
ns
ity
 (a
rb
itr
ar
y 
un
its
)
Co
ntr
ol 
PM
Ns
 + 
EC
Co
ntr
ol 
PM
Ns
 4
o C 
+ E
C
Cy
toc
ha
las
in 
D 
+ E
C
10
µM
 P
P1
 + 
EC
10
0n
M 
Da
sa
tin
ib 
+ E
C
0
1000
2000
3000
4000
ns
A B
   
  130 
3.5.8 Oxidative burst 
Results: Figure 3-23A opposite shows that both PP1 and dasatinib inhibit 
extracellular superoxide release, a marker of oxidative burst, after priming of 
neutrophils in suspension with PAF and stimulation with fMLP.  
We have already seen from the degranulation experiments that the 
mechanisms of PMA-induced degranulation are independent of src kinases, so 
the results shown in Figure 3-23B are not unexpected. 
Comments: This finding suggests that src kinase inhibition impairs the 
assembly of NADPH oxidase, an observation also made by Futosi et al, who 
showed similar results using a lucigenin assay to detect extracellular superoxide 
release in response to fMLP, anaphylatoxin C5a, LPS and TNFα (Futosi et al. 
2012). 
 
 
 
 
 
 
Figure 3-23 Both PP1 and dasatinib impair extracellular superoxide 
release in response to PAF/fMLP but do not affect intracellular ROS 
production in response to PMA 
Extracellular superoxide release from isolated neutrophils (from healthy 
volunteers) pre-treated with control, 10 µM PP1 or 100 nM dasatinib and 
stimulated with 100 nM PAF followed by 100 nM fMLP, as measured by the 
cytochrome C reduction assay (A). Intracellular ROS production by neutrophils 
in heparinised blood (from healthy volunteers) loaded with 1 µM DHR 123 and 
pre-treated with control, 10 µM PP1 or 100 nM dasatinib before stimulation with 
50 nM PMA, as measured on a FACSCanto II machine by neutrophil 
fluorescence generated by the oxidation of intracellular DHR 123 to rhodamine 
123 (B). Data shown are median and IQR (A) and mean and SD MFI (B) values 
from 5 (A) and 4 (B) experiments using samples from 5 (A) and 4 (B) 
independent volunteers. p=0.0023 by Friedman test; *p<0.05 by Dunn’s post-
hoc test (A) and p=0.336 by repeated measures ANOVA, excluding no PMA 
and diphenyleneiodonium (DPI) control values (B). 
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3.5.9 Live bacterial killing 
The final neutrophil function to test in vitro is perhaps the most important: live 
bacterial killing. I initially started doing the PP1 bacterial killing experiments 
using PA01 (Figure 3-25 overleaf), but found the organism’s growth curve and 
behaviour in such assays less predictable than those of SA NCTC 8325, and 
therefore changed to using this pathogen strain for subsequent killing assays 
(Figure 3-24). 
The results graphs below can be difficult to interpret at first glance. Aliquots of 
the neutrophil/pathogen co-culture are taken at 2 timepoints = 0 min and 30 
min, the neutrophils lysed to release all viable intracellular bacteria and the 
samples diluted appropriately, spread on agar plates and cultured overnight 
before counting colonies to estimate the initial concentration of viable bacteria in 
each sample (in cfu/ml). The fold change in the concentration after 30 min 
therefore measures the net growth or death of the bacterial population during 
this time period.  
Results: Figure 3-24A opposite is a control experiment showing that 1 µM 
dasatinib does not affect natural S. aureus growth and survival in short-term 
culture. However with the addition of healthy neutrophils at an MOI of ~10 SA:1 
PMN, the neutrophils are approximately ‘bacteriostatic’ and there is neither net 
growth or death of the bacterial population at 30 min. Interestingly, Figure 3-24B 
shows that pre-treatment of healthy neutrophils with 10 nM, 100 nM or 1 µM 
dasatinib has no effect on their killing efficacy in suspension. 
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Figure 3-24 Dasatinib does not impair live killing of serum-opsonised S. 
aureus by neutrophils in suspension 
Control experiment (A) in which live serum-opsonised S. aureus was incubated 
in medium alone, with 1 µM dasatinib (no neutrophils) or with 106 neutrophils 
(MOI~10 SA: 1 PMN) and net growth after 30 min measured. Dose response of 
dasatinib treatment on neutrophil killing of live S. aureus in suspension (B). 
Data shown are mean and SE values from 3 (A) and 4 (B) experiments using 
samples from 3 (A) and 4 (B) independent volunteers. p=0.1 by Mann-Whitney 
test (A) and p=0.938 by repeated measures ANOVA (B) 
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Results: The results for PP1 are displayed opposite in Figure 3-25. Again PP1 
has no effect on natural growth and survival of PA01 (A) and only significantly 
impairs bacterial killing in adherent (B) and suspension (C) conditions at very 
high concentrations (100 µM).  
Comments: This effect may well be attributable to excessive neutrophil death 
due to PP1, as demonstrated earlier in section 3.5.1. It should be noted that 
these killing assays are unable to distinguish intracellular bacterial killing from 
extracellular killing by NETs formation. NETs formation is an NADPH-
dependent mechanism that takes around 4 h in vitro (Gray et al. 2013) so it is 
unlikely to be a factor in short 30 min killing assays.  
 
 
 
 
 
 
 
 
 
 
Figure 3-25 PP1 only impairs live killing of serum-opsonised P. 
aeruginosa by neutrophils at a concentration of 100 µM 
Control experiment (A) in which live serum-opsonised P. aeruginosa was 
incubated in medium alone, with 30 µM PP1 (no neutrophils) or with 106 
neutrophils (MOI~10 PA01: 1 PMN) and net growth after 30 min measured. 
Dose response of PP1 treatment on neutrophil killing of live P. aeruginosa in 
adherent conditions (B) or suspension conditions (C). Data shown are mean 
and SD values from 3 (A) and 6 (B+C) experiments using samples from 3 (A) 
and 6 (B+C) independent volunteers. p=0.1 by Mann-Whitney test (A) and 
p<0.0001 by repeated measures ANOVA; ***p<0.001 by Dunn’s post-hoc test 
comparing with ‘Control PMNs + PA01’ and excluding PA01 control condition 
(B+C). 
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3.5.10 Clinical relevance of findings  
Taken together, my in vitro findings imply that careful src kinase inhibition of 
neutrophils with drugs such as PP1 or dasatinib, can theoretically reduce 
neutrophil recruitment to sites of lung inflammation, whilst attenuating the 
degree of extracellular degranulation from recruited cells and maintaining 
effective bacterial killing.  
Patients with chronic myeloid leukaemia (CML) taking dasatinib have an 
increased risk of developing mild to moderate infections (EMEA 2015) but 
consistent with our data, Futosi et al. found that there was only a modest 
decrease to 75% control killing values using concentrations as high as 1 µM 
dasatinib with a negligible effect at 100 nM (Futosi et al. 2012).  
Interestingly, the most common daily dose of dasatinib in patients with CML is 
100 mg/day. In pharmacokinetic studies, a 70 mg/day dose resulted in a 
maximum serum dasatinib concentration of 50-100 ng/ml, equating to 
approximately 100-200 nM (Demetri et al. 2009).  
These findings suggest that any increased infection frequency in patients taking 
dasatinib is unlikely to be due to impaired bacterial killing by neutrophils but 
may be due to impaired recruitment to sites of infection. 
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 Summary of Key Findings 3.6
These data confirm previously published findings regarding the potent effect of 
src kinase inhibition on neutrophil function in in vitro models of acute 
inflammation as well as providing many further insights into its effect in more 
clinically relevant models of infection involving live and killed bacteria, as well as 
the action of the clinically licensed src kinase inhibitor, dasatinib. 
My key findings are summarised as follows: 
1. Src kinase inhibition of healthy human neutrophils with concentrations of 
PP1 in excess of 10µM reliably inhibits in vitro neutrophil degranulation 
stimulated by: 
• G-protein coupled formyl peptide receptor activation 
• Toll-like receptor-4 ligation by LPS 
• Contact with live serum-opsonised PA01 and S. aureus, 
but not by PKC-mediated PMA activation.  
2. At lower concentrations of PP1 (10 µM) that are capable of inhibiting 
degranulation, only certain key neutrophil functions of chemotaxis, 
adherent phagocytosis and extracellular superoxide anion release are 
impaired. At moderately high concentrations (30 µM), further functions 
are affected, including a minor but significant effect on cell viability (but 
not apoptosis), cell adhesion and L-selectin shedding. Only at very high 
concentrations of PP1 (100 µM) is effective killing of PA01 affected in 
both adherent and suspension conditions, in part due to its cytotoxic 
effect at this concentration. 
 
3. Taking the findings in 1 and 2 above together, one can speculate that 
there is an optimum concentration range of src kinase inhibition with PP1 
(estimated between 10 µM and 30 µM) at which extracellular 
degranulation to sterile and non-sterile stimuli is impaired without a 
significant effect on efficient bacterial killing or cell viability. This concept 
has exciting implications for potential anti-inflammatory treatment 
strategies in conditions such as ARDS where maintaining an effective 
innate immune response to primary or secondary lung infection is crucial. 
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4. These findings can be replicated using a less specific, but clinically 
licensed, src/Abl kinase inhibitor, dasatinib. Consistent with previously 
published data (Futosi et al. 2012), 100 nM dasatinib, which equates to 
plasma concentrations found when taking a daily oral dose of less than 
70mg, inhibits degranulation from healthy neutrophils stimulated by fMLP 
and LPS but not PMA. My data extend these observations to 
degranulation assays involving stimulation with live Staphylococcus 
aureus. 100 nM dasatinib also impairs only adhesion, chemotaxis, 
extracellular superoxide release and adherent phagocytosis with no 
effect on viability, apoptosis, L-selectin shedding and bacterial killing of 
S. aureus. 
My original hypothesis:  
“In vitro src kinase inhibition of human neutrophils reduces extracellular 
degranulation in response to both chemical and live bacterial stimuli, 
without impairing efficient neutrophil phagocytosis and intracellular 
killing of bacteria” 
has therefore been satisfied in all aspects except that src inhibition affects 
phagocytosis by adherent neutrophils with no effect on purified neutrophils in 
suspension or in whole blood. 
These data were sufficiently robust to proceed to test my second hypothesis in 
in vivo models of sterile and non-sterile acute lung inflammation, which I will 
describe in chapter 4. 
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Chapter 4. An Investigation into the Effect of the Src Kinase 
Inhibitor Dasatinib on In Vivo Models of Bacteria and Acid-
Induced Acute Lung Inflammation 
 Chapter Overview 4.1
This chapter describes the experiments I carried out to test the following 
hypothesis: 
“Inhibition of the src kinase pathway attenuates neutrophil recruitment to 
the alveolar and interstitial spaces, neutrophil degranulation and 
endothelial cell injury and leak in in vivo models of bacteria and acid-
induced acute lung inflammation” 
In Chapter 3, dasatinib was identified as a safe and effective in vitro src kinase 
inhibitor of human neutrophils. In mice, the drug has been shown to exert an 
inhibitory effect on ex vivo leukocyte adhesion to foetal calf serum-coated plates 
in response to TNFα at doses of 5 mg/kg and above when administered orally 
(Futosi et al. 2012). Each experiment that follows compares a group of mice 
treated with i.p. dasatinib (at various concentrations) with a control group of 
mice treated with control vehicle alone (DMSO). The paired ‘dasatinib’ and 
‘control’ groups were both stimulated in separate experiments by direct 
intratracheal administration of either i) live E. coli (Section 4.2) or ii) pH 2.0 
hydrochloric acid (Section 4.3).  Specific details of experimental methods used 
can be referred to in Chapter 2 on page 31. 
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 Effect of Dasatinib on an In Vivo Murine Model of E. coli-induced 4.2
Acute Lung Inflammation 
E. coli was used as the bacterial stimulus for these experiments because it 
represents a thoroughly studied gram negative pathogen with a rapid and 
predictable growth rate, able to survive in many growth conditions. It is also a 
commonly isolated pathogen in sepsis, ventilator-associated pneumonia and 
ARDS. Professor Rossi’s group, with whom I collaborated on these 
experiments, had optimised the methods using this pathogen.  
As discussed in Chapter 2 (Materials and Methods), experiments plotting the 
time course of neutrophil influx into the alveolar and interstitial space in 
response to i.t. E. coli demonstrated an initial 6 h peak influx (alveolar) followed 
by a 12 h peak (interstitial) with a second wave of alveolar neutrophils (and 
persistently high interstitial neutrophils) at 24 h.  
Pharmacokinetic data obtained in rats show that peak plasma concentrations of 
dasatinib are achieved within 1 hour of i.p. administration at both 1 mg/kg and 
10 mg/kg with the serum concentrations falling to 50% of the peak 
concentration by 10 h (Seferian et al. 2013). These experiments also measured 
peak plasma concentrations of 100 ng/ml (~200 nM) and 1 µg/ml (~2 µM) using 
doses of 1 mg/kg and 10 mg/kg respectively, similar to the dose range used in 
my in vitro experiments.  
Using these figures, we decided to treat the mice twice with up to 10 mg/kg i.p. 
dasatinib or control at 0h and 12 h to correspond to neutrophil influx into 
alveolar and interstitial spaces at these timepoints and cull the mice at 24 h. 
Based on the results of the intial 10 mg/kg experiment, the experiment was 
repeated using a lower dose of 1 mg/kg. The results are presented together but 
the experiments were carried out on separate occasions using different batches 
of mice. In all experiments between 8 and 10 mice were used per group. This 
group size was calculated from previous experiments by Drs Dorward and 
Lucas as the minimum number of mice required to observe a significant 
difference between control and treated groups, assuming a normally distributed 
spread of data within each group. 
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4.2.1 Cellular influx to alveolar space: control experiments 
Important control experiments shown in Figure 4-1 and Figure 4-2 overleaf were 
initially carried out to confirm that i.p. treatment with 1 mg/kg and 10 mg/kg 
dasatinib itself (using the dual dosing strategy at 0 h and 12 h) does not itself 
cause a meaningful cellular influx into the alveolar space in mice untreated with 
i.t. E. coli.  
Comments: As expected, lavages from unstimulated mice are relatively 
acellular, containing predominantly alveolar macrophages alone in very small 
total numbers. This can be appreciated by comparing the graph scale used in 
Figure 4-2 (approximately 20 cells/µL of BALF) with the scale used in Figure 4-
3A (over 400 cells/µL fluid in stimulated mice). 
Figure 4-1 shows the expected BALF cytospin appearance of control mice 
exposed to E. coli (neutrophilic influx with some capillary haemorrhage into the 
alveolar space). Interestingly, treatment with 10 mg/kg dasatinib appears to 
result in more haemorrhage (than 1 mg/kg or control). This was readily apparent 
from the macroscopic appearance of the fluid, but was not formally quantified. 
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Figure 4-1 Neutrophilic influx into the alveolar space accompanies i.t. E. 
coli delivery in mice 
Representative x200 images of cytocentrifuge preparations of BALF retrieved 
from mice treated with i.p. control vehicle, 1 mg/kg dasatinib or 10 mg/kg 
dasatinib and exposed to either i.t. E. coli or no stimulus. Images taken from 1 
experiment using 1 mouse per condition (top row) and 2 experiments using >8 
mice per condition (bottom row) 
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Figure 4-2 Dasatinib itself does not induce a significant cellular influx into 
the alveolar space of control mice 
Dose response control experiment to demonstrate no meaningful effect of i.p. 
dasatinib treatment on cellular influx in control mice unexposed to i.t. E. coli, 
n=1 mouse per condition. Results obtained using NucleoCounter© machine 
method. 
  
0 1 10
0
5
10
15
20
25
Dasatinib (mg/kg)
N
o.
 o
f c
el
ls
 p
er
 µ
l B
AL
 fl
ui
d
   
  146 
4.2.2 Cellular influx to alveolar space: effect of dasatinib 
Results: Figure 4-3 opposite shows that treatment with both 1 mg/kg and 10 
mg/kg dasatinib does not attenuate cellular influx into the alveolar space in 
response to E. coli. Specifically both the total number of neutrophils and the 
percentage neutrophil content of the BALF is not affected.  
Comments: This result is unexpected given the clear effect of dasatinib on 
neutrophil adhesion and integrin-mediated activation in vitro. 
Reassuringly, the inter-experiment control group variability is relatively good in 
these assays (indicated by the red dotted significance bars), with only a slight 
difference in % neutrophils in BALF as assessed by flow cytometry (Figure 
4-3C).  
The Figure 4-3A values were obtained very shortly after sample retrieval using 
the Nucleocounter method and the Figure 4-3B values the following day using 
flow cytometry. This may explain any apparent discrepancies in estimated total 
cell and total neutrophil numbers in the same samples. The same can be said 
for any discrepancies between % neutrophil values obtained using flow 
cytometry or cell morphology on cytospin. In the case of any major discrepancy, 
results obtained by cell morphology are favoured.  
 
 
 
Figure 4-3 Dasatinib treatment does not affect cellular influx into the 
alveolar space in response to E. coli 
Effect of i.p. treatment with 1 mg/kg dasatinib (left panel) and 10 mg/kg 
dasatinib (right panel) on the total number of cells (A), the total number of 
neutrophils (B) and the % neutrophils (C+D) in BAL samples from mice exposed 
to i.t. E. coli. Results obtained using NucleoCounter© machine method (A), flow 
cytometry (B+C) and cell morphology on cytospin staining (D). Data show mean 
and SD values from 2 experiments using samples from 8 mice per group; the 1 
mg/kg+control and 10 mg/kg+control values are separate experiments. Control 
vs dasatinib: p=0.221 (1 mg/kg), p=0.931 (10 mg/kg) (A); p=0.398, p=0.450 (B); 
p=0.457, p=0.056 (C); p=0.274, p=0.497 (D). Inter-experiment control group 
difference: p=0.661 (A), 0.548 (B), **p=0.0028 (C) and p=0.967 (D) by unpaired 
t-test. 
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4.2.3 Cellular influx to lung interstitium 
This method of measuring neutrophil influx into the lung interstitium estimates 
the number of activated neutrophils migrating through activated endothelium 
into the interstitial space. The lung samples are taken after BAL and right 
ventricular/pulmonary artery flushing and therefore the counts obtained should 
exclude cells present in these other inflamed spaces. It is known that murine 
lungs harbour a considerable number of marginated neutrophils in the vascular 
and interstitial compartments of the lung in the stable state and that these can 
mobilise into the alveolar space in response to inflammation (Barletta et al. 
2012). 
Results: Figure 4-4A opposite shows that treatment with 10 mg/kg dasatinib 
induces a neutrophilia in peripheral blood in response to E. coli challenge, 
presumably due to bone marrow release.  
At the lower dose of 1 mg/kg, there is a small significant drop of approximately 
5% in the percentage of neutrophils present in the lung interstitium, with no 
change in the total number of neutrophils present. It is unknown which other 
types of cell undergo a corresponding increase, by inference. There is possibly 
an associated trend to an effect on the equivalent percentage of neutrophils in 
the alveolar space in Figure 4-3D above. 
Comments: A neutrophil percentage of 10-20% of total leukocytes, although 
appearing low compared to human blood (where the figure is much higher at 
50-70%), is in keeping with expected values in C57/Black 6 mice, in which 
lymphocytes comprise 75-90% of the total leukocytes (Doeing et al. 2003).  
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Figure 4-4 Treatment with 1 mg/kg Dasatinib reduces neutrophil influx into 
the lung interstitium in response to i.t. E. coli 
Effect of i.p. treatment with 1 mg/kg dasatinib (left panel) and 10 mg/kg 
dasatinib (right panel) on the % neutrophils of all leukocytes in peripheral blood 
(A), the total number of neutrophils in lung homogenate (B) and the % 
neutrophils of all cells in lung homogenate (C) samples from mice exposed to 
i.t. E. coli. Data show mean and SD values from 2 experiments using samples 
from 8 mice per group; the 1 mg/kg+control and 10 mg/kg+control values are 
separate experiments. Control vs dasatinib: p=0.939 (1 mg/kg), *p=0.034 (10 
mg/kg) (A); p=0.074, p=0.351 (B); *p=0.018, p=0.068 (C). Inter-experiment 
control group difference: *p=0.0313 (A), 0.305 (B), p=0.851 (C) by unpaired t-
test. 
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4.2.4 Evidence of neutrophil degranulation 
Although dasatinib does not appear to significantly affect the neutrophil influx 
into the interstitial space, does it affect the degree of degranulation of primary 
and secondary granules as assessed by surface CD63 expression (primary 
granule release) and CD11b expression (surrogate for secondary granule 
release) on Ly6+ lung homogenate cells (Ly6 is specific for murine 
neutrophils)? 
Results: As shown in Figure 4-5 opposite, dasatinib does not have any effect 
on degranulation of Ly6+ neutrophils in the interstitial space at both 1 mg/kg 
and 10 mg/kg doses. Baseline control values, although significantly different 
between the two experiments, show a degranulation response to E. coli 
exposure compared to unexposed mice (data not shown).  
Comments: Of note, levels of CD63 expression (Figure 4-5B) are consistently 
low throughout all experiments, possibly reflecting either poor antibody-receptor 
affinity or weakly fluorescent PE. 
It is possible that the homogenisation process itself affects surface receptor 
expression. Neither proteases nor protease inhibitors were used in the process 
except collagenase and those released by the tissue itself. Theoretically these 
may exert an autocrine effect on receptor expression. 
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Figure 4-5 Dasatinib treatment does not affect neutrophil degranulation in 
the lung interstitium 
Effect of i.p. treatment with 1 mg/kg dasatinib (left panel) and 10 mg/kg 
dasatinib (right panel) on neutrophil expression of CD11b (A) and CD63 (B) in 
lung homogenate samples from mice exposed to i.t. E. coli. Data show mean 
and SD values from 2 experiments using samples from 8 mice per group; the 1 
mg/kg+control and 10 mg/kg+control values are separate experiments. Control 
vs dasatinib: p=0.289 (1 mg/kg), p=0.542 (10 mg/kg) (A); p=0.228, p=0.900 (B). 
Inter-experiment control group difference: ****p<0.0001 (A), ****p<0.0001 (B) by 
unpaired t-test. 
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Similarly, does dasatinib affect the degree of degranulation of neutrophils 
entering the alveolar space?  
Results: When measured by CD63 and CD11b expression, it appears not, as is 
shown below in Figure 4-6. There is a modest increase in CD63 expression in 
mice treated with 10 mg/kg dasatinib, though it is difficult to know how to 
interpret this, when the control group fluorescence values are so low and there 
is apparent inter-experiment control group variability. 
 
Figure 4-6 Treatment with 10 mg/kg, but not 1 mg/kg of Dasatinib, 
increases neutrophil degranulation in the alveolar space 
Effect of i.p. treatment with 1 mg/kg dasatinib (left panel) and 10 mg/kg 
dasatinib (right panel) on neutrophil expression of CD11b (A) and CD63 (B) in 
BAL samples from mice exposed to i.t. E. coli. Data show mean and SD values 
from 2 experiments using samples from 8 mice per group; the 1 mg/kg+control 
and 10 mg/kg+control values are separate experiments. Control vs dasatinib: 
p=0.152 (1 mg/kg), p=0.473 (10 mg/kg) (A); p=0.242, ***p=0.0005 (B). Inter-
experiment control group difference: ****p<0.0001 (A), ***p=0.0004 (B) by 
unpaired t-test. 
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Although there is no observed effect of dasatinib on degranulation, as 
measured by flow cytometry, we also determined levels of degranulation by 
measuring MPO activity (Figure 4-8A overleaf), MPO concentration (Figure 
4-8B overleaf) and LTF concentration (Figure 4-7 below) in cell-free alveolar 
fluid, but not in the interstitial space. As it is an assumption that all MPO antigen 
detected by ELISA is associated with a functional enzyme and that methods of 
measuring MPO activity are inconsistent and dependent on sample acquisition 
techniques (Pulli et al. 2013), we also calculated a separate measurement of 
MPO activity per unit of MPO enzyme, expressed in arbitrary units (BAL MPO 
concentration ÷ OD450 value) as shown in Figure 4-8C overleaf.  
Results: The results below show that at 1 mg/kg, dasatinib significantly reduces 
BALF MPO concentration but has no effect on MPO activity or LTF 
concentration. At 10 mg/kg, BALF MPO activity is markedly higher with no 
apparent corresponding difference in enzyme concentration. BALF LTF 
concentration is significantly reduced compared to control values, but these 
results should be interpreted with caution as the 10 mg/kg control group values 
are significantly higher than the 1 mg/kg control group values and may account 
for this apparent difference. 
 
Figure 4-7 Treatment with 10 mg/kg Dasatinib reduces lactoferrin 
concentration in the alveolar space 
Effect of i.p. treatment with 1 mg/kg dasatinib (left panel) and 10 mg/kg 
dasatinib (right panel) on the LTF concentration in BAL samples from mice 
exposed to i.t. E. coli. Data show mean and SD values from 2 experiments 
using samples from 8 mice per group; the 1 mg/kg+control and 10 
mg/kg+control values are separate experiments. Control vs dasatinib: p=0.576 
(1 mg/kg), **p=0.003 (10 mg/kg).  Inter-experiment control group difference: 
***p=0.0008 by unpaired t-test. 
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Figure 4-8 Treatment with 1 mg/kg Dasatinib reduces MPO concentration 
with no effect on enzyme activity, but 10 mg/kg dasatinib increases MPO 
activity, in the alveolar space 
Effect of i.p. treatment with 1 mg/kg dasatinib (left panel) and 10 mg/kg 
dasatinib (right panel) on total MPO activity (A), MPO concentration (B) and 
effective MPO activity per unit of MPO enzyme (C) in BAL samples from mice 
exposed to i.t. E. coli. Data show mean and SD values from 2 experiments 
using samples from 8 mice per group; the 1 mg/kg+control and 10 
mg/kg+control values are separate experiments. Control vs dasatinib: p=0.364 
(1 mg/kg), **p=0.008 (10 mg/kg) (A); *p=0.025, p=0.338 (B); p=0.076, **p=009 
(C). Inter-experiment control group difference: p=0.0825 (A), p=0.314 (B) and 
**p=0.0093 (C) by unpaired t-test.  
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4.2.5 Bacterial survival 
The effect of dasatinib on bacterial survival is perhaps of most practical interest 
and will help to put some of the degranulation results above in context.  
Results: Looking at the results displayed overleaf in Figure 4-9, it is 
immediately clear that treatment with 10 mg/kg results in increased bacterial 
survival and spread. Not only are the bacteria not cleared from the alveolar 
space, but the total concentration of bacteria in the interstitial space is 
considerably increased compared to control, by a factor of 100. Bacteria are 
also seen in the liver and spleen of some mice, suggesting haematogenous or 
lymphatic spread. 
At the lower dose of 1 mg/kg there is no apparent spread outside of the lungs 
and the alveolar space remains virtually sterile, but there is a marginal but 
significant increase in bacteria surviving within the lung interstitium by a factor 
of approximately 2. 
Comments: Interpreting these data, it is clear that dasatinib impairs bacterial 
clearance after i.t. E. coli  exposure and this effect is dose-dependent. It is 
highly unlikely that dasatinib itself promotes bacterial growth, as demonstrated 
by in vitro experiments in Chapter 3. At higher doses of dasatinib, the delicate 
balance between bacterial replication, invasion and spread on one hand, and 
bacterial killing by the innate immune system on the other hand, favours the 
bacteria, allowing relatively unrestrained exponential bacterial growth.  
I would hypothesise that this dynamic process subsequently presents a 
significantly larger inflammatory stimulus to the immune system, leading to 
accelerated inflammation and tissue damage. This theory may well explain 
some of the results presented above, including the increased BALF MPO 
activity, alveolar neutrophil CD63 expression, increased peripheral blood 
neutrophilia and increased alveolar haemorrhage in mice treated with 10 mg/kg 
dasatinib. 
In this in vivo model, dasatinib is administered systemically and is therefore 
likely to be acting to varying degrees on every murine cell, as src kinases are 
known to be ubiquitously expressed in all mammalian cells. Granulocytes 
constitutively express certain src kinases specifically involved in acute 
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inflammation (Hck, Lyn, Fgr). It is impossible to conclude from these 
experiments whether this apparent immunoparalysis is specifically due to an in 
vivo effect on neutrophil function. There are no published experiments 
investigating the direct in vitro or in vivo effect of dasatinib on any immune cells 
except neutrophils (Futosi et al. 2012) and murine monocyte-derived 
macrophages (MDMs) and bone marrow-derived macrophages (BMDMs) 
(Fraser et al. 2009; Ozanne et al. 2014), but we know from work involving other 
src kinase inhibitors such as PP1 that src kinases are crucial in macrophage 
and monocyte (Byeon et al. 2012), pulmonary endothelial cell (Chang et al. 
2008; Han et al. 2013), and alveolar epithelial cell (Li et al. 1998; Huang et al. 
2003) function. 
 
 
 
 
 
 
 
 
 
Figure 4-9 Treatment with 10 mg/kg Dasatinib reduces bacterial killing and 
increases extrapulmonary dissemination 
Effect of i.p. treatment with 1 mg/kg dasatinib (left panel) and 10 mg/kg 
dasatinib (right panel) on bacterial presence and survival in peripheral blood 
(A), spleen (B), liver (C) and lung homogenates (D) and BALF (E) from mice 
exposed to i.t. E. coli. Data show median and IQR values from 2 experiments 
using samples from 8 mice per group; the 1 mg/kg+control and 10 
mg/kg+control values are separate experiments. Control vs dasatinib: p=1.00 (1 
mg/kg+10 mg/kg) (A); p=1.00, p=0.077 (B); p=1.00, p=0.382 (C); *p=0.05, 
***p=0.0002 (D); p=0.111, ***p=0.0004 (E). Inter-experiment control group 
difference: p=1.00 (A,B,C), p=0.140 (D) and *p=0.0129 (E) by Mann Whitney 
test. 
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4.2.6 Alveolar leak 
Alveolar protein leak is another detrimental effect of alveolar inflammation and 
represents a direct marker of alveolar-capillary injury, which can be also 
detected in conditions less severe than ARDS. A control experiment in Figure 
4-10 below shows that dasatinib at both 1 mg/kg and 10 mg/kg does not itself 
induce meaningful alveolar protein leak in unexposed mice (BAL protein in 
unstimulated mice receiving 1mg/kg dasatinib ~200µg/ml compared with  
~400µg/ml in mice exposed to E. coli). 
 
Figure 4-10 Dasatinib itself does not induce significant protein leak into 
the alveolar space of control mice 
Dose response control experiment to demonstrate no meaningful effect of i.p. 
dasatinib treatment on protein levels in the alveolar space of mice unexposed to 
i.t. E. coli, n=1 mouse per condition.  
Protein leak was measured by two methods: i) immediate total protein 
measurement of the cell-free BALF using a BCA assay and ii) mouse soluble 
IgM concentration of frozen cell-free BALF samples using ELISA.  
Results: Both techniques demonstrate considerably higher protein content in 
BALF from mice treated with 10 mg/kg dasatinib, with no effect at 1 mg/kg 
(Figure 4-11 opposite).  
Comments: This is likely to be a direct effect of increased bacterial survival and 
pathogenicity in these mice. 
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Figure 4-11 Treatment with 10 mg/kg Dasatinib increases alveolar protein 
leak in response to i.t. E. coli 
Effect of i.p. treatment with 1 mg/kg dasatinib (left panel) and 10 mg/kg 
dasatinib (right panel) on the total protein concentration (A) and soluble IgM 
concentration (B) in BAL samples from mice exposed to i.t. E. coli. Data show 
mean and SD values from 2 experiments using samples from 8 mice per group; 
the 1 mg/kg+control and 10 mg/kg+control values are separate experiments. 
Control vs dasatinib: p=0.250 (1 mg/kg), **p=0.0069 (10 mg/kg) (A); p=0.0959, 
**p=0.0048 (B). Inter-experiment control group difference: p=0.536 (A), p=0.824 
(B) by unpaired t-test. 
  
Control Dasatinib 1mg/kg
0
200
400
600
800
1000
To
ta
l p
ro
te
in
 in
 B
AL
 fl
ui
d
 (µ
g/
m
l)
ns
Control Dasatinib 1mg/kg
0
1000
2000
3000
4000
5000
BA
L 
so
lu
bl
e 
Ig
M
 (n
g/
m
l)
ns
Control Dasatinib 10mg/kg
0
200
400
600
800
1000
To
ta
l p
ro
te
in
 in
 B
AL
 fl
ui
d
 (µ
g/
m
l)
**
Control Dasatinib 10mg/kg
0
1000
2000
3000
4000
5000
BA
L 
so
lu
bl
e 
Ig
M
 (n
g/
m
l)
**B
A
ns
ns
   
  160 
4.2.7 Pro/anti-inflammatory cytokines in BALF 
The balance of pro- and anti-inflammatory cytokines present in BALF after 
stimulation gives important, but non-specific information on the degree of 
inflammation present as well as any ‘counter-inflammatory’ or ‘resolutionary’ 
processes that may be occurring simultaneously. The 3 pro-inflammatory 
cytokines we chose to measure were: 
• KC or CXCL1 (chemokine C-X-C motif ligand 1). This murine cytokine is 
expressed by neutrophils, macrophages and epithelial cells and is a 
potent neutrophil chemoattractant (Moser et al. 1990). It is the murine 
equivalent of human IL-8. 
• MCP-1 (monocyte chemotactic protein 1). This is a potent chemokine 
that regulates the recruitment and infiltration of monocytes, 
macrophages, memory T lymphocytes and natural killer (NK) cells. It is 
mainly produced by monocytes and macrophages themselves at sites of 
inflammation, but can also be produced by many other immune cells 
(Deshmane et al. 2009). Although not able to directly cause neutrophil 
influx and degranulation, MCP-1 levels regulate activation of different 
cellular components of the innate immune system. In a murine model of 
LPS-induced acute lung inflammation, 3 methods of monocyte depletion 
attenuated the observed late neutrophil influx by as much as 82% from 
control (Dhaliwal et al. 2012). However, when these findings were 
translated into a randomised-controlled trial of peripheral blood monocyte 
depletion in a human model of LPS-induced lung inflammation, no 
significant effects on neutrophil influx were observed (Barr et al. 2013). 
• TNFα (tumor necrosis factor alpha). TNFα is potently released by 
activated macrophages and neutrophils as well as other cell types in 
response to LPS, bacterial products and IL-1 (Walsh et al. 1991). It has 
numerous local and systemic pro-inflammatory effects. 
The anti-inflammatory cytokine we chose to measure was: 
• IL-10 This is primarily produced by monocytes and in unstimulated 
tissues the expression is minimal. It is generally synthesised in response 
to pathogenic stimuli (Mosser & Zhang 2008).  
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Results: Figure 4-12 overleaf shows that at high doses of dasatinib, there are 
higher levels of pro-inflammatory cytokine production (KC and TNFα) in the 
alveolar space, with no activation of IL-10. At a dose of 1 mg/kg, there is slightly 
less TNFα production in dasatinib-treated mice, but no change in MCP-1 or KC 
production. Again IL-10 is undetectable.  
Comments: It is possible that a 24 h timepoint is too early to observe markers 
of resolution such as IL-10 release, as suggested by the neutrophil influx graph 
in Chapter 2 that shows peak neutrophil levels in interstitial and alveolar spaces 
falling back to normal between 24 h and 48 h. Although monocyte (the primary 
source of IL-10) counts were not quantified in these 2 spaces, very few 
monocytes were observed on cytospins of BALF. 
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Figure 4-12 Effect of dasatinib treatment on the pro/anti-inflammatory 
cytokine profile of the alveolar space 
Effect of i.p. treatment with 1 mg/kg dasatinib (left panel) and 10 mg/kg 
dasatinib (right panel) on the concentration of KC (A), MCP-1 (B), TNFα (C) and 
IL-10 (D) in BAL samples from mice exposed to i.t. E. coli. Data show mean and 
SD values from 2 experiments using samples from 8 mice per group; the 1 
mg/kg+control and 10 mg/kg+control values are separate experiments. The 
horizontal dotted green lines indicate the lower level of detection for each ELISA 
kit. Control vs dasatinib: p=0.786 (1 mg/kg), ****p<0.0001 (10 mg/kg) (A); 
p=0.197, p=0.0528 (B); *p=0.177, **p=0.0035 (C); p=1.00 (D). Inter-experiment 
control group difference: p=0.523 (A), p=0.823 (B), p=0.852 (C) and p=1.00 (D) 
by unpaired t-test. 
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4.2.8 Evidence of extrapulmonary toxicity 
Results: As expected, mice treated with 10 mg/kg dasatinib are visibly more 
unwell than control mice due to an increased bacterial burden and this is 
reflected in simple markers of extrapulmonary toxicity or ‘sepsis’: serum lactate 
(a marker of suboptimal supply of oxygen to the peripheral tissues) and ALT (a 
direct marker of liver inflammation) levels, as shown below in Figure 4-13 
below. 
 
Figure 4-13 Treatment with 10 mg/kg Dasatinib increases markers of 
extrapulmonary toxicity in E. coli-treated mice  
Effect of i.p. treatment with 1 mg/kg dasatinib (left panel) and 10 mg/kg 
dasatinib (right panel) on the serum concentration of lactate (A) and ALT (B) in 
mice exposed to i.t. E. coli. Data show mean and SD values from 2 experiments 
using samples from 8 mice per group; the 1 mg/kg+control and 10 
mg/kg+control values are separate experiments. Control vs dasatinib: p=0.992 
(1 mg/kg), **p=0.0095 (10 mg/kg) (A); p=0.779, ****p<0.0001 (B). Inter-
experiment control group difference: p=0.224 (A), p=0.227 (B) by unpaired t-
test. 
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 Effect of Dasatinib on an In Vivo Murine Model of Acid-induced Acute 4.3
Lung Inflammation 
I investigated the second part of my hypothesis by using a sterile model of 
acute lung inflammation. One reason for sterility was to remove the potentially 
complicating factor of simultaneous bacterial replication and invasion 
encountered in the model described above. Also, acid inhalation represents the 
second most common cause of direct lung injury that may lead to ARDS (Ware 
& Matthay 2000) and is therefore a clinically relevant model to study.  
Direct acid instillation into murine lungs results in a robust TNFα dependent 
neutrophilic alveolitis with alveolar oedema from increased vascular and 
epithelial permeability that usually heals with fibrosis, in a similar way to human 
ARDS (Maniatis et al. 2012). However in humans, ARDS caused by acid 
aspiration is invariably complicated by primary lung infection (upper airway 
commensals mixed with regurgitated stomach contents at the time of aspiration) 
or secondary lung infection (subsequent bacterial/fungal invasion of a damaged 
alveolar epithelial cell layer in the context of acquired immune cell dysfunction) 
so it is rarely a true ‘sterile’ condition. Interestingly, neutrophil recruitment in 
acid models is partly β2-integrin dependent and partly mediated by platelet-
neutrophil interactions though P-selectin (Zarbock et al. 2006). We expected to 
see an effect of dasatinib in this model. 
Based on our results from the E. coli model, we chose to start with a modest 
dasatinib dose of 5 mg/kg and increase the group size to 10 to ensure any 
subtle effects were picked up in the data. We chose the higher dose of 10 
mg/kg for the second experiment (kindly carried out by Drs Dorward and Lucas 
in my absence; all data analysis and interpretation carried out by me) based on 
the results of the 5 mg/kg experiment. Only 9 mice per group were available for 
the 5 mg/kg experiment.  
Certain assays (e.g. alveolar and interstitial fluid cytokine levels, MPO and LTF 
levels) carried out in the 5 mg/kg experiment were not repeated in the 10 mg/kg 
experiment as we decided that the extra data would not offer any more insight 
into the effects of dasatinib. It is practically too difficult for 2 operators to carry 
out these experiments on more than 2 groups (of 8+ mice) at once, without 
compromising the experimental accuracy and reliability, so the 2 experiments 
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were carried out separately. Despite this, inter-experiment control variability was 
once again good. 
4.3.1 Cellular influx to alveolar space 
Using identical methods to the E. coli experiments, cellular influx to the alveolar 
space in response to acid injury was measured. The total cell/neutrophil influx in 
response to acid was lower than to E. coli.  
Results: At 5 mg/kg there is no effect on total cell and total neutrophil influx 
(Figure 4-14A and B opposite) but there is an observed reduction in the 
percentage of neutrophils on BAL cytospin (Figure 4-14D).  
Comments: This finding is not observed using the flow cytometric method, 
however the control group variability in these experiments means these figures 
should be interpreted with care (Figure 4-14C). As discussed in section 4.2.2 
above, in such cases of discrepancy, the results obtained by cell morphology 
are favoured. However, it should be indicated again that as the total number of 
neutrophils in BALF is the same between control and 5 mg/kg dasatinib, the 
cytospin results again suggest that there is a corresponding relative increase in 
other unidentified cell types. 
Results: 10 mg/kg dasatinib results in increased total cell and total neutrophil 
influx compared to control. Data is missing for the 10 mg/kg cytospins as the 
slides were inadvertently disposed of before counting. 
Figure 4-14 Treatment with 5 mg/kg Dasatinib reduces % neutrophilia in 
the alveolar space but 10 mg/kg Dasatinib increases cellular influx to the 
alveolar space 
Effect of i.p. treatment with 5 mg/kg dasatinib (left panel) and 10 mg/kg 
dasatinib (right panel) on the total number of cells (A), the total number of 
neutrophils (B) and the % neutrophils (C+D) in BAL samples from mice exposed 
to i.t. hydrochloric acid. Results obtained using NucleoCounter© machine 
method (A), flow cytometry (B+C) and cell morphology on cytospin staining (D). 
Cytospin slides for 10 mg/kg+control experiment were mislaid before counting. 
Data show mean and SD values from 2 experiments using samples from 10 
mice per group (5 mg/kg experiment) and 9 mice vs 8 mice due to a failed 
lavage (10 mg/kg experiment); the 5 mg/kg+control and 10 mg/kg+control 
values are separate experiments. Control vs dasatinib: p=0.997 (5 mg/kg), 
*p=0.037 (10 mg/kg) (A); p=0.602, *p=0.0197 (B); p=0.550, p=0.191 (C); 
***p=0.0002 (D). Inter-experiment control group difference: *p=0.047 (A), 
p=0.061 (B), ***p=0.0008 (C)  by unpaired t-test. 
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4.3.2 Cellular influx to lung interstitium 
Results: As shown in Figure 4-15 opposite, 5 mg/kg dasatinib has no effect on 
cellular influx into the lung interstitium, but 10 mg/kg results in a clear increase 
in total and % neutrophil content in the interstitial space, matching the response 
seen in the alveolar space.  
Comments: Total neutrophil influx to the lung interstitium is considerably less 
than for E. coli (see Figure 4-4), by a factor of over 10-1. However the influx 
appears to be more neutrophilic in composition, with a control group mean % 
neutrophil content of 64% (acid) vs 38% (E. coli). See Figure 4-4 above and 
Figure 4-15 opposite.  
Together these data suggest enhanced recruitment of neutrophils to the 
alveolar and interstitial spaces in mice treated with 10 mg/kg dasatinib. 
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Figure 4-15 Treatment with 10 mg/kg Dasatinib increases neutrophil influx 
into the lung interstitium in response to acid injury 
Effect of i.p. treatment with 5 mg/kg dasatinib (left panel) and 10 mg/kg 
dasatinib (right panel) on the % neutrophils in blood (A), the total number of 
neutrophils (B) and the % neutrophils (C) in lung homogenates from mice 
exposed to i.t. hydrochloric acid. Data show mean and SD values from 2 
experiments using samples from 10 mice per group (5 mg/kg experiment) and 9 
mice vs 8 mice due to a failed lavage (10 mg/kg experiment); the 5 
mg/kg+control and 10 mg/kg+control values are separate experiments. Control 
vs dasatinib: p=0.853 (5 mg/kg), p=0.547 (10 mg/kg) (A); p=0.158, *p=0.0249 
(B); p=0.453, ****p<0.0001 (C). Inter-experiment control group difference: 
p=0.101 (A), p=0.351 (B), **p=0.007 (C) by unpaired t-test. 
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4.3.3 Evidence of neutrophil degranulation 
Due to the weakly fluorescent PE-CD63 antibody in the E. coli experiments, we 
chose to measure only CD11b expression on neutrophils in the acid-injury 
model.  
Results: 5 mg/kg dasatinib reduces CD11b expression on interstitial 
neutrophils with no effect on alveolar neutrophils. 10 mg/kg dasatinib, on the 
other hand, causes significantly higher expression of CD11b in the interstitium, 
indicating increased activation and degranulation (Figure 4-16 below). 
 
Figure 4-16 CD11b expression on neutrophils in the lung interstitium in 
response to acid injury is reduced by treatment with 5 mg/kg Dasatinib 
but increased with 10 mg/kg Dasatinib 
Effect of i.p. treatment with 5 mg/kg dasatinib (left panel) and 10 mg/kg 
dasatinib (right panel) on neutrophil expression of CD11b in lung homogenate 
(A) and BAL (B) samples from mice exposed to i.t. HCl. Data show mean and 
SD values from 2 experiments using samples from 10 mice per group (5 mg/kg 
experiment) and 9 mice vs 8 mice due to a failed lavage (10 mg/kg experiment); 
the 5 mg/kg+control and 10 mg/kg+control values are separate experiments. 
Control vs dasatinib: ***p=0.0005 (5 mg/kg), ****p<0.0001 (10 mg/kg) (A); 
p=0.931, p=0.368 (B).  Inter-experiment control group difference: p=0.29 (A), 
p=0.07 (B) by unpaired t-test. 
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In a variation to the E. coli experiments, we also measured MPO concentration 
in the cell-free lung homogenate fluid in the 5 mg/kg experiment.  
Results: Although there is no effect on alveolar or interstitial MPO 
concentration using 5 mg/kg dasatinib, there is evidence of significantly reduced 
LTF (secondary granule) release into BALF, indicating an effect on neutrophil 
degranulation (Figure 4-17 below). 
 
Figure 4-17 Treatment with 5 mg/kg dasatinib reduces alveolar lactoferrin 
release in response to acid injury 
Effect of i.p. treatment with 5 mg/kg dasatinib on the concentration of MPO in 
lung homogenates (A) and the concentration of MPO (B) and LTF (C) in BAL 
samples from mice exposed to i.t. HCl. Data show mean and SD values from 1 
experiment using samples from 10 mice per group. LTF concentration only 
measured in BALF. Both assays only carried out in initial 5 mg/kg+control 
experiment. p=0.257 (A), p=0.422 (B) and **p=0.009 (C) by unpaired t-test. 
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4.3.4 Alveolar leak 
Mice receiving 10 mg/kg dasatinib with acid injury were visibly more unwell at 
12 h than the control group with more haemorrhagic lavage fluid. Their large 
bowel appeared more ischaemic.  
Results: Although there is no significant effect on alveolar leak at both doses 
(as measured by total protein concentration in the BALF), there is a clear trend 
towards an effect at 10 mg/kg, indicating increased epithelial and endothelial 
cell dysfunction (Figure 4-18 below).  
Comments: This may be due to a direct effect of src kinase inhibition on barrier 
function. In response to LPS in mice, c-src and Yes kinases have been shown 
to mediate vascular leakage with an opposing effect of Lyn kinase activation in 
stabilising endothelial adherens junctions (Han et al. 2013). 
 
Figure 4-18 Treatment with dasatinib has no effect on alveolar leak in 
response to acid injury 
Effect of i.p. treatment with 5 mg/kg dasatinib (left panel) and 10 mg/kg 
dasatinib (right panel) on the total protein concentration in BAL samples from 
mice exposed to i.t. HCl. Data show mean and SD values from 2 experiments 
using samples from 10 mice per group (5 mg/kg experiment) and 9 mice vs 8 
mice due to a failed lavage (10 mg/kg experiment). Control vs dasatinib: 
p=0.905 (5 mg/kg) and p=0.052 (10 mg/kg). Inter-experiment control group 
difference: p=0.872 by unpaired t-test. 
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4.3.5 Pro/anti-inflammatory cytokines in BALF and lung interstitium 
Cytokines were measured in both cell-free alveolar and interstitial fluid in the 5 
mg/kg experiment, but not in the subsequent 10 mg/kg experiment (Figure 4-19 
overleaf).  
Results: As shown, dasatinib significantly reduces MCP-1 production in the 
alveolar space with no effect in the interstitial space.  
Comments: All other cytokine levels are unchanged in both compartments, 
although alveolar TNFα and IL-10 values are below the minimum detection 
levels of their respective ELISA kits. However, the positive values obtained in 
Figure 4-19H indicate that the IL-10 ELISA kit was indeed working.  
A more sensitive method of measuring IL-10 in lavage samples, such as a 
cytometric bead array (CBA) kit or a more sensitive ELISA kit may have 
revealed more information about anti-inflammatory processes. 
It is difficult to know how to interpret the significant effect of dasatinib treatment 
on BALF MCP-1 values in the context of the normal levels of other cytokines. 
The graph in Figure 4-19C does however demonstrate a marked effect. If the 
effect is real, it suggests that dasatinib inhibits alveolar monocyte and 
macrophage activation, most likely through Hck, Fgr or Lyn kinase inhibition 
(Okutani et al. 2006).  
Taken with the other findings above, it does suggest a modest anti-inflammatory 
effect of 5 mg/kg dasatinib in response to sterile acid injury through inhibition of 
neutrophil degranulation. 
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Figure 4-19 Treatment with 5 mg/kg dasatinib reduces alveolar MCP-1 
release in response to acid injury 
Effect of treatment with 5 mg/kg dasatinib on the concentration of KC (A+B), 
MCP-1 (C+D), TNFα (E+F) and IL-10 (G+H) in BAL (A, C, E and G) and lung 
homogenate (B, D, F and H) samples from mice exposed to i.t. HCl. Data show 
mean and SD values from 1 experiment using samples from 10 mice per group. 
The horizontal dotted green lines indicate the lower level of detection for each 
ELISA. Assays only carried out in initial 5 mg/kg+control experiment. p=0.376 
(A), p=0.179 (B), *p=0.0301 (C), p=0.699 (D), p=0.131 (E), p=0.216 (F), 
p=0.874 (G), p=0.483 (H) by unpaired t-test. 
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4.3.6 Evidence of extrapulmonary toxicity 
Results: Perhaps surprisingly, 5 mg/kg dasatinib appears to reduce markers of 
impaired tissue perfusion (lactate) but increase markers of liver inflammation 
(ALT), whereas 10 mg/kg dasatinib results in increased liver toxicity alone.  
Comments: The control group variability in ALT levels may account for this 
unexpected result in the 5 mg/kg experiment. 
 
Figure 4-20 Treatment with dasatinib increases liver toxicity in response 
to acid injury 
Effect of i.p. treatment with 5 mg/kg dasatinib (left panel) and 10 mg/kg 
dasatinib (right panel) on the concentration of lactate (A) and ALT (B) in serum 
from mice exposed to i.t. HCl. Data show mean and SD values from 2 
experiments using samples from 10 mice per group (5 mg/kg experiment) and 8 
per group due to insufficient samples (10 mg/kg experiment); the 5 
mg/kg+control and 10 mg/kg+control values are separate experiments. Control 
vs dasatinib: **p=0.0040 (5 mg/kg), p=0.664 (10 mg/kg) (A); ****p<0.0001, 
**p<0.0094 (B).  Inter-experiment control group difference: p=0.34 (A), *p=0.010 
(B) by unpaired t-test. 
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 Summary of Key Findings 4.4
These experiments have tested my hypothesis in two in vivo murine models of 
E. coli and acid-induced acute lung inflammation. My key findings are 
summarised as follows: 
1. Intratracheal instillation of live E. coli into healthy mice reproducibly 
causes intense neutrophilic influx into the alveolar and interstitial spaces 
with evidence of degranulation, inflammation and alveolar leak. 
Treatment with dasatinib has a variable effect dependent on the dose 
administered. At low dose (1 mg/kg) there is reduced interstitial 
neutrophil content, reduced alveolar release of MPO and TNFα but 
slightly increased bacterial survival in the lung interstitium, with no effect 
on other markers. At high dose (10 mg/kg) there is a clear detrimental 
effect that is likely to be due to increased bacterial survival and 
exponential growth in all compartments of the lung as a result of impaired 
neutrophil phagocytosis and killing. The dose threshold of this effect is 
however unknown. 
 
2. In a sterile model of lung inflammation using acid instillation, a moderate 
dose of dasatinib (5 mg/kg) reduces alveolar neutrophil content, 
degranulation of LTF and MCP-1 release, with reduced interstitial 
neutrophil CD11b activation and no major effect on other markers. Again, 
the higher dose of 10 mg/kg induces a detrimental effect, with increased 
alveolar and interstitial neutrophil influx and degranulation, and increased 
alveolar haemorrhage. 
Therefore in these experiments, my hypothesis: 
“Inhibition of the src kinase pathway attenuates neutrophil recruitment to 
the alveolar and interstitial spaces, neutrophil degranulation and 
endothelial cell injury and leak in in vivo models of bacteria and acid-
induced acute lung inflammation” 
has not been fully satisfied. Instead src inhibition has a moderating effect on the 
composition of the inflammatory cell infiltrate in both models, with reduced 
markers of degranulation at lower doses and no effect on endothelial cell injury 
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and leak. At higher doses, src inhibition has the opposite effect with increased 
neutrophil influx, degranulation and alveolar leak.  
These findings will be further discussed in Chapter 6 (General Discussion), 
particularly with regard to their significance in further understanding the 
pathogenesis of ARDS. 
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Chapter 5. An Investigation into the Effect of Src Kinase Inhibitors 
on the Processes of Neutrophil-Mediated Epithelial Cell 
Damage and Macrophage Efferocytosis of Apoptotic Cells 
 Chapter Overview 5.1
This chapter describes the work I carried out to test my third hypothesis: 
“In vitro src kinase inhibition of human neutrophils attenuates neutrophil-
mediated epithelial cell damage whilst promoting a pro-resolutionary 
environment, allowing efficient apoptotic cell clearance” 
I investigated whether PP1 or dasatinib affected secondary epithelial cell 
inflammation as well as alveolar repair, processes that are important in the 
pathogenesis and resolution of ARDS. Section 5.2 details the optimisation and 
implementation of an in vitro model of neutrophil-mediated epithelial cell injury, 
using bacterial stimulation to simulate an infected alveolus, to extend my in vitro 
work from Chapter 3. Section 5.3 describes experiments to confirm that ex vivo 
neutrophils from critically ill patients are dysfunctional and pro-inflammatory, 
and test whether this behaviour can be inhibited with src kinase inhibitors. 
Finally, in Sections 5.4 and 5.5, I investigate the effects of src kinase inhibition 
on alveolar repair, by incorporating an apoptotic cell efferocytosis assay into the 
experimental design.  
As the experimental design in this chapter is particularly complex, I have 
detailed it both pictorially and in text throughout this chapter to aid the reader in 
interpreting the results. Methods for routine techniques such as ELISA, flow 
cytometry, neutrophil phagocytosis and bacterial killing and cell culture are not 
repeated, and can be referred to in Chapter 2 on page 31. 
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 Effects on Epithelial Cell Inflammation and Damage  5.2
Aim: The experimental aim was to test whether src kinase inhibition of human 
neutrophils exposed to live bacteria indirectly affected epithelial cell 
inflammation and damage. 
5.2.1 Experimental design 
This description refers to Figure 5-1 opposite. Briefly, 2 x 106 neutrophils in 
serum-free IMDM (no phenol red) from healthy volunteers were treated for 30 
min at 37oC in a shaking water bath with 10 µM PP1 or 100 nM dasatinib with 
appropriate controls (Step 1).  
The cells were then washed twice in warm PBS- to remove the effect of the 
inhibitors for the remainder of the experiment, before resuspending at the same 
concentration in IMDM. Each condition was then stimulated with serum-
opsonised S. aureus (NCTC 8325) or E. coli (K-12 strain) for 30 min at 37oC in 
a shaking water bath at an MOI of ~10 bacteria: 1 neutrophil (Step 2).  
Each individual co-culture supernatant was filter-sterilised through a separate 
0.2 µm filter and transferred to an individual well of a 24-well plate containing 
cultured, adherent A549 epithelial cells at ~70% confluence in serum-free 
conditions. From further preliminary experiments, I found that serum-free 
conditions were required to observe evidence of damage and inflammation in 
the epithelial cell monolayer. The A549s were cultured in the supernatants for 
24 h at 37oC, 5% CO2 (Step 3).  
At this point, photographs of the monolayer integrity were taken using inverted 
light microscopy before transferring each supernatant to a fresh eppendorf tube. 
The tubes were centrifuged at 10,000g for 3 min and the upper debris-free 
supernatants were transferred to fresh eppendorf tubes and frozen at -80oC for 
later analysis. The samples were tested in duplicate for inflammatory cytokine 
release (IL-8 and MCP-1) and cytotoxicity (LDH release) (Step 4). 
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Figure 5-1 Experimental design for section 5.2
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5.2.2 Src kinase inhibition of neutrophils: effect on epithelial cell 
monolayer integrity in an in vitro model of infection 
From my preliminary experiments and previously published data (Conway 
Morris et al. 2009), it was observed that LPS-stimulated neutrophils induce 
A549 cell monolayer disruption with inflammatory cytokine and LDH release 
through both direct membrane-mediated effects and when the cells are 
separated by a permeable membrane, suggesting the effect is partly due to a 
soluble factor.  
Results: Figure 5-2 opposite shows representative images of the A549 
monolayer integrity after 24 h incubation with filter-sterilised supernatants from 
various combinations of src kinase-treated healthy neutrophils with live SA or 
EC and appropriate controls. 
Comments: The top 2 rows of Figure 5-2 demonstrate two important control 
observations: 
• A549s at 70% confluence incubated in serum-free media alone reach near 
100% confluence at 24 h. The supernatant of unpre-treated, unstimulated 
healthy neutrophils has no obvious effect on this growth. 
• When the src kinase inhibitors, PP1 and dasatinib are ‘carried over’ in the 
supernatant from treated neutrophils to A549 cells, the inhibitors themselves 
appear to cause disruption of the A549 monolayer. The cells are clumped 
and spherical with some detachment into suspension.  
This effect is not observed when PP1 and dasatinib-treated neutrophils are 
washed before they are incubated for a further 30 min in media alone and their 
supernatant is transferred to the A549s, suggesting it is due to a direct effect of 
the inhibitors. This would be expected, given the importance of src family 
kinases in integrin function. For this reason, the inhibitors were routinely 
washed from the cells for all subsequent experiments, as shown in Figure 5-1 
above. 
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Figure 5-2 Products of the interaction of neutrophils with PP1, Dasatinib 
and SA disrupt A549 monolayer integrity 
X200 representative images of confluent A549 monolayers incubated for 24 h in 
the filter-sterilised, serum-free supernatant of the following neutrophil 
interactions: Neutrophils (from healthy volunteers) pre-treated for 30 min with 
control medium, 10 µM PP1 or 100 nM dasatinib before being washed twice in 
PBS- to remove the effects of drugs (second row) or left unwashed (top row). 
Healthy neutrophils pre-treated for 30 min with control medium, 10 µM PP1 or 
100 nM dasatinib, washed twice in PBS- and subsequently stimulated for 30 
min with SA (MOI~10 SA:1 PMN) (third row) or EC (MOI~10:1) (bottom row). An 
extra set of control conditions tested neutrophil-free control medium with or 
without bacteria (first column). Representative images from 3 experiments using 
neutrophils from 3 independent volunteers. 
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The photos displayed in the 3rd and 4th rows in show an interesting effect:  
• The supernatant of live SA and EC alone does not cause any monolayer 
disruption, but the supernatant of untreated neutrophil/SA co-culture 
severely disrupts the monolayer, suggesting this effect is caused by 
soluble factors released by neutrophils and/or SA in response to their 
interaction. This observation is not seen when using a neutrophil/E. coli 
co-culture. The SA effect is not reversed when neutrophils are pre-
treated with 10 µM PP1 or 100 nM dasatinib, using precisely the same 
experimental conditions (PP1/dasatinib concentration and MOI) as in 
Chapter 3. This suggests that the causative soluble factors are not 
products of neutrophil degranulation.  
Although I did not test this theory, it is possible that these results are explained 
by the release of lipoteichoic acid (LTA) in the SA experiments. LTA is a cell 
wall component in Gram-positive organisms such as S. aureus released upon 
bacteriolysis by leukocytes and mediates inflammation through ligation of TLR2. 
Gram-negative organisms such as E. coli do not contain LTA. At 30 µg/ml, LTA 
is known to induce production and release of the opsonin surfactant protein A 
through NF-κB activation from A549 cells in vitro, though without any effect on 
cell viability (Liu et al. 2012). It also induces a dose-dependent increase in 
cyclooxygenase-2 (COX-2) and prostaglandin E2 (PGE2) expression and activity 
(Lin et al. 2001). So although LTA has not been previously shown to disrupt 
epithelial cell barrier function, it does however induce endothelial cell barrier 
dysfunction in pulmonary microvessel endothelial cell monolayers through 
generation of ROS/Reactive nitrogen species (RNS) (Pai et al. 2012). 
It is also possible that the effect seen is due to virulence factors specific to S. 
aureus NCTC 8325 that are not exhibited by E. coli K-12 strain. For example, S. 
aureus releases several leukotoxins such as leukocidin in response to 
neutrophil interaction that can induce both NETs production and breakdown 
(Malachowa et al. 2013; Thammavongsa et al. 2013). 
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5.2.3 LDH/cytokine release from epithelial cells: control experiments  
I carried out the following control experiments to assess two potential 
confounding factors: 
The first control experiment investigated whether relative cytokine or LDH 
release from A549s cells may simply be dependent on the exact number of cells 
present in each well. 
Results: These are summarised in Figure 5-3A opposite. The results confirm 
that neither pre-treatment of the neutrophils in Step 1, nor stimulation of the 
neutrophils with bacteria (only SA used in this control experiment) in Step 2, 
significantly affect the total protein concentration of the lysed A549 monolayer 
harvested in Step 4 of the experimental protocol. Total protein concentration 
gives a crude but fairly accurate comparison of the total number of A549 cells 
present.  
Comments: As the results were consistent, I did not measure this parameter 
again in subsequent experiments and attributed any difference in relative 
cytokine or LDH levels between experimental conditions to an actual difference 
in A549 cell expression and release. 
The second control experiment investigated whether the majority of IL-8 
measured in the final A549 supernatant in Step 4 was released by A549 cells 
rather than neutrophils, a known source of vigorous IL-8 release. 
Results: These are summarised in Figure 5-3B opposite. As shown in the left 
hand condition, quiescent neutrophils release relatively low levels of IL-8, with 
or without 30 min of live bacterial stimulation. The middle condition also shows 
that quiescent A549 cells release low levels of background IL-8, even when 
exposed to SA supernatant. IL-8 release from A549s is increased approximately 
3-fold by exposure to the supernatant of SA-stimulated neutrophils. This effect 
is dependent on neutrophil stimulation.  
Comments: In subsequent experiments, these control conditions were not 
repeated and any relative differences in cytokine release in Step 4 were 
therefore attributed to true effects on A549 cell expression and release. 
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Figure 5-3 Neutrophil/bacterial supernatants do not significantly affect the 
A549 monolayer total protein content or contribute to IL-8 generation in 
the absence of A549s 
Protein concentration of washed A549 monolayers incubated for 24 h in the 
filter-sterilised, serum-free supernatant of neutrophils pre-treated for 30 min with 
control medium, 10 µM PP1 or 100 nM dasatinib before washing twice with 
PBS- and being left unstimulated or stimulated for 30 min with live serum-
opsonised SA (A). Data show mean and SD values from 3 experiments using 
duplicate samples from 3 independent volunteers. p=0.836 by 2-way ANOVA. 
IL-8 concentration in the supernatant of unstimulated and SA-stimulated 
neutrophils (left hand condition), A549s incubated for 24 h in the filter-sterilised 
supernatant of control medium or SA alone (middle condition) and A549s 
incubated for 24 h in the filter-sterilised supernatant of unstimulated neutrophils 
or neutrophils exposed to live SA (right hand condition) (B). Data show mean 
and SD values of duplicate ELISA wells from 3 experiments using samples from 
3 independent volunteers. ****p<0.0001 by 2-way ANOVA. 
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5.2.4 Effect of src kinase inhibition on neutrophil-mediated epithelial 
inflammation 
Results: Figure 5-4 opposite, Figure 5-5 (overleaf) and Figure 5-6 (overleaf)  
show IL-8, MCP-1 and LDH release from A549 cells in Step 4 respectively. In 
Figure 5-4 A and B, PP1 and dasatinib pre-treatment appears to attenuate the 
release of an unknown pro-inflammatory soluble factor from neutrophils 
exposed to SA, indirectly leading to significantly reduced release of pro-
inflammatory IL-8 from A549 cells.  
Comments: Interestingly, supernatant from neutrophil:SA interactions induces 
the release of almost double the amount of IL-8 from A549 cells than from 
neutrophil:EC interactions, also suggesting that SA NCTC 8325 is more virulent 
and pathogenic at a similar MOI.  
These observations are consistent with the A549 monolayer appearances 
displayed in Figure 5-2 except that the indirect reduction in IL-8 release due to 
src kinase inhibition of neutrophils is not matched by improved monolayer 
integrity. 
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Figure 5-4 PP1 and Dasatinib treatment of neutrophils exposed to SA 
results in an attenuated IL-8 release from A549 cells 
IL-8 release from A549s incubated for 24 hours in filter-sterilised, serum-free 
supernatants from healthy neutrophils pre-treated with 10 µM PP1 or 100 nM 
dasatinib and exposed to live SA (A) or live EC (B). Data show mean and SD 
values of duplicate ELISA wells from 2 experiments, each using samples from 3 
independent volunteers (total n=6). p<0.0001 (A) and p=0.0316 (B) by repeated 
measures ANOVA; **p<0.01, ***p<0.001 by Dunn’s post-hoc test comparing 
treated with control untreated neutrophils. 
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Comments: MCP-1 is released by endothelial cells. There is some in vitro 
evidence to suggest it can actually be released by neutrophils in response to 
the products of GM-CSF-treated mononuclear cells and may represent the link 
between neutrophils and the adaptive immune response (Yamashiro et al. 
1999). As discussed in Chapter 4, it may be of particular importance in ALI and 
ARDS because monocyte recruitment appears to control the later phases of 
neutrophil migration in established murine LPS-induced acute lung inflammation 
(Dhaliwal et al. 2012). In Figure 5-5 opposite, the opposite pattern to IL-8 
occurs, in that the intial pre-treatment of neutrophils with PP1 and dasatinib in 
Step 1 appears to indirectly result in increased MCP-1 release from A549s 
when the neutrophils are stimulated by SA in Step 2. Similar findings are not 
seen with E. coli.  
The finding in Figure 5-5A is difficult to explain but there is evidence to suggest 
that in epithelial cells, MCP-1 is conversely anti-inflammatory in its action, 
promoting airway epithelial cell repair. In cultured bronchial epithelial cells, 
MCP-1 is expressed in response to monolayer injury and acts in an autocrine 
manner on its CCR2B receptor to promote proliferation and haptotaxis (Lundien 
et al. 2002). This repair mechanism may also be present in alveolar epithelial 
cells and may explain my findings, suggesting indirect ‘pro-resolutionary’ effects 
of src kinase inhibition of neutrophils. 
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Figure 5-5 PP1 and Dasatinib treatment of neutrophils exposed to SA and 
EC results in an increased MCP-1 release from A549 cells 
MCP-1 release from A549s incubated for 24 hours in filter-sterilised, serum-free 
supernatants from healthy neutrophils pre-treated with 10 µM PP1 or 100 nM 
dasatinib and exposed to live SA (A) or live EC (B). Data show mean and SD 
values of duplicate ELISA wells from 2 experiments, each using samples from 3 
independent volunteers (total n=6). p=0.0003 (A) and **p=0.0011 (B) by 
repeated measures ANOVA; **p<0.01, ***p<0.001 by Dunn’s post-hoc test 
comparing treated with control untreated neutrophils. 
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Comments: To estimate epithelial cell damage, I also measured relative LDH 
release from A549s in the experiments above. In Figure 5-6 below, supernatant 
from untreated neutrophil:bacterial interaction induces LDH release from A549s, 
when both SA or EC are used. Pre-treatment of the neutrophils with PP1 or 
dasatinib reduces this indirect A549 damage when using SA, in the same 
pattern as IL-8. Such an effect is not seen when using EC; indeed dasatinib 
appears to potentiate the damage. As with IL-8 release, the difference in effect 
between SA and EC is likely to be related to their differing mechanisms of 
virulence. 
 
Figure 5-6 PP1 and Dasatinib treatment of neutrophils exposed to SA 
results in reduced A549 cell damage 
LDH release from A549s incubated for 24 hours in filter-sterilised, serum-free 
supernatants from healthy neutrophils pre-treated with 10 µM PP1 or 100 nM 
dasatinib and exposed to live SA (A) or live EC (B). Data show mean and SD 
values of duplicate LDH assay wells from 2 experiments, each using samples 
from 3 independent volunteers (total n=6). ***p=0.0003 (A) and **p=0.003 (B) 
by repeated measures ANOVA; **p<0.01, ***p<0.001 by Dunn’s post-hoc test 
comparing treated with control untreated neutrophils. 
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 Can Src Kinase Inhibition of Neutrophils from Critically Ill Patients 5.3
Reduce Toxicity to A549 cells? 
In these experiments I translated my findings from Section 5.2 into a clinical 
setting to test whether src kinase inhibition of neutrophils from critically ill 
patients affects their ability to induce indirect damage and inflammation in 
epithelial cells. Such patients are a very heterogenous group, with numerous 
different sterile and non-sterile precipitating factors. As discussed in the 
methods in Chapter 2, these patients were all admitted to an ICU within the 
previous 48 hours, with evidence of SIRS and requiring support of at least one 
organ, and expected to survive beyond a further 48 hours after recruitment. 
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5.3.1 Neutrophils from critically ill patients exhibit impaired phagocytosis 
and bacterial killing 
Patients: Neutrophils from a total of 6 critically ill patients were used in 
experiments. As patient recruitment was unpredictable and usually limited to 1 
patient at once, I recruited non-matched healthy controls on the same day and 
carried out the experiments simultaneously. In total, 5 experiments were carried 
out, 1 of which involved 2 critically ill patients and 1 healthy volunteer and 
another involved 1 critically ill patient and 2 healthy volunteers.  
As neutrophils from critically ill patients show marked variability in experimental 
assays, any statistical comparisons were made using non-parametric tests 
(Mann Whitney test for 2 conditions and the Kruskal-Wallis test with Dunn’s 
post-hoc correction for >2 conditions). 
Results: Table 5-1 shows the basic demographic data of the two groups 
together with some basic measures of neutrophil phagocytic and killing function. 
The patients were significantly older with poorer in vitro neutrophil function. 
They were a relatively unwell group, with a median APACHE II score of 24.5, 
predicting an in-hospital mortality rate of 40% (Knaus et al. 1985). Four patients 
had pneumonia, one patient had pancreatitis and one patient had just 
undergone an emergency laparotomy. 
Table 5-1 Demographics, neutrophil phagocytosis and bacterial killing 
rates of critically ill and control groups 
Groups compared using Mann Whitney test 
 Critically ill 
patients 
Healthy controls p value 
Number 6 6  
Age (yrs): median 
(range) 
76 (43-82) 30 (23-34) **0.0022 
APACHE II score: 
median (range) 
24.5 (15-30) n/a n/a 
Phagocytosis of 
zymosan particles 
(%): median 
(range) 
51 (44.1-64) 74 (63.9-76.2) **0.0043 
Bacterial killing 
(SA fold change 
after 30 min): 
median (range) 
0.18 (-0.143 
to +0.349) 
 -0.34 (-0.623 
to +0.002) 
*0.026 
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Results: Figure 5-7 below and Figure 5-8 A overleaf show the results of Table 
5-1 in graphical form. The control group is poorly matched for age and this may 
have a bearing on inherent neutrophil function.  
Comments: It is well described that increasing age is associated with reduced 
phagocytic and bactericidal activity, perhaps due to increased calcium 
concentration in resting neutrophils. This age effect is actually minimal in 
assays involving live E. coli, in which mean phagocytic and bactericidal 
activities are 74% and 59% respectively in a 62-83 yr old age group compared 
to 91% and 64% in a 21-36 yr old group (Wenisch et al. 2000). An age effect 
has previously been demonstrated in the opsonised zymosan assay, in which 
mean zymosan phagocytosis drops from 61% (21-45 yr old group) to 39% (66-
94 yr old group) (Mege et al. 1988). However, using identical experimental 
protocols to myself, Conway Morris showed that neutrophil phagocytosis was 
36% lower in 72 critically ill patients than 21 sex and age-matched healthy 
volunteers and that the effect is associated with level of C5a exposure (Conway 
Morris et al. 2009). I observed a comparable level of reduction of 23% using a 
smaller unmatched group size, suggesting that in these assays, differences are 
mainly due to critical illness. Other additional factors such as concurrent 
pharmacological treatment should be considered when interpreting the results. 
 
Figure 5-7 Critically ill patients are significantly older with poorer 
neutrophil phagocytosis 
Comparison of ages of healthy volunteers and critically ill patients (A). 
Neutrophils isolated from healthy volunteers or critically ill patients containing at 
least 2 serum-opsonised zymosan particles after 30 min exposure (B). Data 
show median and IQR values from 5 experiments using a total of 6 individuals 
per group. **p=0.0022 (A), **p=0.0043 (B) by Mann Whitney test. 
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Results: As shown in Figure 5-8 B opposite, pre-treatment of neutrophils from 
critically ill patients with PP1 or dasatinib neither improved nor reduced ex vivo 
killing of live PA01 in suspension.  
Comments: The results are consistent with the in vitro findings in healthy 
neutrophils described in Chapter 3, but they contradict the in vivo findings 
described in Chapter 4, in which bacterial clearance is impaired by treatment 
with dasatinib. 
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Figure 5-8 Impaired bacterial killing by neutrophils from critically ill 
patients is not affected by treatment with PP1 or Dasatinib 
Viable PA01 in cfu/ml after 30 min incubation in control medium and with 
neutrophils from healthy volunteers or critically ill patients (MOI~10 PA01:1 
PMN) (A). Viable PA01 after incubation in control medium and with neutrophils 
from critically ill patients pre-treated with control medium, 10 µM PP1 or 100 nM 
dasatinib (B). Data show median and IQR values of duplicate colony counts 
from 5 experiments using neutrophils from 6 individual patients and 6 
volunteers. *p=0.026 by Mann Whitney test (A) and p=0.8948 by Kruskal-Wallis 
test (B). 
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5.3.2 Variation in experimental design 
Figure 5-9 opposite shows the slight variation in the experimental protocol 
described above that I used to be able to test whether neutrophils from critically 
ill patients induce more epithelial cell inflammation and damage, and if so, 
whether treatment with PP1 or dasatinib attenuates this. The 30 min step 
involving bacterial stimulation was therefore removed. Both healthy volunteer 
and patient neutrophils were left untreated or exposed to 10 µM PP1 or 100 nM 
dasatinib for 30 min (Step 1), before washing twice to remove PP1/dasatinib. In 
these experiments the neutrophils themselves were transferred to separate 
wells on a 24 well plate containing A549 epithelial cells at ~70% confluence.  
The reasons for changing the protocol to use neutrophils themselves rather 
than their supernatant were: i) the model was more representative of an 
inflamed alveolus in which neutrophils and alveolar epithelial cells are in direct 
contact and ii) a clear difference in baseline neutrophil function between the two 
groups was demonstrated and I felt that this difference would not adequately be 
transmitted to A549 cells via a 30 min release into fresh supernatant without 
stimulation.  
Neutrophils were initially placed both in direct contact with the A549s and 
suspended just above them by a 0.4 µm pore-sized Transwell filter, through 
which only soluble factors can cross. Fresh serum-free IMDM (no phenol red) 
was added to each well and the cells incubated for 24 h (Step 2). A549 cell 
inflammation and damage were measured in the same way as described in 
Section 5.2.1 (Step 3) 
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Figure 5-9 Experimental design for section 5.3 
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5.3.3 Neutrophils from critically ill patients disrupt epithelial cell integrity 
Results: Interestingly, neutrophils from both healthy volunteers and patients 
induce a similar degree of A549 monolayer disruption and this effect appears 
slightly less marked when neutrophils are separated from the A549s by a filter 
(Figure 5-10 opposite 2nd and 3rd rows). After 24 h incubation in culture medium, 
around 50% of neutrophils become apoptotic with some cell death (see Figure 
5-16 below); that may account for this effect. Src kinase inhibition has no effect 
on rates of apoptosis in vitro (Chapter 3). Neutrophil pre-treatment with PP1 (4th 
row) or dasatinib (5th row) appears to have no effect on A549 monolayer 
disruption in both groups.  
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Figure 5-10 Treatment of neutrophils from healthy volunteers or critically 
ill patients with PP1 and Dasatinib does not reduce neutrophil-mediated 
inflammatory damage to A549 epithelial cell monolayer  
X200 representative images of confluent A549 monolayers incubated for 24 
hours either in serum-free medium (top row), or with direct contact with 
neutrophils isolated from healthy volunteers or critically ill patients (second row), 
or neutrophils suspended above a 0.4µm Transwell filter (third row), pre-treated 
with 10 µM PP1 (fourth row) or 100 nM dasatinib (bottom row). Images taken 
from 5 experiments using samples from 6 critically ill patients and 6 
independent volunteers per group. 
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5.3.4 Neutrophils from critically ill patients induce more epithelial cell 
inflammation: control experiments 
I carried out the following control experiment to investigate whether measured 
IL-8, MCP-1 or LDH was released from A549s or neutrophils, or both. 
Results: Figure 5-11 opposite shows that A549 cells release significant 
quantities of IL-8, MCP-1 and LDH when exposed to neutrophils from critically ill 
patients. This effect is more marked when the neutrophils are in direct contact 
with the A549 cells.  
Comments: Although quiescent neutrophils or A549s incubated on their own 
for 24 h release minimal IL-8 and LDH, it is highly likely that in co-culture the 
release of these markers comes from both cell types. However the peak levels 
were approximately 4000pg/ml (IL-8) and an OD490 of ~0.4 (LDH), similar to the 
levels released over 24 h by A549s alone in the experiments displayed in 
section 5.2.4 above, suggesting that the majority of the release is likely to come 
from A549 cells. MCP-1 has only been shown to be expressed by neutrophils in 
response to stimulated mononuclear cells, so any release observed in these 
experimental conditions should come from A549 cells alone. 
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Figure 5-11 Control experiments to demonstrate A549 cell inflammation 
and damage from interaction with neutrophils 
Supernatants from critically ill neutrophils alone, A549s cells alone, A549s and 
neutrophils in direct contact, or separated by 0.4µm Transwell filters tested for 
IL-8 levels (A), MCP-1 levels (B) and LDH activity (C). Data show median and 
IQR values from 5 experiments using samples from 6 critically ill patients in 
duplicate assay wells. ***p=0.001 (A), **p=0.002 (B) and **p=0.002 (C) by 
Kruskal-Wallis test comparing all conditions except PMNs alone. 
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5.3.5 Neutrophils from critically ill patients induce more epithelial cell 
inflammation and damage 
Results: Comparing the effect of neutrophils from both groups on epithelial 
cells in Figure 5-12 opposite, it is clear that neutrophils from critically ill patients 
induce more IL-8 and LDH release, with a small increase in MCP-1 release 
when separated by a filter membrane.  
Comments: As discussed, this pattern of results could conceivably be 
explained by release of IL-8 and LDH directly from activated neutrophils 
themselves in the critically ill patient group. It seems more likely to come from 
the A549s in response to a soluble factor released from the neutrophils. My 
results are consistent with a previous member of our research group (Dr 
Conway Morris, personal communication). 
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Figure 5-12 Neutrophils from critically ill patients induce more epithelial 
cell inflammation and damage through release of a soluble factor 
Supernatants from A549 monolayers incubated for 24 hours with neutrophils 
from healthy volunteers or from critically ill neutrophils maintained in direct 
contact (A, C and E) or separated by 0.4µm Transwell filters (B, D and F) tested 
for IL-8 levels (A+B), MCP-1 levels (C+D) and LDH activity (E+F). Data show 
median and IQR from 5 experiments using samples from 6 critically ill patients 
and 6 independent volunteers in duplicate assay wells. **p=0.0043 (A), 
**p=0.0043  (B), p=0.132 (C), *p=0.0411 (D), **p=0.0087 (E), **p=0.0087 (F) by 
Mann Whitney test. 
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5.3.6 Neutrophils from critically ill patients induce more epithelial cell 
inflammation and damage: effect of src kinase inhibition 
If there is a direct pro-inflammatory and cytotoxic effect of neutrophils from 
critically ill patients on alveolar epithelial cells, can this effect be reduced by src 
kinase inhibition? For these experiments, I chose to only pre-treat neutrophils 
separated from A549s by a filter with PP1 and dasatinib because the effects on 
A549 cells appeared less marked and could potentially be manipulated.  
Results: In Figure 5-13 opposite there is a small, but non-significant, effect of 
both PP1 and dasatinib pre-treatment on both IL-8 and LDH release, with no 
effect on MCP-1 release.  
Comments: With more samples per group, there may be a significant effect. 
Again, it is impossible to confidently conclude that any effect is not due to a 
direct inhibitory effect of PP1 or dasatinib on neutrophil release of IL-8 or LDH. 
Assuming that src kinase inhibition with PP1 or dasatinib inhibits degranulation 
of neutrophils from critically ill patients in a similar way to healthy volunteer 
neutrophils, the results above suggest that the soluble factor(s) responsible for 
epithelial cell inflammation is unlikely to be a product of neutrophil 
degranulation. There are many potential culprits, including ROS/RNS, cytokines 
and chemokines, serine proteases such as neutrophil elastase, matrix 
metalloproteinases such as MMP-8 and MMP-9, neutrophilic-derived cationic 
peptides such as LTF, LL-37 and defensins (Grommes & Soehnlein 2011). 
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Figure 5-13 Treatment of neutrophils from critically ill patients with PP1 or 
Dasatinib does not reduce epithelial cell inflammation and damage 
 Supernatants from A549 monolayers separated by a 0.4µm Transwell filter 
from untreated neutrophils from critically ill patients and neutrophils pre-treated 
with 10 µM PP1 (A, C and E) and 100 nM dasatinib (B, D and F) tested for IL-8 
levels (A+B), MCP-1 levels (C+D) and LDH activity (E+F). Data show median 
and IQR values from 5 experiments using samples from 6 critically ill patients. 
p=0.0931 (A), p=0.589 (B), p=0.589 (C), p=0.818 (D), p=0.589 (E), p=0.394 (F) 
by Mann Whitney test. 
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 Indirect Effects of Src Kinase Inhibition on Macrophage Efferocytosis 5.4
of Apoptotic Cells 
This section describes my final experiments aimed to test the effect of src 
kinase inhibition of neutrophils on a vital component of ‘normal’ acute lung 
inflammation: alveolar repair and efferocytosis of apoptotic cells. I hypothesised 
that an anti-inflammatory treatment such as this would push the balance 
towards resolution and result in improved apoptotic cell clearance in a simple in 
vitro model of macrophage efferocytosis of apoptotic neutrophils.  
5.4.1 Experimental design and assay optimisation 
Experimental methods for culturing apoptotic neutrophils and measuring 
macrophage phagocytosis of apoptotic neutrophils by staining for neutrophilic 
expression of MPO are described in detail on page 54. The basic experimental 
protocol used in section 5.2 above was adjusted slightly as shown below in 
Figure 5-14 opposite.  
As previously, neutrophils from healthy volunteers were pre-treated with 10 µM 
PP1 or 100 nM dasatinib with appropriate controls (Step 1), before washing 
twice to remove PP1/dasatinib and stimulating with S. aureus or E. coli at an 
MOI of ~10:1 with an unstimulated control (Step 2). The filter-sterilised 
supernatant of each tube was transferred to separate wells of a 24 well plate 
containing 7 day old cultured MDMs from a different healthy volunteer and the 
medium supplemented with 10% serum (autologous to the MDM volunteer). 
Apoptotic neutrophils cultured overnight from a separate healthy volunteer were 
washed thoroughly before adding to the MDMs at an MOI of 4 apoptotic 
neutrophils: 1 MDM (Step 3). Autologous serum was found to be necessary to 
opsonise the non-autologous apoptotic cells for optimum levels of phagocytosis. 
In serum-free conditions I observed a complete absence of MDM phagocytosis. 
After 24 h culture at 37oC at 5% CO2, each supernatant was carefully removed, 
centrifuged to remove cell debris and the supernatant frozen at -80oC for 
cytokine analysis. Each well containing MDMs was washed gently with warm 
PBS- to remove non-adherent apoptotic neutrophils before drying, fixing and 
staining for MPO (Step 4). 
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Figure 5-14 Experimental design for section 5.4 
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Figure 5-15 A-D opposite show the dramatic change in appearance and size as 
peripheral blood mononuclear cells (A and C) differentiate and mature into the 
typical “fried egg” appearance of MDMs (B and D) by day 7 in culture. Images E 
and F show the change in morphology from peripheral blood neutrophils to 
apoptotic cells after overnight culture, with condensation of nuclear material into 
dark-staining nuclear bodies. Image G shows the typical appearances of 
‘normal’ in vitro MDM phagocytosis of apoptotic neutrophils and image H shows 
impaired clearance. 
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Figure 5-15 Culture of MDMs, apoptotic neutrophils and phagocytosis of 
apoptotic neutrophils by MDMs 
X200 representative images of purified monocytes adherent to tissue culture 
plastic on day 0 (A) and after 7 days in culture to differentiate into MDMs (B). 
X1000 representative images of cytocentrifuge preparations of purified 
monocytes at day 0 (C) and after 7 days in culture to differentiate into MDMs 
(D). X200 representative images of cytocentrifuge preparations of purified 
neutrophils using Percoll method (E) and after 24 h of culture in IMDM/0.5% 
BSA at 37oC/5% CO2 to promote neutrophil apoptosis (F). X100 representative 
images of MDMs (clear cells) demonstrating normal (G) and impaired (H) 
phagocytosis of apoptotic neutrophils (brown dots), after MPO staining with 
H2O2 and dimethoxybenzidine. Images taken from > 8 individual experiments. 
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Figure 5-16 below shows a typical percentage of neutrophils of ~50% 
undergoing apoptosis in overnight culture in my optimisation experiments. Other 
groups quote higher rates of at least 70-80% (Professor A Rossi’s group, 
Edinburgh, UK, personal communication). It is possible that these relatively low 
rates of apoptosis are due to inadvertent neutrophil activation during the 
isolation process from citrated blood. 
 
Figure 5-16 Neutrophils become apoptotic after 24 h in culture  
Representative flow cytometric plot showing PI and Annexin V APC staining on 
neutrophils incubated for 24 h in IMDM/0.5% BSA at 37oC/5% CO2. Almost half 
of all gated neutrophil events are apoptotic with high Annexin V staining but low 
PI staining. Representative plot taken from 3 control experiments.  
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5.4.2 Effects on MDM pro/anti-inflammatory cytokine release: control 
experiments 
As discussed in the methods in Chapter 2, a combination of pro-inflammatory 
(IL-6, IL-8, TNFα, MCP-1, IL-1β) and anti-inflammatory (IL-1RA, IL-10) 
cytokines were initially tested in the MDM/apoptotic cell supernatant. TNFα, IL-
6, IL-1β and IL-10 were virtually undetectable even in neat media in control 
experiments. This may be due to using a relatively low concentration of 2.5 x 
105 MDMs per well in a total medium volume of 750µl.  
IL-8 (neutrophil recruitment) and MCP-1 (monocyte recruitment) were therefore 
routinely assayed in addition to IL-1RA. IL-1RA is a natural inhibitor of the pro-
inflammatory cytokine IL-1β released by epithelial cells and immune cells. In 
vitro, its release from macrophages is associated with an alternatively activated 
‘M2 phenotype’ that is broadly immunoregulatory in nature, in contrast to a 
classically activated ‘M1 phenotype’ macrophage that is associated with tissue 
destruction (Mantovani 2006).  
It is important to consider when interpreting these experiments that peripheral 
blood monocytes spontaneously differentiating into MDMs after 7 days in 
autologous serum exhibit two distinctly different morphologies and phenotypes: 
i) round cells with higher efferocytosis capacity and IL-10 expression 
(reminiscent of the M2 phenotype) and ii) spindle-shaped cells with increased 
oxidative burst potential and chemokine expression (similar to the pro-
inflammatory M1 phenotype) (Eligini et al. 2013). This effect was readily 
apparent on inverted microscopy in my experiments and although not formally 
quantified, the majority of MDMs at day 7-8 appeared round in morphology (see 
Figure 5-15B above).  
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The aim of my control experiments was to investigate the relative contribution of 
MDMs, 10% serum, neutrophil supernatant and apoptotic neutrophils towards 
the production of the three measured cytokines.  
Results: Figure 5-17 opposite displays the results.  
Comments: Apoptotic neutrophils release background IL-8 when incubated on 
their own, however this is likely to be from residual ‘alive’ neutrophils (~26% of 
‘apoptotic cell’ population were Annexin V-/PI- after 24 h culture – see Figure 
5-16 above). Similarly 10% serum alone contains detectable MCP-1 but no IL-8 
or IL-1RA.  
Peak IL-8 and MCP-1 release, together with a reduced release of IL-1RA 
appears to occur when MDMs are exposed to both neutrophil supernatant and 
apoptotic neutrophils. Neutrophil pre-treatment with PP1 or dasatinib does not 
appear to have an effect on MDM release in the absence of apoptotic 
neutrophils. Surprisingly, MCP-1 is measurable in the supernatant of both 
unstimulated and stimulated neutrophils, well above the ELISA assay detection 
limit of 15.6 pg/ml. 
 
   
  215 
 
Figure 5-17 Control experiments to demonstrate cytokine release from 
MDMs 
Supernatants for the listed control conditions were tested for the concentrations 
of IL-8 (A), MCP-1 (B) and IL-1RA (C). Pre-treated and stimulated neutrophils 
were washed twice in PBS- and the filter-sterilised supernatant transferred to 
washed MDMs in culture, where indicated. Data show mean and SE values of 
one control experiment using MDMs from 3 individual volunteers. 
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5.4.3 Src kinase inhibition of neutrophils: effect on MDM pro/anti-
inflammatory cytokine release 
Results: In Figure 5-18 opposite and Figure 5-19 overleaf, it is unclear from the 
pattern of results whether PP1 or dasatinib exert any overall effect.  
Comments: Supernatants from bacteria-stimulated neutrophils increase IL-8 
release from MDMs in response to apoptotic neutrophils compared to 
supernatants from unstimulated neutrophils. PP1 or dasatinib pre-treatment of 
the neutrophils attenuates this effect when either SA (Figure 5-18A) or EC 
(Figure 5-19A) are used to stimulate the neutrophils. The IL-RA levels are pretty 
similar across all conditions, with some variability between volunteers, 
suggesting no major effect. There is no effect on MCP-1 levels when using S. 
aureus and a slight increase in levels with PP1 when using E. coli, but no 
significant effect of dasatinib. 
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Figure 5-18 PP1 and Dasatinib treatment of neutrophils exposed to SA 
results in an attenuated IL-8 release from MDMs exposed to apoptotic 
neutrophils 
Il-8 (A), MCP-1 (B) and IL-1RA (C) release from MDMs incubated with non-
autologous apoptotic neutrophils for 24 hours in filter-sterilised, 10% autologous 
serum-supplemented supernatants from healthy neutrophils pre-treated with 10 
µM PP1 or 100 nM dasatinib and exposed to live SA. Data show mean and SD 
values of duplicate ELISA wells from 6 replicate sets of conditions. The 6 
replicates were from 2 separate experiments: in each, MDMs were derived from 
3 volunteers, apoptotic neutrophils were derived from another volunteer and 
further donor gave fresh neutrophils to derive supernatants (total n=6). 
*p=0.0134 (A), p=0.625  (B) and *p=0.0294 (C) for stimulated conditions by 
repeated measures ANOVA; *p<0.05 by Dunn’s post-hoc test comparing 
treated with control untreated neutrophils. 
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Figure 5-19 PP1 and Dasatinib treatment of neutrophils exposed to EC 
results in an attenuated IL-8 release from MDMs exposed to apoptotic 
neutrophils 
Il-8 (A), MCP-1 (B) and IL-1RA (C) release from MDMs incubated for 24 hours 
with non-autologous apoptotic neutrophils in filter-sterilised, 10% autologous 
serum-supplemented supernatants from healthy neutrophils pre-treated with 10 
µM PP1 or 100 nM dasatinib and exposed to live EC. Data show mean and SD 
values of duplicate ELISA wells from 6 replicate sets of conditions. The 6 
replicates were from 2 separate experiments: in each, MDMs were derived from 
3 volunteers, apoptotic neutrophils were derived from another volunteer and 
further donor gave fresh neutrophils to derive supernatants (total n=6). 
*p=0.0196 (A), *p=0.0146  (B) and **p=0.01 (C) for stimulated conditions by 
repeated measures ANOVA; *p<0.05, ***p<0.001 by Dunn’s post-hoc test 
comparing treated with control untreated neutrophils. 
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5.4.4 Src kinase inhibition of neutrophils: effect on MDM efferocytosis of 
apoptotic neutrophils 
Of particular interest was the effect of initial PP1 and dasatinib treatment on the 
subsequent efferocytosis capacity of the MDMs in these experiments.  
Results: Figure 5-20A opposite clearly shows that an unknown soluble factor 
released from neutrophil:bacteria interactions impairs effective MDM 
efferocytosis.  
Comments: Either neutrophils or bacteria release the unknown factor. It may 
act on the MDM itself, or it may exert an effect on the “Find me” and “Eat me” 
mechanisms used by the apoptotic neutrophil to facilitate its ingestion (Poon et 
al. 2014). 
Figure 5-20B shows that the impaired efferocytosis shown in A is ‘reversed’ by 
pre-treating the neutrophils with either PP1 or dasatinib, to near expected 
levels. The finding is novel and suggests that release of the unknown factor 
from neutrophils is inhibited by src kinase inhibition.  
It provides further evidence of an anti-inflammatory role of src kinase inhibition 
in promoting resolution after bacterial infection in the lung. 
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Figure 5-20 PP1 and Dasatinib treatment of neutrophils exposed to SA or 
EC results in improved efferocytosis of apoptotic neutrophils 
Rates of phagocytosis of apoptotic neutrophils by MDMs incubated for 24 hours 
in filter-sterilised, 10% autologous serum-supplemented supernatants from 
healthy neutrophils exposed to live SA or EC (A). Phagocytosis rates of MDMs 
incubated in supernatants from healthy neutrophils pre-treated with 10 µM PP1 
or 100 nM dasatinib and exposed to live SA or EC (B). Data show mean and SD 
values of samples from 2 separate experiments, each using MDMs from 3 
volunteers and a single donor of non-autologous apoptotic neutrophils (total 
n=6). ***p<0.001 (A), p=0.0959 (Unstimulated), ***p<0.001 (SA and EC)   (B) by 
repeated measures ANOVA; ***p<0.001 by Dunn’s post-hoc test comparing 
treated with control untreated neutrophils. 
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 Investigation of the Soluble Factors Released From 5.5
Neutrophil/Bacterial Interaction 
For these final experiments I attempted to investigate the nature of this 
unknown factor. There are many possibilities but I chose to test the following: 
LTF, serine proteases (specifically HNE) and ROS.  
Lactoferrin inhibits chemotaxis of granulocytes and is the only known “Keep out” 
signal regulating efferocytosis, being released by apoptotic neutrophils 
themselves (Bournazou et al. 2009). It is also a product of neutrophil 
degranulation inhibited by PP1 and dasatinib, as shown in Chapter 3. 
Neutrophil serine proteases such as cathepsin G, HNE and proteinase 3 are 
released at sites of infection and inflammation by degranulation. Conventionally 
it is believed that any extracellular immunomodulatory properties are neutralised 
by potent, naturally-occurring serine protease inhibitors, or ‘serpins’, present in 
serum. The experiments I carried out all used 10% autologous serum, which 
might be expected to provide enough serine protease inhibition to discount 
these enzymes as culprits. However there is some evidence to suggest that 
proteases can be released so readily that they can overwhelm and inactivate 
their inhibitors (Pham 2006). 
Similarly, ROS produced by activated neutrophils is known to activate RhoA in 
surrounding phagocytes. RhoA negatively regulates efferocytosis and this 
mechanism is well described in the literature (Nakaya et al. 2006; McPhillips et 
al. 2007; Poon et al. 2014). The antioxidant N-acetylcysteine inhibits ROS 
production, RhoA activation and promotes apoptotic cell clearance in LPS-
mediated murine lung inflammation (Moon et al. 2010). 
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5.5.1 Variation in experimental design 
I adjusted the basic experimental protocol again to inhibit these mediators as 
shown in Figure 5-21 overleaf. I chose to measure only efferocytosis without 
associated cytokine release. 
Supernatants from ‘untreated neutrophils’ in Steps 1 and 2 were treated with 
either 1 µg/ml of a mouse anti-human LTF monoclonal antibody (IgG1, κ), a 
mouse anti-human IgG1 isotype control antibody at the same concentration, the 
pan-serine protease inhibitor 4-(2-Aminoethyl) benzenesulfonyl fluoride 
hydrochloride (AEBSF) at 1 mM, the specific HNE inhibitor sivelestat at 100 
µg/ml or N-acetylcysteine at 10 µM. The drugs were present in the supernatant 
for the entire efferocytosis stage (Step 4). The intention was to test whether any 
of the inhibitors mimicked the effect of src kinase inhibition in improving 
efferocytosis. 
Unfortunately due to the complexity of the experiments, with limited time 
available, I carried out the experiments on a single day, using MDMs from 3 
separate healthy volunteers and apoptotic and healthy neutrophils from 2 
further separate volunteers. 
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Figure 5-21 Experimental design for section 5.5 
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5.5.2 Lactoferrin 
Results: Figure 5-22 below demonstrates 2 main findings: the two antibodies 
themselves have no effect on baseline rates of efferocytosis. Additionally they 
do not reverse the effect seen in stimulated neutrophils, suggesting that LTF is 
not responsible for this effect. 
 
Figure 5-22 Lactoferrin is not responsible for impaired efferocytosis by 
MDMs 
Rates of phagocytosis of apoptotic neutrophils by MDMs incubated for 24 hours 
in filter-sterilised, 10% autologous serum-supplemented supernatants from 
healthy neutrophils exposed to live SA or EC. In an additional 2 conditions, 1 
µg/ml IgG1 isotype control antibody (pink) and 1 µg/ml anti-LTF IgG1 antibody 
(yellow) was added to the supernatant prior to transfer to MDM plate. Data 
show mean and SE values of samples from 1 experiment, each using MDMs 
from 3 volunteers and a single donor of non-autologous apoptotic neutrophils 
(total n=3). ***p<0.001 by repeated measures ANOVA; *p<0.05 and **p<0.01 by 
Dunn’s post-hoc test comparing SA and EC-exposed neutrophils with control 
unstimulated neutrophils. p=0.842 (Unstimulated), ***p<0.001 (SA) and 
*p=0.014 (EC) by repeated measures ANOVA; *p<0.05, ***p<0.001 by Dunn’s 
post-hoc test comparing treated neutrophils or supernatant with control 
untreated neutrophils. 
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5.5.3 Serine proteases 
Results: In contrast, there is a very marked effect of the water-soluble, pan-
serine protease inhibitor, AEBSF, as shown in Figure 5-23 opposite, even when 
added to unstimulated neutrophil supernatant.  
Comments: One interpretation might be that serine proteases themselves are 
actually required to drive efferocytosis and that the AEBSF is neutralising all 
activity in the 10% serum added. This is not a recognised phenomenon; 
however there is in vitro evidence to suggest that both macrophages and 
neutrophils, which are both capable of phagocytosing and clearing apoptotic 
autologous neutrophils, are inhibited by the serpin plasminogen activator 
inhibitor-1 (PAI-1) (Park et al. 2008). I used 1 mM AEBSF, a concentration at 
the highest end of the dose range suggested on the product information sheet 
and it is possible that the drug itself is toxic to MDMs at this concentration. Dose 
response experiments would be required to further investigate this finding. 
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Figure 5-23 The pan-serine protease inhibitor, AEBSF, has direct effects 
on MDM function 
Rates of phagocytosis of apoptotic neutrophils by MDMs incubated for 24 hours 
in filter-sterilised, 10% autologous serum-supplemented supernatants from 
healthy neutrophils exposed to live SA or EC. In an additional condition, the 
pan-serine protease inhibitor, 1 mM AEBSF (orange), was added to the 
supernatant prior to transfer to MDM plate. Data show mean and SE values of 
samples from 1 experiment, each using MDMs from 3 volunteers and a single 
donor of non-autologous apoptotic neutrophils (total n=3). ***p<0.001 by 
repeated measures ANOVA; *p<0.05 and **p<0.01 by Dunn’s post-hoc test 
comparing SA and EC-exposed neutrophils with control unstimulated 
neutrophils. ***p=0.0005 (Unstimulated), ***p<0.001 (SA) and ***p=0.0002 (EC) 
by repeated measures ANOVA; *p<0.05, **p<0.01, ***p<0.001 by Dunn’s post-
hoc test comparing treated neutrophils or supernatant with control untreated 
neutrophils. 
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5.5.4 Human neutrophil elastase 
Results: Figure 5-24 below shows that HNE is also not responsible for the 
impaired MDM efferocytosis.  
Comments: I used a concentration of 100 µg/ml of sivelestat, that inhibited 
80% of neutrophil elastase activity in ex vivo pleural effusions post lobectomy 
(Sakuma et al. 1998), so I am confident that any HNE present in the 
supernatants was effectively inhibited. 
 
Figure 5-24 Neutrophil elastase is not responsible for impaired 
efferocytosis by MDMs 
Rates of phagocytosis of apoptotic neutrophils by MDMs incubated for 24 hours 
in filter-sterilised, 10% autologous serum-supplemented supernatants from 
healthy neutrophils exposed to live SA or EC. In an additional condition, 100 
µg/ml sivelestat, a specific neutrophil elastase inhibitor (violet), was added to 
the supernatant prior to transfer to MDM plate. Data show mean and SE values 
of samples from 1 experiment, each using MDMs from 3 volunteers and a single 
donor of non-autologous apoptotic neutrophils (total n=3). ***p<0.001 by 
repeated measures ANOVA; *p<0.05 and **p<0.01 by Dunn’s post-hoc test 
comparing SA and EC-exposed neutrophils with control unstimulated 
neutrophils. p=0.682 (Unstimulated), ***p=0.0003 (SA) and **p=0.0041 (EC) by 
repeated measures ANOVA; *p<0.05, ***p<0.001 by Dunn’s post-hoc test 
comparing treated neutrophils or supernatant with control untreated neutrophils. 
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5.5.5 Reactive oxygen species 
Results: Unexpectedly, 10 µM N-acetylcysteine also has no effect on the 
impaired efferocytosis (Figure 5-25 overleaf).  
Comments: This in vitro concentration was extrapolated from studies showing 
impaired neutrophil release of elastase, IL-8 and ROS in response to fMLP and 
PMA using 10 µM N-acetylcysteine (Sadowska et al. 2006). I had initially 
contemplated whether the N-acetylcysteine is unable to neutralise extracellular 
ROS and that it should have been added directly to the neutrophils in Step 1 but 
it does appear to have direct antioxidant effects as a ROS scavenger via its thiol 
group. Optimum in vitro hypochlorous acid scavenging activity might however 
require higher concentrations of up to 48 µM of N-acetylcysteine (Aruoma et al. 
1989).  
Both PP1 and dasatinib impair extracellular superoxide release from neutrophils 
in response to PAF+fMLP (Chapter 3). ROS production negatively controls 
efferocytosis via RhoA activation, as explained above. This potential 
mechanism is therefore worthy of further study in these experiments, using a 
dose range of 1-100 µM N-acetylcysteine added directly to the transferred 
supernatant or pre-incubated with the neutrophils. 
  
   
  230 
 
Figure 5-25 Reactive oxygen species are not responsible for impaired 
efferocytosis by MDMs 
Rates of phagocytosis of apoptotic neutrophils by MDMs incubated for 24 hours 
in filter-sterilised, 10% autologous serum-supplemented supernatants from 
healthy neutrophils exposed to live SA or EC. In an additional condition, 10 µM 
N-acetylcysteine, a potent antioxidant (brown), was added to the supernatant 
prior to transfer to MDM plate. Data show mean and SE values of samples from 
1 experiment, each using MDMs from 3 volunteers and a single donor of non-
autologous apoptotic neutrophils (total n=3). ***p<0.001 by repeated measures 
ANOVA; *p<0.05 and **p<0.01 by Dunn’s post-hoc test comparing SA and EC-
exposed neutrophils with control unstimulated neutrophils. p=0.752 
(Unstimulated), **p=0.0019 (SA) and ***p=0.0008 (EC) by repeated measures 
ANOVA; *p<0.05, ***p<0.001 by Dunn’s post-hoc test comparing treated 
neutrophils or supernatant with control untreated neutrophils. 
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 Summary of Key Findings 5.6
My key findings are summarised as follows: 
1. Src kinase inhibition of neutrophils stimulated by S. aureus, but not E. 
coli, attenuates secondary alveolar epithelial cell inflammation (with 
reduced IL-8 release) and damage (with reduced LDH release) in vitro. 
An associated increase in MCP-1 release may theoretically be part of an 
autoregulated epithelial cell repair mechanism.  
 
2. Neutrophils from critically ill patients are dysfunctional, with impaired 
phagocytosis and killing ability, as is described in the literature. They are 
also more inflammatory than healthy neutrophils, inducing direct and 
indirect inflammation and damage in alveolar epithelial cells, as seen in 
ARDS. Src kinase inhibition of neutrophils from critically ill patients has 
no effect on secondary epithelial inflammation, suggesting that the 
causative factor is not a product of neutrophil degranulation. 
 
3. Src kinase inhibition of neutrophils promotes resolution in a simple in 
vitro model of apoptotic cell efferocytosis by macrophages. 
Neutrophil:bacteria interaction releases a factor or factors that impair 
efferocytosis, either by a direct effect on macrophage polarity or function, 
or by inhibiting “Eat me” signals on the apoptotic cells themselves. Src 
kinase inhibitors prevent this effect, though the mechanism is not clear 
from the experiments carried out. 
In these experiments, I have tested my original hypothesis, which stated: 
“In vitro src kinase inhibition of human neutrophils attenuates neutrophil-
mediated epithelial cell damage whilst promoting a pro-resolutionary 
environment, allowing efficient apoptotic cell clearance”. 
My hypothesis has therefore been satisfied in an in vitro model of secondary 
epithelial cell inflammation and damage induced by the secreted products of 
healthy neutrophil:S. aureus interactions. Src kinase inhibition also promotes 
the generation of a more pro-resolutionary milieu, specifically permitting more 
efficient clearance of apoptotic neutrophils by macrophages. However, in a 
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similar ex vivo model, my hypothesis was not fully satisfied. Src kinase inhibition 
is unable to attenuate the inflammatory effect exerted on epithelial cells by ex 
vivo neutrophils retrieved from critically ill patients.  
The relevance of these findings, and those of Chapters 3 and 4, will be now be 
further discussed in the next chapter (Chapter 6; General Discussion), together 
with an acknowledgement of the limitations of my work and suggested future 
directions of work. 
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Chapter 6. General Discussion 
 Chapter Overview 6.1
In this chapter, I will further discuss the main findings of the work contained 
within this thesis, relating it to past and recently published data where relevant, 
acknowledging the limitations of my work, before concluding with my thoughts 
on future directions of work. 
 Introduction 6.2
The acute respiratory distress syndrome is an extreme pulmonary manifestation 
of a highly complex interplay between invading pathogens, innate immune cells 
and their mediators of acute inflammation. It remains associated with 
unacceptably high levels of mortality and morbidity. Clinical studies are 
challenging to perform well due to the heterogeneity of the syndrome, but 
standardising its definition in 2012 has helped in this regard (Ranieri et al. 
2012). To date, all randomised-controlled trials of pharmacological therapy have 
shown no effect on mortality. In fact, lung-protective ventilation is the only 
supportive measure to show a mortality benefit. Other clinical studies have 
helped to shape consensus view of current “best practice”. 
Post mortem studies, in vitro and in vivo models have identified some of the key 
features of acute inflammation that lead to ARDS. A central mechanism is the 
rapid recruitment and degranulation of neutrophils, cells once considered to be 
simple “suicide killers”. It is now clear that neutrophils not only kill pathogens in 
various different ways, but can also regulate inflammation and coordinate the 
innate and adaptive immune systems (Mócsai 2013). The src family of tyrosine 
kinases occupy a “gateway” position in controlling the signalling pathways that 
regulate the inflammatory response to a range of stimuli and are strongly 
implicated in the pathogenesis of ARDS. The src kinases therefore represent 
attractive therapeutic targets for studying acute inflammation, potentially leading 
to treatments for conditions such as ARDS. 
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 Src Kinase Inhibition Impairs Neutrophil Degranulation in Response 6.3
to Bacteria without Affecting Killing 
The in vitro results in Chapter 3 are consistent with previous studies showing 
that pharmacological src kinase inhibition of neutrophils with PP1 and dasatinib 
attenuates GPCR-mediated and TLR4-mediated degranulation of primary and 
secondary granules (Mócsai et al. 2000; Futosi et al. 2012). My experiments 
also replicate this finding in whole blood using a novel flow cytometric method of 
measuring membrane expression of the specific granule markers CD63 and 
CD66b. In addition, CR3-mediated degranulation in response to phagocytosis of 
live serum-opsonised Gram +ve and –ve bacteria is added to the list of 
mechanisms controlled by src kinases. Crucially, src kinase inhibition with PP1 
or dasatinib does not significantly impair in vitro intracellular bacterial killing in 
suspension (and in adherent conditions for PP1), supporting my first hypothesis. 
These observations clearly raise the tantalising possibility that under these 
conditions, granule fusion with phagosomes is preferentially maintained to 
permit pathogen killing, perhaps through activation of alternative tyrosine 
phosphorylation pathways. 
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 Src Kinase Inhibition Affects In Vitro Neutrophil Motility But Does Not 6.4
Impair In Vivo Neutrophil Influx  
My data also support the well-described effects of src kinase inhibition on 
adhesion-dependent neutrophil function: adhesion to plastic, chemotaxis along 
glass and adherent phagocytosis/superoxide release are all inhibited by both 
PP1 and dasatinib, but phagocytosis in whole blood was not affected. The 
theory that src kinase inhibition does not affect motility and migration of 
neutrophils in vivo is supported by Futosi’s data. Although dasatinib strongly 
inhibits migration towards fMLP and IL-8 along a fibrinogen-coated surface, it 
affects neither two-dimensional mechanotactic migration over integrin ligand 
surfaces under flow conditions (although sustained adhesion is impaired), nor 
transmigration through polycarbonate Transwell membranes towards fMLP or 
IL-8 (Futosi et al. 2012). In a more physiologically representative model of 
transmigration across an extracellular matrix (Matrigel) suspended above a 
Transwell membrane, dasatinib also has no effect. In Hck-/- Fgr-/- knockout 
models, Giagulli et al. may have explained this finding (Giagulli et al. 2006). 
They addressed the role of src kinases in “inside-out” and “outside-in” integrin 
signalling and found that Hck and Fgr were dispensable for integrin affinity and 
upregulation in response to chemoattractant-induced activation (inside-out 
signalling) but were necessary for sustained adhesion (outside-in signalling) 
(Shattil et al. 2010; Herter & Zarbock 2013). Another possible explanation for 
my findings is the non-specificity of PP1 and dasatinib: both chemicals are dual 
src and Abl kinase inhibitors. Tong et al. showed that c-abl kinase was critical 
for β2 integrin-dependent neutrophil migration in vitro and in vivo using both PP2 
and a specific c-abl inhibitor ST1571 (Tong et al. 2013). Similar to Futosi et al., 
the group used identical transmigration assays across fibrinogen-coated 
Transwell filters.  
As there are different schools of thought regarding the precise role of src 
kinases in neutrophil recruitment in vitro, the actual situation in vivo becomes 
more complicated. As detailed in Chapter 4, in response to E.coli-induced acute 
lung inflammation, low dose dasatinib (1 mg/kg) reduces neutrophil content in 
the lung interstitium with no effect in the alveoli, whilst reducing alveolar MPO 
and TNFα release. There is a slight increase in bacterial survival in the lung 
interstitium, but all other parameters are unchanged. At high dose (10 mg/kg) 
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there is an obvious detrimental effect with increased bacterial survival and 
evidence of extrapulmonary toxicity. It is difficult to conclude whether this 
marked effect is due to impaired bacterial killing or inadequate neutrophil 
recruitment, or both. In Hck-/- Fgr-/- Lyn-/- triple knockout models of blistering skin 
diseases and autoantibody-induced arthritis, mediated by both Fcγ recognition 
of immune complexes and β2 integrin-mediated neutrophil recruitment, the 
authors found that although the neutrophil, monocytes and macrophages all 
exhibited normal in vivo and in vitro migratory capacity, recruitment was 
impaired due to inadequate generation of a pro-inflammatory environment 
(Kovács et al. 2014).  
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 Src Kinase Inhibitors Act on All Inflammatory Cells, Not Just 6.5
Neutrophils 
Targetting src kinases with systemic administration of dasatinib should 
theoretically block all forms of src signalling in every living cell, not simply 
neutrophils. We know something of the role of src kinases in endothelial cells, 
epithelial cells (Severgnini et al. 2005; Chang et al. 2008; Han et al. 2013) and 
alveolar macrophages (Byeon et al. 2012). Alveolar macrophages have been 
shown to promote src-dependent neutrophil transmigration in a septic model by 
releasing ROS through NADPH oxidase (Wang et al. 2008) and induce protein 
leak through iNOS (Farley et al. 2006). The recent discovery by Cohen’s group 
in Dundee that salt-inducible kinase (SIK) signalling in macrophages controls 
the interconversion between classically activated (M1) and regulatory (M2) 
macrophages may also explain our findings (Clark et al. 2012). Both dasatinib 
and bosutinib (at high concentrations = 300 nM and 3 µM respectively) 
polarised murine bone marrow derived macrophages (BMDMs) towards a 
regulatory-like phenotype with high IL-10 and low TNFα, IL-6 and IL-12 
production, through SIK inhibition (Ozanne et al. 2014). It therefore seems likely 
that dasatinib affects the ability of both neutrophils and alveolar macrophages to 
generate a pro-inflammatory environment in the context of infection and may 
explain our finding of reduced neutrophil recruitment to the lung interstitium at 
low doses of dasatinib.  
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 Src Kinase Inhibition is Anti-inflammatory in Acid-induced 6.6
Inflammation 
In a sterile model of lung inflammation free from the unpredictability of bacterial 
survival and stimulus size, such as acid-induced lung inflammation, any effect 
on neutrophil recruitment should theoretically be easier to detect. In the LPS 
model, both PP1 and PP2 reduced neutrophil influx amongst other markers of 
lung inflammation (Severgnini et al. 2005; Lee et al. 2007). Acid-induced lung 
inflammation is initiated by the generation of danger-associated molecular 
patterns (DAMPs) from cell necrosis, which modulate TLR and nod-like receptor 
(NLR) activity (Tolle & Standiford 2013). IL-8 production recruits neutrophils 
(Folkesson et al. 1995) which degranulate and interact with activated platelets 
to form aggregates capable of further damaging endothelial cells through 
thromboxane A2 (TXA2) production (Zarbock et al. 2006). In our model of acid-
induced lung inflammation, we observe a surprisingly mild anti-inflammatory 
effect at a moderate dose of 5 mg/kg dasatinib with reduced alveolar neutrophil 
content, reduced alveolar degranulation of LTF, reduced interstitial CD11b 
expression on sequestered neutrophils. At 10 mg/kg there is a detrimental 
effect, with increased alveolar and interstitial neutrophil influx and 
degranulation, and marked alveolar haemorrhage. Why dasatinib appears pro-
inflammatory in this model at high dose is more difficult to explain. It does not 
appear to be due to impaired neutrophil recruitment. The increased alveolar 
haemorrhage might relate to endothelial injury from inhibition of Lyn kinase, 
known to have an opposing function to other src kinases in strengthening 
endothelial integrity and barrier function (Han et al. 2013).  
Taking the results of both in vivo models together, there appears insufficient 
evidence to conclude that dasatinib impairs neutrophil recruitment in either 
model. As expected, it does exert an anti-inflammatory effect by inhibiting some 
markers of degranulation and inflammation. There is no convincing evidence of 
reduced endothelial cell injury and leak in either model, so my second 
hypothesis is not supported. 
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 The Paradox of Impaired Phagocytosis with Normal Bacterial Killing 6.7
Do src kinase inhibitors therefore truly inhibit bacterial killing by neutrophils? 
Although Mocsai’s group concluded that dasatinib does not have a major effect 
in vitro, there was in fact a ~25% increase in the relative counts of both S. 
aureus and E. coli with 1 µM dasatinib (Futosi et al. 2012). Only at a PP1 dose 
of 100 µM did I observe an in vitro inhibitory effect, using almost precisely the 
same experimental conditions as Futosi: in suspension with serum-opsonised 
pathogens at an MOI of 10 bacteria: 1 neutrophil.  
We have already discussed the possibility that src inhibition may affect NETs 
production by neutrophils in response to bacterial stimulation. In the short 30 
min bacterial killing assay I used, there is insufficient time for NETs to be 
produced, which typically peak at 3-4 h after PMA stimulation. By contrast, in 
my 24 h in vivo murine models, NETs formation is likely to be a significant factor 
in the effective control and clearance of bacteria. As the degranulation product 
MPO is a key extracellular component of NETs also required to generate the 
primary ROS in NETs, namely hypochlorite (Akong-Moore et al. 2012), and as I 
have shown, src kinases themselves are crucial in MPO degranulation and 
NADPH oxidase function, it would be expected that src kinase inhibition also 
impairs NETs formation. This has recently been demonstrated in human 
neutrophils in response to yeasts, where both src and Syk kinase inhibitors 
switched off NETs production to a similar level seen with the NADPH oxidase 
inhibitor, DPI (Nanì et al. 2015). We made no direct measure of neutrophil 
viability in the interstitium or alveoli of the mice exposed to both E. coli and acid. 
Flow cytometric analysis of neutrophil apoptosis and necrosis, together with 
quantification of NETs production using fluorescent microscopy, would have 
given some insight into the relative importance of these processes in bacterial 
clearance. 
It therefore still remains difficult to fully explain my apparently paradoxical 
findings that src kinase inhibition does not affect in vitro bacterial killing, but that 
both adherent neutrophil phagocytosis and NADPH oxidase function is src-
dependent. This may well be an assay-dependent “in vitro phenomenon” and 
the findings should therefore be repeated using alternative phagocytosis and 
bacterial killing assay techniques. However, I found that both PP1 and dasatinib 
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also inhibited phagocytosis of serum-opsonised zymosan particles (data not 
shown), contradicting the findings of Futosi et al., who showed no effect of up to 
1 µM dasatinib on phagocytosis of serum-opsonised GFP-expressing bacteria 
(Futosi et al. 2012).  
The various theories explaining the relative contributions of NADPH oxidase, 
ROS production, pH and proteases to effective bacterial killing in the 
phagosome therefore come into focus. The events within the phagosome are 
dynamic and as such, investigating individual processes is extremely 
challenging.  One might expect some redundancy in the system, such that a 
defect in one component may only result in a minor effect on bacterial 
degradation within the phagosome. Patients with chronic granulomatous 
disease (CGD) have neutrophils defective of NADPH oxidase activity and are 
highly susceptible to infection. However, their neutrophils exhibit normal 
bacteriocidal activity towards certain bacteria in vitro, including Streptococci 
(Kaplan et al. 1968), Pseudomonas aeruginosa (Speert et al. 1994) and E. coli 
(Rosen & Michel 1997). Similarly, neutrophils from patients with MPO deficiency 
are unable to kill Candida and have a reduced activity against S. aureus in vitro 
(Parry et al. 1981), with little overall clinical effect.  
Current consensus opinion would favour the theory that NADPH oxidase 
creates a membrane potential across both the phagosomal and plasma 
membranes of the stimulated neutrophil by providing electrons to generate ROS 
and its downstream metabolites. Granule proteins are then modified and 
activated by changes in pH, ROS and halogen derivatives to act collaboratively 
with oxidants to degrade ingested microbes (Nauseef 2007). The absence of an 
individual component therefore unpredictably alters the balance of the anti-
microbial milieu of the host phagosome, without even taking into account of the 
effect of specific pathogen adaptations to its interaction with the host. 
  
   
  243 
 Src Family Kinases: a Role in Controlling Individual Granule 6.8
Subsets? 
It is beyond the remit of this thesis to draw conclusions on the effects of src 
kinase inhibition on the anti-microbial activity within the phagosome. It is 
interesting to speculate on the possibility that some of my observations (and 
those of others) may be explained by preferential translocation and targeting of 
individual granules to specific locations within the neutrophil, under the control 
of individual src kinases. There is evidence to suggest that specific granule 
populations are associated with individual src kinases. In human neutrophils 
stimulated by fMLP, the src kinase Fgr is localised and expressed in the 
membrane of secondary granules, whereas a 61kDa form of Hck translocates to 
primary granules upon activation (Gutkind & Robbins 1989; Möhn et al. 1995). It 
is technically possible to measure subcellular localisation of individual neutrophil 
granules using immunofluorescence and confocal microscopy (Quinn et al. 
2007), but studies to test these theories are currently limited to knockout murine 
models of individual src kinases. siRNA (‘small interfering’ ribonucleic acid) 
“knock-in” models are technically extremely challenging in human neutrophils, 
but may prove effective in cell lines resembling human neutrophils, such as the 
HL-60 cell line. Due to the similar structure of the countless receptor and non-
receptor tyrosine kinases, specificity of kinase inhibition remains a challenge, 
particularly within the family of 9 src kinases. As pharmaceutical companies 
continue to develop more and more specific individual src kinase inhibitors for 
use in chronic myeloid leukaemia and other malignancies, these may be used 
experimentally in the future to test these theories (Tintori et al. 2013). 
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 Limitations of In Vitro and In Vivo Studies 6.9
There are certain limitations to consider when interpreting my in vitro and in vivo 
data: 
The most important consideration is that although both PP1 and dasatinib are 
known to be potent src kinase inhibitors and I have shown that they inhibit src 
kinase phosphorylation in vitro, there is a significant possibility of numerous ‘off-
target’ effects due to the lack of specificity of most tyrosine kinase inhibitors. 
Although manipulation of src kinase pathways is highly likely to be involved in 
the in vitro and in vivo observations I have made, it is impossible to directly 
attribute any effect to src kinase inhibition alone.  
As discussed earlier, the number of experimental replicates was limited to 
between 3-6 in vitro studies, due to a limited availability of healthy blood donors 
and the logistics of conducting numerous assays within the short lifespan of 
neutrophils. This is an unavoidable issue when conducting neutrophil research. 
Some researchers attempt to circumvent the issue by using the HL-60 cell line 
to study neutrophil biology, but our group believes that research involving 
primary human cells is considerably more applicable. Although it was a valid 
approach to carry out statistical comparison tests assuming a normally 
distributed population where appropriate, there is a risk that I have 
overestimated any underlying statistical difference between individual 
conditions. Planning fewer experiments, with fewer individual conditions, may 
have allowed me to increase my experimental numbers. 
Similarly, with the in vivo experiments, although there was a clear dose-
response effect of dasatinib in both E. coli and acid models, I was surprised that 
there was no difference in a majority of the markers tested between control and 
treated mice. We believe that the decision to administer dasatinib at 0 and 12 h 
was correct, to coincide with the peak neutrophil influx at these timepoints, but 
that the choice of a 24 h timepoint to end the experiment may have been too 
late to observe more significant changes in markers of neutrophil influx, 
activation and degranulation during the earlier stages of acute inflammation. 
Additional timepoints of 3 h, 6 h, 12 h and 48 h may have helped to clarify this 
issue. 
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As previously discussed, our i.p. doses of 1 mg/kg, 5 mg/kg and 10 mg/kg 
dasatinib were extrapolated from pharmacokinetic data in rats (Seferian et al. 
2013). These doses resulted in broadly similar plasma dasatinib levels in rats as 
measured in human patients taking a daily dose of 70 mg (the daily dose in 
CML is 100 mg). In reality, the limited number of experiments we carried out 
were dose-finding in nature, after initial experiments established that doses of 1 
mg/kg and 10 mg/kg dasatinib were not toxic to mice unexposed to lung injury. 
We were therefore reassured to read a recently published paper from Mocsai’s 
group where they used the same doses of 1 mg/kg and 10 mg/kg dasatinib or 
control 1% DMSO administered by oral gavage to pre-treat C57/BL6 mice 
exposed to either 1% DMSO control, i.t. LPS or i.p. LPS. The mice were 
retreated with dasatinib at 6 h and 24 h before the experiment was terminated 
at 48 h. Interestingly, mortality in the 10 mg/kg group exposed to i.t. LPS was 
24% compared to 0% in the 1 mg/kg and DMSO control groups. 1 mg/kg 
dasatinib favourably affected lung dynamics and function and led to a significant 
reduction in neutrophil (and mononuclear cell) influx into the BALF. Lung 
interstitium levels of IL-6, IL-10 and TGFβ were all reduced, with a slight 
reduction in BALF IL-6. 10 mg/kg dasatinib resulted in further adverse 
outcomes, including increased BALF neutrophil influx and a considerable 
increase in Fas receptor positive lung tissue, indicating cell death. Of note, the 
authors measured no specific markers of neutrophil degranulation such as 
CD11b/CD63 expression or release of MPO/LTF (Oliveira et al. 2015). 
These results complement our data well, indicating that at high doses, dasatinib 
administered via the oral route has broadly similar effects to our own 
observations using i.p. administration, irrespective of the aetiology of lung injury. 
In contrast, the anti-inflammatory effects of dasatinib at lower doses appear to 
be dependent on the underlying aetiology. 
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 A Soluble Neutrophil Factor is Responsible for Epithelial Cell 6.10
Damage and Inflammation 
My data in Chapter 5 have also revealed novel indicators of the anti-
inflammatory and pro-resolutionary roles of src kinase inhibition in acute 
inflammation. The data were discussed in detail throughout Chapter 5, and 
generated more questions than they have answered.  
Firstly, what is the nature of the soluble factor released from the interaction of 
neutrophils with S. aureus NCTC 8325, but not E. coli K-12, that induces 
disruption of epithelial cell monolayer integrity? I have postulated that this factor 
may be related to the release of lipotechoic acid or virulence factors specific to 
S. aureus, such as leukotoxins. It may also be an extracellular product of 
degranulation, since pre-treatment of neutrophils with both PP1 and dasatinib 
reduces subsequent release of IL-8 and LDH from A549 epithelial cells, but 
does not prevent monolayer disruption. This finding was not observed in 
identical experiments involving E. coli K-12. The reader will recall that in 
Chapter 3, my original experiments to inhibit degranulation were carried out 
using SA NCTC 8325 and P. aeruginosa PA01 and not E. coli K-12. The reason 
for changing from PA01 to E. coli was to avoid the excessive contamination of 
A549 culture plates with PA01 that I observed, despite using 0.4µm diameter 
filter sterilisation and the addition of gentamicin. Future in vitro experiments 
would therefore need to establish a similar effect of in vitro src inhibition on 
neutrophil phagocytosis, killing and degranulation functions in response to E. 
coli K-12. 
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 Neutrophils from Critically Ill Patients are Pro-inflammatory and 6.11
Unaffected by Src Kinase Inhibition 
It is clear from my data that neutrophils derived from critically ill patients, 
irrespective of underlying disease type, exhibit dysfunctional phagocytosis and 
bacterial killing, whilst inducing inflammation and cytotoxicity in A549 cells  
when in direct contact or when separated by a filter membrane. Unsurprisingly 
src inhibition has no effect on neutrophil dysfunction, nor does it attenuate 
downstream epithelial cell damage and inflammation. This may be a result of 
the excessive levels of inflammation inducing neutrophil activation and 
degranulation via other src-independent signalling pathways in critically ill 
patients. Indeed, the levels of inflammatory mediators, such as C5a 
anaphylatoxin, (indirectly associated with neutrophil dysfunction) present in the 
blood of critically ill patients can reach over 1000 fold higher than those of a 
healthy individual (Ward 2010). In these experiments, I only used a modest 
dose of both PP1 and dasatinib (10 µM and 100 nM respectively). Repeating 
the experiments using higher doses may be required to observe an effect. 
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 Src Kinase Inhibition Prevents the Release of a Neutrophil-derived 6.12
Factor that Impairs Repair and Efferocytosis 
Resolution of acute inflammation is a highly complex and tightly regulated 
process believed to occur alongside acute inflammation, even before the 
clearance of a perpetuating inflammatory stimulus. In resolving lung 
inflammation, alternatively activated M2 alveolar macrophages (and to a lesser 
extent, neutrophils) are capable of ingesting debris and apoptotic cells and 
producing anti-inflammatory cytokines. My experiments showed that a soluble 
factor released from the interaction of healthy neutrophils with both S. aureus 
and E. coli impairs efficient MDM efferocytosis, suggesting that this factor exerts 
a negative effect on MDMs, or acts on the “Find me” and “Eat me” signals on 
apoptotic neutrophils to prevent their recognition and uptake.  
It is very important to consider that the relatively low rates of apoptosis 
observed (~50%) may have influenced the results here. Around 25% of 
‘apoptotic neutrophils’ were actually alive when co-cultured with healthy MDMs. 
This can be appreciated in the control experiments, which show a small but 
significant release of IL-8 and MCP-1 from ‘apoptotic cells’ cultured in media 
alone. The presence of live neutrophils is likely to have influenced MDM and 
apoptotic cell signalling and behaviour. Ultraviolet light irradiation would have 
proved a much more reliable method to induce neutrophil apoptosis and avoid 
this potential effect.  
Initial attempts to elucidate the individual factor(s) involved were unsuccessful. 
Low experiment numbers (n=3) and highly complex assay steps may have 
contributed to this. Future work should target serine proteases and ROS using 
different inhibitors in simplified assays. 
Further limitations of my A549 and MDM experiments include the use of a cell 
line to study the effects on alveolar epithelial cells. It is possible to culture 
primary alveolar epithelial cells obtained from the healthy tissue margins around 
lung cancers at wedge resection or lobectomy, or they can be bought in. 
Additionally, experiments using alveolar macrophages obtained at 
bronchoscopy in healthy volunteers are far more representative than using 
MDMs matured in culture for 7 days, but a regular supply of both of these 
primary human cells is limited.  
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By separating out each co-culture (neutrophil:bacteria, supernatant:A549s, 
supernatant:MDMs/apoptotic neutrophils) into different assay steps, these 
experiments became progressively more complex, requiring numerous control 
conditions. My experimental approach did have the advantage of working with 
live bacteria instead of chemical stimuli, making my findings more clinically 
relevant. In reality it is impossible to recreate the inflammatory cell milieu of an 
inflamed lung in any model except an in vivo model, but such in vitro 
experimental systems are important in studying individual components. 
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 Future Directions and Concluding Remarks 6.13
This thesis has investigated the role of src kinases in controlling acute 
inflammation and its resolution in vitro, as well as their role in in vivo models of 
experimental lung inflammation. There is still a considerable difference between 
these models and the situation in ARDS, but the work has nonetheless provided 
further insights into the mechanisms of neutrophil activation, degranulation, 
extracellular signalling and repair that are central to the pathogenesis of this 
and many other serious conditions. Progressing towards the ultimate goal of 
testing potential ARDS treatments in randomised-controlled trials, I believe 
there is sufficient evidence to test the role of src inhibition in EVLP models of 
acid, bacteria and LPS-induced acute lung inflammation. In addition, there are 
two other potential lines of future investigation relevant to the mechanisms of 
ARDS that particularly interest and excite me: firstly, the accurate identification 
of the neutrophil factor(s) responsible for epithelial cell inflammation and 
damage in vitro and impaired macrophage efferocytosis. Secondly, the 
possibility of understanding and ultimately controlling the processing and 
targeting of individual granule subsets to phagosomal and plasma membranes 
by modulating the function of individual src kinases. 
In time, I believe we will discover the “holy grail” of acute lung inflammation, by 
identifying highly specific therapeutic strategies designed to attenuate acute 
lung inflammation and promote repair, whilst maintaining a functional immune 
response to pathogens. 
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Appendix 1. Presentations of work contained within this thesis 
Spoken presentations  
Macfarlane JG, Dorward DA, Lucas CD, Scott JA, Ruchaud-Sparagano MH, 
Khan CMA, Rossi AG, Simpson AJ. In vitro and in vivo studies of the Src/Bcr-
abl inhibitor Dasatinib in sterile and non-sterile acute lung inflammation. British 
Thoracic Society Winter Conference, London, Dec 2014 
Macfarlane JG, Ruchaud-Sparagano MH, Scott JA, Bulmer DA, Khan CMA, 
Simpson AJ. Src kinase inhibition attenuates neutrophil degranulation without 
impairing bacterial killing: a possible therapeutic strategy for acute lung injury. 
Newcastle University Institute of Cellular Medicine Research Day, Newcastle, 
Jun 2013 
Gertig H, Ruchaud-Sparagano MH, Hester KLM, Macfarlane JG, Corris PA, 
Simpson AJ, De Soyza A. Are neutrophils dysfunctional in idiopathic 
bronchiectasis? Spoken presentation by first author at American Thoracic 
Society International Conference, San Francisco, May 2012 
Poster presentations  
Macfarlane JG, Ruchaud-Sparagano MH, Scott JA, Bulmer DA, Khan CMA, 
Simpson AJ. Dasatinib inhibits neutrophil degranulation in response to sterile 
and non-sterile stimuli without impairing bacterial killing. Poster discussion at 
American Thoracic Society International Conference, San Diego, May 2014 
Macfarlane JG, Ruchaud-Sparagano MH, Scott JA, Bulmer DA, Khan CMA, 
Simpson AJ. Src kinase inhibition attenuates neutrophil degranulation without 
impairing bacterial killing: a possible therapeutic strategy for acute lung injury. 
Poster presentation at British Thoracic Society Winter Conference, London, 
Dec 2013 
Macfarlane JG, Ruchaud-Sparagano MH, Scott JA, Bulmer DA, Khan CMA, 
Simpson AJ. Neutrophil dysfunction in respiratory infection: impaired killing 
efficiency after successive phagocytic stimuli? Poster discussion at European 
Respiratory Society Annual Congress, Barcelona, Sep 2013 
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Appendix 2. Publications arising from work contained within 
this thesis 
Scott J, Harris GJ, Pinder EM, Macfarlane JG, Hellyer TP, Rostron AJ, Conway 
Morris A, Thickett DR, Perkins GD, McAuley DF, Widdrington JD, Wiscombe S, 
Baudouin SV, Roy AI, Linnett VC, Wright SE, Ruchaud-Sparagano MH, 
Simpson AJ. Exchange protein directly activated by cyclic AMP (EPAC) 
activation reverses neutrophil dysfunction induced by β2-agonists, 
corticosteroids, and critical illness. J Allergy Clin Immunology 2015 Sep [Epub 
ahead of print] 
Ruchaud-Sparagano MH, Gertig H, Hester KL, Macfarlane JG, Corris PA, 
Simpson AJ, De Soyza A. Effect of GM-CSF on neutrophil function in idiopathic 
bronchiectasis. Respirology. 2013 Nov;18(8):1230-5  
------------------------------------------------- 
Macfarlane JG et al. The effects of dasatinib in experimental acute lung 
inflammation. Manuscript in preparation for submission, Oct 2015. 
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